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Abstract 
 
Through the use of a knockout mouse line, we have identified flavin-containing 
monooxygenase 5 (FMO5) as a regulator of energy homeostasis. The characterisation 
of the FMO5 knockout (FMO5 KO) phenotype reveals the mutant animals are 
resistant to age-related and diet-induced weight gain when compared to age-matched 
wild-type (WT) controls.  The FMO5 KO mice exhibit higher insulin sensitivity and 
need lower circulating insulin to maintain normal glycaemia. The knockout mice are 
also more responsive to an exogenous dose of insulin and they do not gain weight 
when fed a high fat diet. 
 
FMO5 is expressed in the murine digestive tract of WT animals and is further induced 
in high-fat feeding.  Investigations into the intestine of the knockout animal reveal 
differences in the intestinal microbiota and a different processing of a colonic 
hormone, RELMβ. This hormone is involved in intestinal inflammation and less was 
detected in circulation of the knockout mouse.  Furthermore, lower levels of 
circulating cytokine TNFα was detected and inflammation of adipose tissue, 
peripheral to the intestine, was found to be lower in the knockout mice.   
 
The findings implicate FMO5 to be a modulator of the intestinal environment and an 
mediator of inflammation.  By influencing the processing of RELMβ, the protein 
contributes to the systemic inflammatory profile of the animal.  Reduced 
inflammation of sites such as adipose tissue in the absence of the protein correlates 
with higher insulin sensitivity and a leaner animal.   
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Chapter 1: Introduction 
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The investigations presented in this thesis are regarding flavin-containing 
monooxygenase 5.  This chapter will briefly introduce the members of the flavin-
containing monooxygenase gene family and discuss their role in endogenous, as well 
as xenobiotic metabolism.  Experiments described in following chapters were 
conducted to characterise the phenotype of the flavin-containing monooxygenase 5 
knockout mouse (FMO5 KO) in comparison to the wild-type (WT).  One of the most 
striking phenotypes of the FMO5 KO is an attenuation in age-related weight gain.  
The recent proposal of the intestinal microbiota as an integral entity of the host, 
capable of modulating energy storage, led us to consider this population in the WT 
and FMO5 KO.  The commensal bacteria of the intestine and its involvement in the 
host phenotype will therefore also be discussed in this chapter. 
 
1.1 FLAVIN CONTAINING MONOOXYGENASES 
 
Xenobiotic metabolism is a critical function of any living organism.  Metabolism of 
foreign compounds, such as therapeutic drugs, pesticides and dietary constituents, 
ensures the elimination of non-nutritional or potentially toxic agents.  Second to 
cytochrome P450s (CYPs), the flavin-containing monooxygenases (FMOs) play a 
fundamental role in the Phase I processing of such foreign chemicals.  The FMOs are 
present in the endoplasmic reticulum (ER) membrane of several different tissues and 
catalyse the oxidation of nucleophilic nitrogen-, sulfur-. selenium- and phosphorous-
containing compounds.  Generally, the oxygenated product is less toxic or 
pharmacologically active and the modification facilitates further processing (Phase II) 
or elimination of the parent compound.  In 1971 Zeigler purified the first FMO from 
porcine liver microsomes (Ziegler and Mitchell, 1972).  Shortly after, two groups 
independently isolated an FMO from rabbit lung microsomes that was distinct to the 
hepatic form in activity and physical stability (Williams et al., 1984; Tynes et al., 
1985).  This was evidence for the existence of multiple forms of FMOs and since, a 
further three additional isoforms have been identified.  The proteins were named, in 
order of their identification, FMO1-5 (Lawton and Philpot, 1993). 
 
In humans there are 11 FMO genes, five of which encode the functional proteins 
FMO1-5.  Human FMOs 1-5 share 51-57% sequence identity and FMOs isolated 
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from other mammals have >80% sequence identity to their human orthologues 
(Phillips et al., 1995).  All five genes are located on chromosome 1.  FMOs 1-4 are 
contained within a cluster in the region q24.3, also containing a pseudogene 
(FMO6p).  FMO5 however, is not part of this cluster, and lies closer to the centromere 
in region 1q21.1.  Another cluster consisting of five additional pseudogenes (FMO7p 
to 11p) has also been identified on chromosome 1.  The gene family is thought to be a 
result of several gene duplications estimated to have occurred over 200 million years 
ago, long before the divergence of mammals from their common ancestor 85 million 
years ago.  We can therefore predict the five functional FMO genes FMO1-5 are 
common among all mammals (Hernandez et al., 2004; Phillips et al., 2007).   Like 
humans, out of the nine members of the Fmo gene family in mice, only Fmo1 through 
5 produce functional protein products.  Similarly, Fmo1, 2, 3, and 4 are clustered 
together on chromosome 1 whereas Fmo5 is located separately on chromosome 3 
(Hernandez et al., 2004).   
 
1.1.1 Catalysis 
No crystal structure has been obtained for mammalian FMOs, however information 
can be inferred from the crystal structure of the yeast FMO (Eswaramoorthy et al., 
2006).  The Schizosaccharomyces pombe wild-type FMO has been crystalised, along 
with the protein-cofactor and protein-substrate complexes.  Structures however reveal 
the cytosolic yeast protein has a mechanism distinct to that of the mammalian FMOs.  
From kinetic evidence, the mechanism of action of mammalian and bacterial FMOs 
instead seems very similar (Ziegler, 2002). Using NADPH and FAD, FMOs 
oxygenate a soft nucleophile (Figure 1.1).   
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The catalytic cycle begins with the association of NADPH and the reduction of FAD 
to FADH2 (Figure 1.1-a).  Upon the addition of molecular oxygen (Figure 1.1-b), a 
hydroperoxyflavin is formed (shown inset).  Even in the absence of substrate, this 
complex is stable and is believed to be the most predominant form of the enzyme in 
the cell.  Contact with a substrate (S) containing a soft nucleophile results in 
nucleophilic attack of the distal oxygen atom of the hydroperoxyflavin and 
oxygenation of the parent compound (Figure 1.1-c).  Water is then released from the 
hydroxyflavin, regenerating FAD (Figure1.1-d) and finally NADP+ is released (figure 
1-e) (Krueger and Williams, 2005; Phillips et al., 2007; Testa and Krämer, 2007). 
 
  
O2
[(FADH-OOH)(NADP+)]
S: SO
[(FADH-OH)(NADP+)]
H2O
[(FAD)(NADP+)]
FAD
[(FADH2)(NADP+)]
NADP+NADPH + H
+
V
V
V
1
2
3
4
5a 
b 
c 
d 
e 
Figure 1.1- The catalytic cycle of an FMO.  FAD is reduced after the 
association of NADPH (a).  Upon the addition of molecular oxygen, a 
hydroperoxyflavin (FADH-OOH) is formed (b).  Nucleophilic attack from the 
distal O atom of the hydroperoxyflavin (shown inset) results in the 
oxygenation of the parent compound S (c).  Water is then released from the 
hydroxyflavin (d) reforming FAD and, finally NADP
+
 is released (e).  Figure 
adapted with permission from Phillips, I. R., & Shephard, E. A. (2008). 
Flavin-containing monooxygenases: mutations, disease and drug response. 
Trends in Pharmacological Sciences, 29(6), 294–301.  
	   16 
The unique property of this catalysis, with respect to most other enzymes that use 
oxygen, is the ability of FMOs to activate molecular oxygen in the absence of 
substrate.  The ‘loaded gun’ nature of the FMOs is thought to explain the broad 
substrate range of the family; the determining factor for substrate specificity therefore 
being the substrate’s ability to access the active site (Ziegler, 2002; Zhang et al., 
2007).  Using tertiary amine substrates, with carbon chains of varying length, Zhang 
et al. showed catalysis of FMO1 was independent of chain length, suggesting the 
hydroperoxyflavin of this isoform is easily accessed by the substrate.  Catalysis by 
FMO3, and more so FMO5, was however dependent on the aliphatic chain length.  
FMO5 was proposed to have a much deeper active site, requiring a chain of at least 5 
carbon atoms to deliver the soft nucleophile for catalysis (Zhang et al., 2007).   
 
More recently investigations have also proposed certain mammalian FMOs can 
mediate catalysis in a mechanism distinct to the other family members.  Baeyer-
Villiger monooxygenases, another group of flavin-containing enzymes, convert a 
ketone group to its corresponding ester using dioxygen and NAD(P)H.  Similar to the 
catalysis described above, an intermediate hydroperoxyflavin is formed, which 
mediates substrate oxygenation (Fraaije et al., 2002).  FMO1 was initially found to 
catalyse the Baeyer-Villiger oxidation of salicylaldehyde to prycrocatechol (Chen et 
al., 1995) and more recently Lai et al. have shown specifically FMO5 is able to 
perform Baeyer-Villiger catalysis of a potential anti-cancer therapeutic (Lai et al., 
2011).  Taken together with several other factors discussed below, we suggest FMO1 
and, in particular, FMO5 may behave as atypical FMOs. 
Although the substrate specificities of the isoforms overlap (Krueger and Williams, 
2005), the FMOs exhibit distinct developmental and tissue-specific patterns of 
expression. Each isoform will be briefly introduced.  	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1.1.2 FMO1 
FMO1 has the widest range of substrates of the FMO family.  Although expressed in 
several organs, its main site of expression in humans is the kidney (Krueger and 
Williams, 2005; Zhang and Cashman, 2005).  In most other mammals studied, FMO1 
is one of the most prominent enzymes of the liver, however the FMO1 gene is 
silenced shortly after birth in humans (Dolphin et al., 1991; Koukouritaki et al., 2002).  
This is in contrast to the kidney, where gene expression increases after birth (Phillips 
et al., 1995; Krause et al., 2003) and the amount of FMO1 protein exceeds the total 
concentration of renal CYPs (Shephard and Phillips, 2010).  This indicates the 
prominent role for FMO1 in human renal metabolism of drugs.   
 
Five nonsynonymous single nucleotide polymorphisms of FMO1 have been 
identified, however these mutations happen at a very low frequency in a discrete 
number of populations (Phillips et al., 2007).  FMO1 mRNA has however been shown 
to be dysregulated in certain pathologies.  FMO1 expression is up regulated in tissue 
samples from patients suffering with atrial fibrillation, an arrhythmia thought to be 
caused by oxidative stress (Kim et al., 2003).  FMO1 mRNA was also originally 
reported to be downregulated in the spinal cord in amyotrophic lateral sclerosis 
(ALS); a neuro-muscular disorder caused by the continuous loss of spinal cord, brain 
stem and motor cortex neurons (Malaspina et al., 2001).  However, using a mouse 
model for ALS, Gagliardi et al. went on to report FMO1 mRNA was contrastingly up 
regulated in diseased spinal cord (Gagliardi et al., 2010).  The ALS mediated increase 
in FMO1 mRNA was however gender dependent, occurring specifically in males, 
which may explain the disagreement with Malaspina et al.  The role of FMO1 in the 
development of atrial fibrillation and ALS remains unclear, however Gagliardi et al. 
propose the induction of Fmo1 expression may be in response to the increase in 
oxidative stress, which is characteristic of both pathologies.    
 
1.1.3 FMO2 
In humans and most mammals the main site of FMO2 expression is the lung, where it 
is the most prominent enzyme of this tissue.  In humans, the protein is however 
mostly non-functional due to a nonsense mutation contained within an allele 
(FMO2*2).  Most humans are homozygous for FMO2*2, however the ancestral allele 
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(FMO2*1), which produces the full-length functional protein, has been identified in 
African American individuals (Dolphin et al., 1998).  In fact, it is estimated that 
around 220 million individuals in Africa express functional FMO2 (Veeramah et al., 
2008).  This has implications when considering the bioactivation functionality of the 
enzyme.  For example, thiourea and its derivatives undergo S-oxygenation catalysed 
by FMO2, resulting in exposure of the individual to more toxic metabolites.  Recent 
investigations have identified that FMO2 indeed oxygenates two anti-tubercular 
drugs, thiacetazone and ethionamide, producing harmful metabolites and reducing the 
amount of the available prodrug (Francois et al., 2009).  Therefore, great 
consideration should be taken in the prescription and distribution of therapeutics in 
Africa, which are a substrate for FMO2 mediated metabolism (Phillips et al., 2007; 
Veeramah et al., 2008).  
 
1.1.4 FMO3 
Alongside FMO1, FMO3 is one of the most important FMOs in human xenobiotic 
metabolism.  Gene expression is switched on after birth in the liver, where FMO3 
reaches concentrations close to that of the most prominent hepatic CYPs 
(Koukouritaki et al., 2002; Phillips et al., 2007).  Whereas birth appears necessary to 
induce the repression of FMO1 in the liver (described above) induction of FMO3 is 
not as tightly linked to birth; the age at which expression is switched on varies from 
birth to two years of age.  The resultant possible absence of a hepatic FMO in the first 
years of life diminishes the ability of the organism to metabolise therapeutic drugs.  
Hence, further examination of this temporal switch is required to understand the 
toxicology and efficacy of certain paediatric therapies.  Post puberty, FMO3 is not 
expressed in specifically the male mouse liver (Cherrington et al., 1998), hence the 
adult male mouse is a natural hepatic FMO3 knockout model.  
 
The FMO3 gene has gained interest in light of the disease trimethylaminuria (TMAU) 
being attributed to polymorphisms of FMO3 (Dolphin et al., 1997).  Distinct to the 
other family members, FMO3 is highly polymorphic.  Loss of function mutations 
within the gene abolishes the ability of an individual to N-oxygenate the odorous 
dietary-derived trimethylamine (TMA) to its non-odorous N-oxide.  TMA is instead 
secreted in the breath, sweat and urine of the affected individual and the disease 
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manifests as an unpleasant smell, similar to that of rotting fish (Mitchell and Smith, 
2001).  Little can be done to treat sufferers, however microbial intervention targeting 
intestinal flora that produces TMA has been recommended.  In addition, a diet 
restricted in TMA precursors, i.e. choline and lecithin, has been shown to help 
(Phillips et al., 2007). 
 
It is also expected that patients diagnosed with TMAU will have an altered response 
to therapeutics that are substrates of FMO3.  This is indeed the case in treatment of 
familial adenomatous polyposis with the pro-drug sulindac.  Inactivation of sulindac 
is, in part, catalysed by FMO3, and individuals possessing loss of function variants of 
FMO3 had a better response to sulindac treatment (Hisamuddin et al., 2005).   
 
1.1.5 FMO4 
FMO4 mRNA is found in the liver and kidney amongst many other human tissues, 
however protein expression levels are comparatively low.  Little is known about the 
enzymes substrate specificity, due to the instability of the protein preventing 
functional studies (Hernandez et al., 2004; Zhang and Cashman, 2005).   
 
1.1.6 FMO5 
Like FMO4, little is known about the substrate specificity of FMO5.  However, unlike 
FMO4, FMO5 is highly expressed in certain tissues making it a more intriguing 
isoform.  FMO5 expression has been reported in both mouse and human liver.  It was 
found to be the most predominant isoform in mouse liver and expression in humans 
nearly equaled that of FMO3, which was previously thought to be the most important 
hepatic FMO (Janmohamed et al., 2004; Zhang and Cashman, 2005).  FMO5 mRNA 
is also the most prevalent of the FMO genes in the small intestine and is expressed in 
other human tissues including brain and skin, albeit at much lower levels than the 
liver	   (Janmohamed et al., 2001; Zhang and Cashman, 2005).  The consideration of 
FMO5 as an unusual FMO will be discussed further.   	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1.1.7 An Endogenous Role of the FMOs 
As well as a role in the metabolism of xenobiotics, it is possible the enzyme family 
also serves a physiological role.  The FMOs are not normally induced by 
environmental factors and genetic factors are thought to be responsible for the inter-
individual variations reported.  Genetic variations are however very rare, often 
isolated to a single population and at a very low frequency.  The very few 
nonsynonymous mutations found, in particularly of FMO1 and FMO5, suggests a 
potential endogenous role of these FMOs (Furnes et al., 2003; Sevasti B 
Koukouritaki, 2005; Motika et al., 2007).  
 
In addition to the few diseases described above, an association with the FMOs and 
diabetes has also been recorded.  Studies show streptazoan-mediated insulin deficient 
and, to a lesser extent, congenitally insulin resistant animals have higher hepatic FMO 
activity (Rouer et al., 1988; Borbás et al., 2006).  Conversely, FMO5 expression was 
found to be downregulated in livers of type 2 diabetic patients (Takamura et al., 
2004). Functional information is however sparse and although insightful, the changes 
identified in the disease states do not clarify whether FMO modification is a cause or 
consequence of disease pathogenesis.  Regardless, it is evidence for changes in FMO 
expression and activity in disturbances of endogenous metabolism.   
 
Furthermore, although rare, some endogenous compounds have been identified as 
FMO substrates.  As described previously, specifically FMO3 metabolises dietary-
derived trimethylamine.  Methionine (Duescher et al., 1994), cysteine-s-conjugates 
(Sausen and Elfarra, 1990) and lipoic acid (Krueger and Williams, 2005) have also 
been recognised as targets of FMO mediated oxidation, however the physiological 
relevance of these catalyses remains unknown.  More interestingly, hepatic 
microsomes have shown FMOs to be capable of oxidizing cysteamine to cystamine.  
Cystamine is a powerful thiol oxidant, critical for the formation of disulphide bonds 
and correct protein assembly.  Along with its known location on the ER membrane, 
Poulsen et al. therefore proposed the FMOs to be implicated in the folding of nascent 
proteins by influencing the local oxidising environment (Poulsen and Ziegler, 1977).  
Indeed in the case of yeast, where there is only one FMO, an FMO knockout strain 
was defective in the active expression of specifically ER proteins containing 
disulphide bonds.   It is clear the lone cytosolic FMO in yeast is a fundamental part of 
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the redox machinery, as the knockout was also unable to grow in the presence of 
reducing agents (Suh et al., 1999).  Therefore, it is possible FMOs may function in a 
general endogenous capacity by regulating the thiol:disulphide ratio.   
 
Most recently, a potential ‘short-circuiting’ of the catalytic cycle has been reported of 
the FMOs.  Normally, a soft nucleophile that can gain access will react with the 
hydroperoxyflavin.  However, another uncoupled function of the enzyme exists.   
Instead of oxygenating a substrate, an FMO can also oxidise NADPH, generating a 
superoxide anion or H2O2 (figure 1.2-x).  This has been shown for FMO1, 2 and 4 and 
is surprisingly accelerated in the presence of a substrate (Siddens et al., 2014).  
Considering the ‘loaded gun’ nature of an FMO, i.e. the predominant form of the 
enzyme is the C4a hydroperoxyflavin; this continual cycling and generation of 
reactive oxygen species (ROS) may be physiologically relevant.  Therefore, in 
addition to potentially influencing the oxidising environment of a cell, FMOs may 
also contribute to the production of ROS, which are now regarded as functional 
signaling molecules themselves (Neish, 2009).   	    
Figure 1.2 - Proposed short-circuiting of the FMO catalytic 
cycle.  Association of  NADPH and the reduction of FAD (a) 
followed by  the addition of molecular oxygen results in the 
formation of the hydroperoxyflavin (b).  Instead of the 
oxygenation of a substrate (c) and release of H2O (d) oxidised 
NADPH (NADP+) and a H2O2 molecule is released (x).   
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1.1.8 FMO5 as an Atypical FMO 
FMO5 is an isoform that has gained a particular amount of attention as an atypical 
FMO.  As described previously, regardless of its pervasive expression, very little is 
known about the isoform’s function and substrate specificity and a role is yet to be 
defined for the enzyme in xenobiotic metabolism (Phillips et al., 2007).  FMO5 shows 
no catalytic activity towards known FMO substrates trimethylamine (Lang et al., 
1998), methimazole (Overby et al., 1995) and benzydamine (Lang and Rettie, 2000).  
Tertiary amine containing 5-DPT and 8-DPT are substrates for FMO5, although 
catalytic activity was much higher in the other isoforms FMO1 and 3 (Zhang et al., 
2007).  S-methyl-esonarimod is also an FMO5 substrate in both humans and mice 
(Ohmi et al., 2003; Zhang et al., 2007).   
 
Along with its substrate profile, FMO5 also differs from the other FMOs in physical 
properties such as thermal and pH stability (Krueger and Williams, 2005; Zhang et al., 
2007) and protein expression further separates the isoform from its family members.  
It is inducible; in cellular assays, FMO5 was induced following treatment with 
hyperforin (Krusekopf and Roots, 2005), a progesterone analogue (Miller et al., 1997) 
and rifampin (Rae et al., 2001), and large interindividual differences are reported 
(Overby et al., 1997).  Additionally, in contrast to other isoforms, hepatic FMO5 is 
not influenced by gender.  Cherrington et al. reported higher FMO1 activity in 
females and FMO3 is exclusively expressed in the female mouse, whereas FMO5 
expression is gender independent.   
 
Most intriguingly, FMO5 is also found to behave distinctly to the other isoforms in 
particular models of intestinal inflammation.  During murine infection with 
Citrobacter rodentium; a model of human enteropathogenic Escherichia coli infection 
that results in intestinal inflammation, unlike the reduced expression of the other 
Fmos, the level of hepatic Fmo5 mRNA was unchanged.  Characterisation of hepatic 
Fmo expression was further investigated in a mouse line lacking toll like receptor 4 
(HeJ).  Dextran sodium sulphate treatment (a chemical model of colonic 
inflammation) in HeJ mice specifically induces Fmo5 expression.  Induction of Fmo5 
suggests a specific role of the isoform in the stress response to this extreme model of 
intestinal injury.  LPS treatment resulted in downregulation of Fmos 1, 3 and 5, 
however, unlike the other orally delivered agents, LPS was injected intraperitoneally 
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(Zhang et al., 2009).  This is evidence for the FMO5 isoform being differentially 
regulated by inflammatory mediators of the intestine and, in corroboration with all 
other observed characteristics, warrants further investigation of this atypical FMO.   
 
Due to the lack of specific inhibitors, and the inefficiency of antibody-mediated 
catalytic inhibition, the further characterisation of FMOs requires the utilization of 
mouse knockout models (Shephard and Phillips, 2010).  Specific FMO mouse 
knockout models have been used to clarify the participation of particular isoforms in 
xenobiotic metabolism (Hernandez et al., 2009) and, in further investigations, have 
also highlighted a potential endogenous role of isoforms FMO1 and 5 (Veeravalli et 
al., 2014; Gonzalez Malagon et al., unpublished).  This will be further discussed in 
chapter 3.   
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1.2 INTESTINAL BACTERIA 
 
A vast array of bacteria colonises the human gastrointestinal tract.  With over a 100 
trillion microorganisms present, it is one of the most extensively populated microbial 
communities on earth (Ley et al., 2006a).  It is estimated the collection of microbes is 
comprised of more than 400 bacterial species, the number of microbial cells 
exceeding that of total human cells in the body (Palmer et al., 2007).  Within this 
community, only 8 of the known 55 bacterial divisions are represented and the 
composition is strongly dominated by two phyla; Bacteroidetes and Firmicutes 
(Bäckhed et al., 2005; Ley et al., 2006a; Krajmalnik-Brown et al., 2012).  The 
collective genomes of the bacteria residing in the gut, the microbiome, contain more 
genes than that of the host and therefore can be considered as an integral entity of the 
human body; a supplement which is now known be essential for human health.  The 
collection of microorganisms has coevolved with the host, resulting in the 
specialisation of energy harvest from the available sources (the host diet) alongside 
the adaption of the host to utilise such products (Neish, 2009; Burcelin et al., 2011).  
Amongst many proposed roles, the microbiome functions to complement the host 
genome in protection against pathogens, the production of vitamins and co-factors and 
the catabolism of dietary components which are resistant to host-mediated digestion 
(Palmer et al., 2007; Zoetendal et al., 2008; Neish, 2009; Thomas et al., 2011). 
 
Even though there are extensive inter-individual differences in the microbial 
populations of the gut, it has been speculated that there is an essential core at the 
functional (i.e. gene) level.  Despite the dynamic property of the community, with 
external factors such as diet having a dramatic effect on composition, the microbial 
population is thought to be relatively stable at the phyla level in healthy individuals 
(Palmer et al., 2007; Thomas et al., 2011; Walker et al., 2011).  Although variation at 
the species level has been observed, a cross continent study of individuals from four 
countries only identified three enterotypes.  These three classifications of the 
microbiota, which differ in routes of energy harvest related to the available substrates 
in the colon, do not appear to be nation or continent specific (Arumugam et al., 2011).  
This further demonstrates the presence of a ‘functional core’ of the microbiota, with a 
distinct number of stable host-microbial symbiotic states.   
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1.2.1 Development and Ageing 
At birth, the gastrointestinal (GI) tract is free from bacteria, however after delivery 
colonisation begins and progresses dependent on functional requirement.  It is thought 
that the infant gut microbiota is a very simple community, predominately composed 
of Lactobacillus and Bifidobacteria species. This is thought to be due, but not 
restricted, to the ability of these genera to digest human milk (Koropatkin et al., 
2012).  Given a more sophisticated requirement of the microbiota by the host, and 
hence competition therein, a more diverse population develops. Within the first two 
years of life a more complex ‘adult-like’ environment is established (Palmer et al., 
2007; Angelakis et al., 2012).  For instance, with the introduction of more complex 
components of the diet (cereals, fruits, vegetables etc.) organisms which metabolise 
the resultant glycans will prevail, namely the Bacteroidetes, Firmicutes and 
Actinobacteria phyla (Koropatkin et al., 2012).   
 
Although the establishment of the microbiota has received a lot of attention, little is 
known about the changes in the population with the progression of age in later life.  It 
is now well understood that the microbiota has a substantial role in the health of the 
host, providing nutrients and protection from pathogens (Neish, 2009). A hypothesis 
that has recently therefore emerged, is that an age-related change in composition of 
the gut microbiota may be responsible for a decline in the well-being of an individual 
and perhaps progression of disease (Biagi et al., 2010).  Limited investigations into 
this question have, however produced conflicting results with respect to the ratio of 
the two most dominant phyla in the gut, Firmicutes to Bacteroidetes (F:B).  F:B has 
been reported to increase (Mariat et al., 2009), decrease (Marathe et al., 2012) or 
remain stable with age (Biagi et al., 2010).  This phenomenon may be due to the 
varying origins of the individuals sampled or, in fact be dependent on the method of 
analysis used.  In a more detailed analysis of lower taxonomy levels however, 
significant differences were found in samples of the most aged individuals.  This 
group had a lower abundance of Bifidobacteria species and members of the clostridia 
class, both groups are thought to be beneficial in the health status of an individual.  
These changes correlated with a more inflamed status of the individual (Biagi et al., 
2010) and several other studies are in agreement with this trend, perhaps highlighting 
a new aspect of the gut microbiota (Hopkins et al., 2001; Mariat et al., 2009).  Many 
elderly people are receiving antibiotic treatment that, with an already perturbed gut 
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microbiota, may have deleterious affects.  This therefore presents a definitive time in 
which pre and probiotics should be considered to promote beneficial bacteria residing 
in the gut, with the aim of conferring advantageous health consequences.   
 
1.2.2 Energy Homeostasis 
The significance of the microbiota in host energy homeostasis is simplistically 
illustrated in the comparison of animals raised in the absence of any microorganisms 
(germ-free) and those with a microbiota developed from birth (conventionally raised).  
When compared to their age and genotype matched germ-free counterpart, 
conventionally raised animals have more body fat even though they consume less 
chow.  Introduction of the intestinal microbiota into germ-free animals 
(conventionalisation) results in an increase in body fat, and specifically epididymal fat 
pad weight, with values now equaling that of the conventionally raised animal.   
Conventionalisation of the germ-free animal was also associated with elevated plasma 
insulin and glucose and impaired insulin sensitivity and glucose tolerance (Bäckhed et 
al., 2004).  Bäckhed at al went on to show the germ-free mouse was also protected 
from diet-induced obesity and explained the difference to be a result of gut microbiota 
mediated induction of lipoprotein lipase and suppression of fatty acid oxidation in the 
conventional animal (Bäckhed et al., 2007).  Since however, the germ-free mediated 
protection from diet-induced obesity has been shown to be diet composition-
dependent and the molecular mechanisms proposed by Bäckhed et al. have been 
disputed (Fleissner et al., 2010).   
 
Regardless, from these early experiments, we know the presence of the microbiota 
can influence the intestinal absorption of dietary energy and the host genes involved 
in energy expenditure and storage.  Akin to this, an explosion of studies using 
antibiotics to reduce the microbial load of the intestine have shown an improved 
glucose tolerance in standard chow conditions (Vijay-Kumar et al., 2010; Bech-
Nielsen et al., 2012) and ameliorated metabolic consequences (i.e. weight gain, 
hyperglycaemia and impaired insulin signaling) of high-fat feeding (Membrez et al., 
2008; Cani et al., 2008a; Carvalho et al., 2012; Murphy et al., 2013).  Of note, 
consequences of these sub-therapeutic, or ‘low-dose’, defined treatment regimes are 
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converse to the growth promoting, and obesity associated outcomes associated with 
sustained antibiotic use (Ternak, 2005; Swann et al., 2011). 
 
1.2.3 Dysbioses in Disorders 
A multitude of studies have linked several disease states to a deviation from a 
functional core of the microbiota and, as a consequence, the number of functions now 
attributed to this population of organisms in host homeostasis is ever increasing.  
Disorders from Crohn’s disease (Dicksved et al., 2008) to autism (Song et al., 2004) 
have been associated with a disturbed intestinal microbiota.  The former perhaps 
unsurprisingly as Crohn’s disease is an inflammatory disorder of the gut, however, 
although cause or consequence is not clarified, the latter provides evidence for 
consideration of this population in pathologies not just concerning the digestive tract.   
 
A potential role of the gut microbiota in specifically the development of metabolic 
disorders has received a lot of interest.  Recently obesity has become a prevalent 
problem in both developing and industrialised countries, the most recent data 
indicating a staggering 68% of the population of the United States, over 20 years old, 
are obese.  It is a serious perturbed health state of an individual, often accompanied by 
the incidence of several other metabolic disorders such as type 2 diabetes, 
cardiovascular disease, inflammation and hypertension (Kallus and Brandt, 2012).  A 
simple idea is that obesity is a state resultant of energy intake far exceeding that of 
energy expenditure.  However, a consensus is emerging that some individuals seem 
more susceptible to this state than others (Krajmalnik-Brown et al., 2012; Angelakis 
et al., 2012; Kallus and Brandt, 2012).  With the intestinal bacteria identified as a 
contributor to host digestion and energy storage (Bäckhed et al., 2004; 2007), this 
population has subsequently been the focus of the search for non-canonical methods 
to alleviate the prevalence of obesity.  Indeed, changes in the microbiota (Ley et al., 
2005; Turnbaugh et al., 2009a) and its corresponding microbiome (Turnbaugh et al., 
2006) are reported in the obese state, which are thought to increase the ability of the 
host to harvest energy from the diet (Ley, 2010).   Hence, microbiota modulation was 
proposed to be a potential therapeutic intervention in obesity.  This hypothesis will be 
explored further in chapter 4.   
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Diabetes is another metabolic disorder that has been extensively linked with a 
dysbiosis of the gastrointestinal tract. Type 1 diabetes is an autoimmune disease, in 
which activated immune cells destroy insulin-producing pancreatic beta cells, and an 
importance of the gut microbiota in disease occurrence has been implied.  The 
‘Hygiene Hypothesis’ proposes that inadequate exposure to microbial antigens, and 
resultant dysregulation of immune effector cells, is detrimental.  As a result, the rise 
in autoimmune and inflammatory disorders has been attributed to the advent of 
antibacterial products producing a dysbiosis of their own (Neish, 2009; Russell et al., 
2012).  It has been shown that exposure to antigens early in life did reduce the risk of 
developing type 1 diabetes in diabetes prone rats.  Furthermore, a causative role of the 
gut microbiota in disease development was indicated when faecal flora differences 
predated the onset of diabetes in the animals (Brugman et al., 2004; 2006).  An 
additional more established link has developed between the gut microbiota and type 2 
diabetes.  Type 2 diabetes is an acquired disorder, governed by certain genetic factors 
and lifestyle, in which tissues become insulin resistant.  Insulin signaling and function 
is under the inhibitory control of inflammation.  In its expanse and proximity to the 
host intestinal cells, the intestinal microbiota has been postulated as a factor which 
would increase the inflammatory tone of an individual, thereby capable of influencing 
insulin signaling (Boroni Moreira and de Cássia Gonçalves Alfenas, 2012).  This is 
exemplified in investigations of germ-free and antibiotic treated animals (described 
above); absence and reduction of the intestinal microbiota improved parameters of 
insulin sensitivity and glucose tolerance.  The role of the microbiota in insulin 
signaling will be further explored in chapters 3 and 5.   
 
1.2.4 Host Genetics 
Although the importance of the host genome in shaping the gut microbiota has been 
presented (Zoetendal et al., 2001; Benson et al., 2010), very little information exists 
on how specific genetic variation may influence the population of bacteria in the gut.  
Mouse lines lacking either toll-like receptor 5 or resistin-like molecule β are found to 
have a different microbiota compared to their wild-type counterparts (Hildebrandt et 
al., 2009; Vijay-Kumar et al., 2010).  These findings are perhaps to be anticipated as 
these proteins are involved in intestinal homeostasis; an immune receptor of the of 
intestinal epithelial cells and a goblet cell-secreted hormone of the intestinal lumen 
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respectively.  Furthermore, mice with mutations in the leptin gene (ob/ob) (Ley et al., 
2005), leptin receptor (db/db) (Geurts et al., 2011) and PPARγ (Zuo et al., 2011) also 
present with an altered intestinal microbiota.  However, as these genetic disturbances 
are associated with the development and severity of the obese state, it remains unclear 
whether the dysbiosis is a direct consequence of genetics, or secondary to the 
perturbed energy state of an individual.  To briefly consider the reverse relationship, 
the microbiota is in fact found to be capable of modulating expression of host genes 
of predominantly, but not limited to, intestinal function (Pai and Kang, 2008; Claus et 
al., 2011; Sahasakul et al., 2012).  What has emerged as a much more dominating 
influence of bacterial composition in the human and murine gut is diet (Moreno-
Indias et al., 2014) and the influence of diet and genetics will be further described in 
chapter 4.   
 
In summary, the resident microbes of the intestinal tract clearly have a strong 
influence on host physiology; their presence alters energy absorption from the diet, 
metabolism of such energy and the maintenance of good health in an individual.  
After development, the microbiota is relatively stable and is influenced by genetics 
and even more so diet.  Although there is now a wealth of information regarding 
dysbioses occurring in disorders and unfavourable metabolic outcomes, currently 
information does not distinguish between a cause or consequence of this association.  
More recently gut transplants employed in pathologies such as Crohn’s disease 
illustrate the complexity of the paradigm.  Although a donor phenotype is 
transmittable via the transfer of gut luminal contents, ‘relapse’ to the original 
phenotype is commonly observed, thus indicating an additional host component 
(Kaila et al., 2004).  Furthermore, weight loss was not found to be a gut-transmittable 
phenotype in human faecal transplant studies, thus further questioning the microbiota 
as a source of surplus energy (DeWeerdt, 2014).  The extensive characterisation and 
description of the intestinal microbiota in different physiologies to date has been 
insightful.  However, moving forward into investigations of the functionality of the 
microbiota and its interaction with the host will prove more conclusive and necessary 
for the development of microbiota modulation as a therapeutic.    
  
	   30 
1.3 GENERAL AIMS OF THE PROJECT 
 
 
The investigations of this thesis are concerned with the characterisation of the FMO5 
KO mouse. Initially the FMO5 KO gross phenotype will be described and 
investigations will aim to further characterise the age-related changes in the glucose 
profile and insulin sensitivity of FMO5 KO and WT animals.   
 
Following ageing, the response to a high-fat diet will also be compared in the WT and 
FMO5 KO and, in the aim of targeting commensal bacteria of the intestine, a low-
dose antibiotic treatment is used to determine the role of the intestinal microbiota.   
 
The consequence of FMO5 expression in the intestine will then be considered.  The 
intestinal microbiotas of the WT and FMO5 KO mice will be characterised, along 
with the expression of FMO5 and an additional protein of interest RELMβ.  To 
further investigate the intestine as a potential site of inflammation, the inflammatory 
profiles of the WT and FMO5 KO animals will also be determined and a role of 
inflammation in insulin signaling will be discussed.    
 
Each results chapter (Chapters 3 to 5) will introduce the relevant background and 
research questions of the area of interest and detail the corresponding experimental 
findings.   
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Chapter Two: Materials and Methods 
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2.1 ANIMAL HUSBANDRY 	  
2.1.1 Mice 
A wild-type, C57BL/6J (WT), and a Fmo5(-/-) (FMO5 KO) strain that has been back-
crossed for 8 generations onto the C57BL/6 strain, were kept in the same animal 
holding room of a conventional facility and fed a standard chow diet (Harlan Teklad 
Global 2018); 18 % total protein, 5 % fat and 56 % carbohydrate, except where stated 
otherwise. The lighting schedule was, lights raised gradually 6 to 7 am, lights on full 
7am to 6pm, lights dimmed gradually 6 to 7 pm. FMO5 KO mice were previously 
created by insertional inactivation of the Fmo5 gene; Exon 2 was replaced with the 
neomycin resistance cassette via homologous recombination (Hernandez et al., 
2006b).    	  
2.1.2 Blood Collection 
Blood samples were taken between 9:30am – 12pm.  Topical anaesthetic (EMLA®) 
was applied to the tail tip and to induce vasodilation, animals were placed in a 37 ⁰C 
chamber, for a minimum of 15 minutes prior to bleeding.  Blood was then collected 
from the tail tip using EDTA or heparin coated microtubes (Sarstedt, Microvette® 
CB300).  Blood was placed on ice immediately upon collection. Blood was then 
centrifuged at 4 ⁰C for 10 minutes at 3000 g.  The top partition of plasma was then 
removed and aliquots were stored at -80 ⁰C. 
 
2.1.3 High-Fat Feeding 
At 33-weeks of age, WT and FMO5 KO animals were split into cohorts and ad 
libitum fed either a high-fat diet (Modified TestDiet® AIN-93G Rodent Diet 58M1 
with 35% kcal Fat as Lard); 22.6 % protein, 16.1 % fat and 48.6% carbohydrate or the 
standard chow diet (as above).  The diet intervention lasted 7 weeks, during which the 
animals were weighed twice weekly.  On day 41 (~week 6) the glucose tolerance test 
was performed (see 2.1.7).  After a 7-day recovery period post glucose tolerance 
testing, plasma was collected (see 2.1.2).   
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2.1.4 Antibiotic Treatment 
At 30.5–32.5 weeks of age, treatment groups of WT and FMO5 KO animals were 
given ampicillin and neomycin in their drinking water (1 g.L-1 and 0.5 g.L-1 
respectively).  Using sterilised equipment, the antibiotic was dissolved in drinking 
water and replenished twice weekly with freshly prepared solution. Animals were 
housed in the same animal room as the control groups (non-antibiotic-treated) and 
were given free access to the standard chow diet.  The antibiotic treatment lasted 4 
weeks and the animals were weighed twice weekly. On day 14 of treatment glucose 
tolerance was measured (see 2.1.7).  After a 7-day recovery period post glucose 
tolerance testing, plasma was collected (see 2.1.2).   	  
2.1.5 Faecal Sample Collection 
For microbiota analysis, faecal samples were collected from the base of the cage using 
sterile containers.  Replica faecal samples were taken from different cages, each 
housing 3 to 4 mice.  Where possible, the content of the stomach was also harvested 
ex vivo for microbiota analysis of particular conditions.  Upon collection, the slurry 
was placed immediately on ice.   
For protein analysis, freshly voided faecal pellets were collected from individual 
animals and placed immediately on ice.  Where possible, the content of the colon was 
also harvested ex vivo for protein measurements in particular conditions.  Upon 
collection, the slurry was placed immediately on ice.   
Samples were collected from male WT and FMO5 KO mice aged 7-, 10-, 15- and 30-
weeks old, and after a period of high-fat diet feeding or antibiotic treatment. Samples 
were stored at -80 °C.   
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2.1.6 Glucose Tolerance Test 
Mice were fasted overnight (15 hours) and weighed the following morning.  15 
minutes prior to the procedure, topical anaesthetic (EMLA®) was applied to the base 
of the tail of each animal.  
 
Basal Blood Glucose  
Using a sterile blade, a small incision was made within the anaesthetised area nicking 
the tail vein.  From the bleed, a drop of blood was applied to a glucose test strip 
(Bayer, CONTOUR® NEXT Test Strips) connected to a glucometer (Bayer, 
CONTOUR® XT Meter).   
 
Glucose Test 
Glucose doses were calculated to 2g/Kg of body weight and administered via 
intraperitoneal injection.  A 20 % (w/v) glucose solution (Baxter) was used for 
injection (10 µL administered per g of body weight). 
 
Time Course Measurements 
Subsequent blood glucose measurements were taken at 15, 30, 60, 90 and 120 minutes 
post glucose injection.  This was performed by reopening the initial incision and 
applying a fresh drop of blood to clean glucose test strips secured to the glucometer.   
 
Area Under the Curve (AUC) 
For statistical analysis, AUC was calculated as described previously (Heikkinen et al., 
2007):- 
 
AUC =   !!!!!! x 𝑇𝑛 + 1   −   𝑇𝑛 !"!!"!!! +min 𝐺𝑡,𝐺𝑡 + 1 − 𝐺𝑡0  
 
G: glucose concentration 
t: time 
n: time point number 
χ: total number of time points 
min(Gt,Gt+1): the lower value of two consecutive glucose concentrations 
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2.1.7 Insulin Sensitivity Test 
Mice were fasted for 5.5 hours (9 am to 14:30 pm) and then weighed.  15 minutes 
prior to the procedure, topical anaesthetic (EMLA®) was applied to the base of the 
tail of each animal.  
 
Basal Blood Glucose 
Using a sterile blade, a small incision was made within the anaesthetised area nicking 
the tail vein.  From the bleed, a drop of blood was applied to a glucose test strip 
(Bayer, CONTOUR® NEXT Test Strips) connected to a glucometer (Bayer, 
CONTOUR® XT Meter).   
 
Insulin sensitivity Test 
Insulin doses were then calculated to 0.25 IU/Kg of body weight and administered via 
intraperitoneal injection.  1000 IU/mL insulin (Actrapid®) was diluted 1:1000 in 
sterile 0.9 % (w/v) NaCl (Sigma-Aldrich®).  The working 1 IU/mL insulin solution 
was used for injection (2.5 µL administered per g of body weight). 
 
Time Course Measurements 
Subsequent blood glucose measurements were taken at 15, 30, 45, 60, 75 and 90 
minutes post insulin injection.  This was performed by reopening the initial incision 
and applying a fresh drop of blood to clean glucose test strips secured to the 
glucometer.  Percentage values of baseline glucose were then calculated for each time 
point: - 
% Baseline Glucose = !"!"!  X 100 
G: glucose concentration 
t: time 
 
Inverse Area Under the Curve (iAUC) 
For statistical analysis, inverse AUC was calculated as described previously 
(Heikkinen et al., 2007):- 
AUC =   !!!!!! x 𝑇𝑛 + 1   −   𝑇𝑛 !"!!"!!! + 𝐺𝑡0 −   max 𝐺𝑡,𝐺𝑡 + 1  
G: glucose concentration 
t: time 
n: time point number 
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χ: total number of time points 
max(Gt,Gt+1): the higher value of two consecutive glucose concentrations 
 
2.1.8 Tissue Insulin Sensitivity Test 
Animals were fasted for 5.5 hours (9 am to 14:30 pm) and weighed.  Insulin doses 
were then calculated to 0.5 U/Kg of body weight and administered via intraperitoneal 
injection.  At exactly 10 minutes post insulin injection, individual animals were culled 
by dislocation of the neck.  Using clean instruments, the animal was dissected and 
epididymal fat samples were collected.  Tissues were collected in the same order from 
each animal and always within 5 minutes post cull.  Tissue was washed in ice-cold, 
sterile phosphate buffered saline and excess liquid was carefully blotted on tissue 
paper.  Tissue samples were snap-frozen on dry ice and stored at -80 °C for further 
analysis.   
 
2.1.9 Animal Dissection and Tissue Collection 
Animals were culled by a Schedule 1 procedure according to Home Office 
regulations.  At their experimental end, mice were exposed to carbon dioxide and 
death was confirmed with dislocation of the neck.  For tissue harvest, when a more 
immediate method is required, cervical dislocation was employed.  Mice were culled 
between 9:30am and 12pm.  Clean instruments were then used to dissect and record 
the internal anatomy of the animal. In high-fat diet investigations, photographic 
records were taken.  
 
2.1.9.1 Tissues For Western Blot Protein Analysis and RNA Quantification 
Dependent on requirement, liver, muscle and epididymal fat, was collected following 
standard dissection instructions.  Tissue was washed in ice-cold, sterile phosphate 
buffered saline (PBS) (10 mM Na2HPO4, 2 mM KH2PO4, 2.7 mM KCl and 137 mM 
NaCl, pH 7.4) and excess liquid was carefully blotted on tissue paper.  In some cases, 
tissues were weighed.  For protein analysis, tissue was snap-frozen on dry ice and 
stored at -80 °C.  For RNA analysis, tissue was immersed in RNAlater® (Sigma) and 
stored at -80 °C.   	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2.1.9.2 Tissues For Immunohistological and Immunohistochemical Analyses  
For immunohistological and immunohistochemical analysis, a skin sample and 
sections of the gastrointestinal (GI) tract were harvested.  Following cull and 
dissection, a small patch of skin from the inguinal region of the mouse was taken, 
mounted on 3 MM chromatography blotting paper (Whatman™) and immersed in 10 
% (v/v) neutral buffered formalin (Leica Biosystems).  The entire GI tract (from 
stomach to anus) was then removed from the abdomen and sectioned.  Making a cut at 
the start of the duodenum, the stomach was first isolated.  Using a needled syringe, 
the tissue was inflated with 10 % (v/v) neutral buffered formalin before being placed 
directly into 10 % (v/v) neutral buffered formalin.  The small intestine was then 
liberated, by making a further cut above the cecum.  Three sections of equal length; 
denoted top (duodenum), middle (jejunum) and bottom (ileum), were partitioned and 
a transverse section from each partition was taken and placed directly into 10 % (v/v) 
neutral buffered formalin.  Making a cut just after the cecum of the remaining tract 
isolates the colon.  A transverse section of the colon was placed directly into 10 % 
(v/v) neutral buffered formalin.   
 
To assess morphological and histochemical differences along the length of the 
digestive tract, Swiss rolls were then prepared from the duodenum and ileum portions 
of the small intestine and colon as previously described (Moolenbeek and Ruitenberg, 
1981; Park et al., 1987).  The mesentery was first stripped and each segment was then 
slit open longitudinally and washed with PBS.  Faecal contents were removed by 
gently sweeping the mucosa with a clean instrument.   Fine-pointed forceps were used 
to pinch the caudal end of the segment and, with the mucosa remaining on the outside, 
the tissue was wound around the forceps and itself.  Sufficient tension was used to 
prevent the butterflied lumen re-adhering to itself, hence maintaining the outer edge 
flat.  The strip of tissue remained aligned during rolling, further ensuring the complete 
spiral structure in later sectioning.  Once fully rolled, a needle was used to impale the 
entire structure and liberate the roll from the forceps.  Together, this was fixed in 10 
% (v/v) neutral buffered formalin.   
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2.2 PLASMA MEASUREMENTS AND BIOCHEMICAL ANALYSES 
 
2.2.1 Glucose 
Plasma glucose was measured by applying a drop of blood to a glucose test strip 
(Bayer, CONTOUR® NEXT Test Strips) connected to a glucometer (Bayer, 
CONTOUR® XT Meter). 
 
2.2.2 Insulin 
Plasma insulin was quantified using an enzyme-linked immunosorbant assay (ELISA) 
(Millipore, Rat / Mouse Insulin Elisa). Manufacturer’s instructions were followed.  
Plasma was applied to a microtiter plate pre-coated with a monoclonal antibody to 
mouse insulin, allowing plasma insulin to be captured and immobilised on the plate.  
After washing, a second detection antibody was added to the plate, linking the 
immobilised complex to horseradish peroxidase.  Following the addition of a 
chromogenic substrate, horseradish peroxidase catalyses a colorimetric reaction which 
can be measured photometrically.  Absorbance at 450 nm is therefore proportional to 
the amount of detected insulin.  Concentrations of unknown samples are interpolated 
from a standard curve of absorbance values from solutions of known concentration. 
 
2.2.3 Lipopolysaccharide (LPS) 
Plasma LPS (or endotoxin) was measured at Lonza Endotoxin Service Europe.  The 
Limulus Amebocyte Lysate (LAL) test was used for endotoxin quantification.  
Endotoxin, from the outer membrane of gram-negative bacteria, converts a 
proenzyme of LAL into an active enzyme.  The active enzyme will then catalyse the 
release of p-nitroaniline from a synthetic substrate, producing a yellow colour.   
Enzyme activation, hence endotoxin concentration, can therefore be quantified 
photometrically.   
Plasma samples were heat inactivated for 10 minutes at 72 °C and diluted 1:40 in 
endotoxin free water (Lonza).  Diluted plasma samples were mixed with LAL and 
incubated with the substrate.  Resultant absorbance at 410 nm is proportional to the 
amount of endotoxin in the original sample.  Endotoxin concentrations of unknown 
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samples were interpolated from a standard curve, generated from absorbance values 
of known concentrations.   
2.2.4 Resistin Like Molecule β (RELMβ) 
Plasma levels of resistin like molecule β (RELMβ) were measured using an enzyme-
linked immunosorbant assay (ELISA) (MyBiosource, Mouse Resistin Like β ELISA).  
Plasma samples were diluted 1:10 in phosphate buffered saline (PBS) (137 mM NaCl, 
2.7 KCl, 10 mM Na2HPO4, 1.8 mM KH2PO4) and manufacturer’s instructions were 
followed.  The diluted plasma was applied to a plate pre-coated with a RELMβ 
antibody.  After washing, a second detection antibody was then applied to the plate, 
linking horseradish peroxidase to the immobilised antigen-antibody complex.  
Following the addition of the enzyme substrate, a colour change occurs proportional 
to the amount of immobilised enzyme, hence antigen present.  Concentrations of 
unknown samples are then interpolated from a standard curve, generated by samples 
of known concentration.   
2.2.5 Tumour Necrosis Factor α (TNFα) 
TNFα was quantified using an ELISA (Enzo, TNFα mouse EIA kit).  Plasma was 
diluted 1:8 in the assay buffer provided and manufacturer’s instructions were 
followed.  Diluted plasma was applied to a microtiter plate pre-coated with a 
monoclonal antibody to mouse TNFα.  After washing, a second anti- TNFα antibody 
is applied to wells, binding the captured TNFα.  A detection antibody conjugated to 
horseradish peroxidase is then incubated, linking the immobilised complex to a 
colourmetric reaction.  Addition of enzyme substrate results in a colour change, 
proportional to the amount of TNFα present, which can be measured at 450 nm.  
Concentrations of samples are interpolated from a standard curve, generated by 
standards of known TNFα concentration.   
 
2.2.6 Lipid Profiling 
An Olympus Diagnostic Systems AU400 Automated Clinical Chemistry Analyzer, 
equipped with an ion selective electrode, was used to measure plasma lipids.  Plasma 
samples were analysed at the Medical Research Council Mammalian Genomics Unit 
in Harwell, Oxfordshire as described previously (Hough et al., 2002).  Levels of total 
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cholesterol, HDL cholesterol, LDL cholesterol, triglycerides, free fatty acids and 
glycerol were quantified.   
 
2.3 INTESTINAL MICROBIOTA ANALYSIS 
 
Despite the highly conserved sequence of the 16S rRNA gene in bacteria, it contains 
nine variable regions that can be utilised in comparative sequence analysis to classify 
microbial species (Ludwig and Schleifer, 1994; Zoetendal et al., 2008; Hamady and 
Knight, 2009; Rajendhran and Gunasekaran, 2011).  In conjunction with the rich 
databases available, 16S rRNA sequences isolated from faecal matter can therefore be 
used to assay the microbial diversity of the gastrointestinal tract of the mouse.   
 
2.3.1 Isolation of Faecal DNA 
DNA was isolated from faecal samples using a commercially available kit (Isolate 
Faecal DNA Kit, Bioline).  Three faecal pellets (~150 mg), harvested from the same 
cage, were used for each sample and duplicate or triplicate samples were performed 
per condition.  For stomach content analysis, samples from 3 individual animals were 
pooled and 140 mg of slurry was used.  Manufacturer’s instructions were followed.  
As samples had been frozen prior to processing, sufficient homogenisation required 
an additional 30 minutes of shaking, after addition of lysis buffer.  Homogenates were 
centrifuged and a spin column was used to filter the lysate supernatant. The flow 
through was applied to a separate column to bind DNA.  Bound DNA was then 
washed before being eluted.  The DNA solution was then re-filtered using a spin 
column and heated at 80 °C for 20 minutes to denature any DNases present.  DNA 
Extraction was confirmed with a 0.8 % agarose gel electrophoresis and samples were 
then stored at 4 °C.   
 
2.3.2 Selection of Primers 
Using available, online tools such as the Probe Match function of the Ribosomal 
Database Project (RDP) (http://rdp.cme.msu.edu/probematch/search.jsp) (Cole et al., 
2009) and Blast (http://blast.ncbi.nlm.nih.gov/Blast.cgi), all currently available 
universal bacterial 16S rRNA primers were ranked on their coverage.  Queries, using 
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both forward and reverse primers, were conducted to identify the pair that would 
amplify the most bacterial 16S rRNA genes sequences and specifically only amplify 
this gene.  In conjunction with a literature search for compatibility information, 
forward primer 8FE (5’-AGAGTTTGATCCTGGCTCAG-3’) and reverse primer 
1387FE (5’-GGGCGGTGTGTACAAGGC-3’) were selected and synthesized by 
MWG. 
2.3.3 Polymerase Chain Reaction (PCR) Amplification of 16S rRNA Gene 
Sequences 
The bacterial 16S rRNA gene sequences were specifically amplified using the 
universal 16S rRNA primer pair 8FE and 1387FE.  PCR conditions consisted of a 5-
minute ‘hot start’ at 95 °C.  This was followed by 30 cycles; 95 °C for 1 minute, 51 
°C for 1 minute and 72 °C for 1 minute, and a final elongation at 72 °C for 5 minutes.  
5 pmoles of each primer and approximately 16ng of isolated DNA (see 2.3.1) was 
used per 25 µL reaction.  Each reaction included 2.5 µL dNTPS (10 mM), 0.25 µL 
BioTaq polymerase (5 U.µL-1), 0.75 µL of MgCl2 (50 mM) and 2.5 µL of 10X NH4 
buffer.  DNA amplification was confirmed with a 1 % agarose gel electrophoresis and 
the samples were stored at -20 °C.   
 
2.3.4 Ligation of 16S rRNA Gene Sequences 
PCR products (see 2.4.3) were ligated into the pGEM-T vector system (Promega) and 
the manufacturer’s instructions were followed.  3 µL of amplified DNA (~100 ng) 
was added to the ligation reaction, containing 1 µL of vector (50 ng.µL -1), to achieve 
an insert: vector ratio of 2:1. The reaction was left at room temperature for 30 minutes 
and then overnight (16 hours) at 4 °C.  Samples were then stored at -20 °C.  
 
2.3.5 Preparation of Chemically Competent Cells 
10 mL of Luria Broth (LB) with MgCl2  (1 % w/v tryptone, 0.5 % w/v yeast extract, 1 
% w/v NaCl, 20mM MgCl2, pH 7.5) was inoculated with a single colony of 
Escherichia coli	  DH5α.  Cultures were grown overnight, shaking at 37 °C.  The 10 
mL culture was then reinoculated into 500 mL LB with MgCl2 and left shaking at 37 
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°C.  When an OD600 of 0.3-0.4 was reached (~2-3 hours), cultures were cooled on ice 
for 30 minutes and kept at 4 °C for all subsequent steps.  Cells were centrifuged at 
10,000 g for 10 minutes at 4 °C. The supernatant was discarded and the resultant 
pellet resuspended in 100 mL of 75 mM ice-cold CaCl2.  The cell suspension was then 
centrifuged again at 10,000 g for 10 minutes at 4 °C.  The supernatant was discarded 
and the resultant pellet resuspended in 12.5 mL of 75 mM ice-cold CaCl2. The cell 
suspension was transferred to chilled microcentrifuge tubes and aliquots were snap-
frozen in a dry ice-ethanol bath and stored at -80 °C until required.   
 
2.3.6 Transformation of Chemically Competent Cells 
5 μL of the ligated DNA product (see 2.3.4) was added to chilled microcentrifuge 
tubes.  20 ng of pUC19 DNA was also added to a positive control tube.  An aliquot of 
chemically competent cells (see 2.3.5) was thawed on ice and 50 μL of the cell 
suspension was added to each DNA tube, followed by a gentle mix.  Reactions were 
left on ice for 20 minutes and then heat shocked at 42 °C for 50 seconds.  This was 
followed by a further 2-minute incubation on ice, after which the sample was 
transferred into 500 µL super optimal broth with catabolite repression (SOC) (2% w/v 
tryptone, 0.5% w/v yeast extract, 0.5 % w/v NaCl, 10 mM MgCl2, 2.5 mM KCl, 20 
mM glucose) at room temperature.  Cultures were left to recover at 37 °C with 
shaking for 1 hour.  After recovery, cells were plated on LB-Agar (1 % w/v tryptone, 
0.5 % w/v yeast extract, 1 % w/v NaCl, 1.5 % w/v agar, pH 7.5) containing ampicillin 
(100 µg.mL-1), X-gal (40 µg.mL-1) and IPTG (0.1 mM).  Plates were grown overnight 
(16 hours) at 37 °C. 
 
2.3.7 Preparation of Electrocompetent Cells 
A single colony of Escherichia coli JM109 was inoculated into 5mL of LB medium (1 
% w/v tryptone, 1 % w/v NaCl, 0.5 % w/v yeast extract, pH 7.5) and grown overnight 
at 37 °C with shaking.  1 mL of culture was reinoculated into 200 mL LB and grown 
at 37 °C with shaking until an OD600 of 0.5 was reached (~4 hours).  Cells were then 
chilled for 30 minutes on ice.  Cells were kept at 4 °C for all subsequent steps.  Cells 
were centrifuged at 5500 g for 10 minutes at 4 °C and the supernatant was discarded.  
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The pellet was resuspended in a small volume of ice-cold water, mixed with 200 mL 
of ice-cold water and chilled for 10 minutes.  The cells were centrifuged at 15,000 g 
for 10 minutes at 4 °C.  The supernatant was immediately discarded and the pellet 
was resuspended in the residual liquid.  Another 200 mL of ice-cold water was added 
and the cells were chilled for 10 minutes before being centrifuged for at 15,000 g for 
10 minutes at 4 °C.  The supernatant was discarded immediately and the pellet was 
resuspended in the residual liquid.  The cells were resuspended in an equivalent 
amount of ice-cold 10 % glycerol, aliquoted into pre-chilled microcentrifuge tubes 
and frozen in a dry ice-ethanol bath.  Cell aliquots were then stored at -80 °C until 
required. 
 
2.3.8 Transformation of Electrocompetent Cells 
An aliquot of electrocompetent cells (see 2.3.7) was thawed on ice.  7 µL of ligated 
DNA product (see 2.3.4) was added to 100 µL of electrocompetent cells on ice.   For 
a positive control, 40 pg of pUC19 DNA was also added to 100 µL of 
electrocompetent cells.  DNA-cell suspensions were then transferred to individual 
pre-chilled electroporation cuvettes (BioRad, gap width 2mm).  Once placed in the 
sample chamber of the electroporator (BioRad, Gene Pulser™), a pulse was applied 
(2.5 kV, resistance: 200 ohms, capacitance: 25 μFD). Cells were then immediately 
transferred to 600 µL SOC at room temperature and incubated without shaking at 37 
°C for 1 hour.  Cells were plated on LB-Agar (1 % w/v tryptone, 0.5 % w/v yeast 
extract, 1 % w/v NaCl, 1.5 % w/v agar, pH 7.5) containing ampicillin (100 µg.mL-1), 
X-gal (40 µg.mL-1) and IPTG (0.1 mM).  Plates were grown overnight (16 hours) at 
37 °C. 
 
2.3.9 Selection of Successful Transformants 
Growth plates from transformation procedures (see 2.3.6 and 2.3.8) were used to 
screen for successful transformants.  The pGEM-T vector contains the ampicillin 
resistance gene (Figure 2.1).  Therefore, LB-agar containing ampicillin will only 
allow growth of bacteria which have been transformed with pGEM-T.   
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Figure 2.1 – pGEMT vector.  The vector contains the ampicillin resistance gene 
(Ampr). The β-galactosidase gene (lacZ), under the control of the lac operon, is 
interrupted by the multiple cloning site.  (Taken from pGEM®-T and pGEM®-T 
Easy Vector Systems Technical Manual, Promega) 
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The ligation reaction (see 2.3.4) does not result in a homogeneous solution of positive 
ligations (vector containing insert); the vector may self ligate with no insert.  
Therefore it is necessary to screen for transformants which have specifically taken up 
plasmids containing inserts. 
The vector contains the β-galactosidase gene under the control of the lac operon.  The 
multiple cloning site of pGEM-T is however situated within the gene sequence.  
Ligation of an insert into the vector will subsequently interrupt the gene.  Therefore, 
due to the presence of IPTG; an inducer of the lac operon, and X-gal; a substrate of β-
galactosidase in the growth medium, we are also able to identify bacteria which have 
been transformed with an empty vector.   
X-gal is cleaved by β-galactosidase, producing galactose and 5-bromo-4-chloro-3-
hydroxyindole.  5-bromo-4-chloro-3-hydroxyindole immediately dimerises, resulting 
in a blue product.  A blue colony on the growth plate therefore indicates 
transformation of the pGEM-T plasmid with uninterrupted β-galactosidase 
expression, hence no insert.  Conversely, white colonies indicate clones, which have 
taken up the pGEM-T vector without functional β-galactosidase, hence containing an 
insert.     
White colonies were therefore picked and stabbed into 96-well microtiter plates of 
LB-agar containing ampicillin (100 µg.mL-1).  Plates were incubated overnight (16 
hours) at 37 °C.  Plates were then further processed at LGC Genomics.  An automated 
service of plasmid extraction and Sanger sequencing of insert DNA provided us with 
sequence reads of around 1200 bp for each isolate.  Single read sequencing was 
performed with the pGEM1 primer (5’-CGACTCACTATAGGGCGAATTGGG-3’).   
 
2.3.10 Phylogeny Classification 
Sequence alignments were performed for all isolates using the Ribosomal Database 
Project (RDP) (http://rdp.cme.msu.edu).  Sequence sets from each condition were 
compared to the RDP library of known 16S rRNA gene sequences and classifications 
above an 80 % confidence threshold were recorded.  
  
	   46 
2.4 WESTERN BLOT ANALYSIS 
 
Gel electrophoresis allows the separation of proteins according to their molecular 
weight.  Biological samples are loaded into polyacrylamide gels and application of a 
current results in the migration of proteins, through the gel matrix, proportional to 
protein size.  Separated proteins can then be transferred onto membranes, which are 
probed with antibodies against proteins of interest.  Western blot analysis was used to 
compare the presence, abundance and oligomeric state of different protein targets in 
various biological samples.   
 
2.4.1 Sample Collection Protein Isolation 
WT and FMO5 KO mice of different ages, or following different treatments, were 
culled and appropriate tissues were collected as described above (see 2.1.9 and 
2.1.10).  Faecal samples and the contents of the colon were also collected from WT 
and FMO5 KO mice of different ages, or following different treatments (2.1.5).  
Tissues and faecal samples were stored at -80 °C.   
 
2.4.1.1  Liver 
Liver samples were placed on ice and, using clean implements, 5-10 mg of tissue was 
weighed and immersed immediately in 1mL aliquots of ice-cold Triton lysis buffer 
(1% Triton X-100, 140 mM NaCl, 10 mM Tris pH8, 1 mM EDTA, 1 mM PMSF) 
containing Halt™ Protease and Phosphatase Inhibitor Cocktail (Thermo Scientific).  
A 5 mm stainless steel bead was placed into each sample and tubes were loaded into 
the Tissue Lyser II (Qiagen).  Samples were homogenised at 25 Hz for 30 seconds, 
left to cool on ice for 1 minute and homogenised for a further 30 seconds at 25 Hz.  
To ensure complete homogenisation, samples were rotated on a spinning wheel at 4 
°C for 15 minutes.   
Homogenates were then spun in a microcentrifuge for 20 minutes at 12,000 g, 4 °C.  
The supernatant was transferred into a clean microcentrifuge tube and the pellet was 
discarded.   
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2.4.1.2  Epididymal Adipose Tissue 
Epididymal adipose tissue samples were placed on ice and clean implements were 
used to weigh 10 mg of tissue.  Weighed tissue was immediately immersed in 1 mL 
aliquots of ice-cold Triton lysis buffer (1% Triton X-100, 140 mM NaCl, 10 mM Tris 
pH8, 1 mM EDTA, 1 mM PMSF) containing Halt™ Protease and Phosphatase 
Inhibitor Cocktail (Thermo Scientific).  A 5 mm stainless steel bead was placed into 
each sample and tubes were loaded into the Tissue Lyser II (Qiagen).  Samples were 
homogenised at 25 Hz for 30 seconds, left to cool on ice for 1 minute and 
homogenised for a further 30 seconds at 25 Hz.  To ensure complete homogenisation, 
samples were rotated on a spinning wheel at 4 °C for 15 minutes.   
Homogenates were then spun in a microcentrifuge for 20 minutes at 12,000 g, 4 °C.  
Due to the origin of the sample, the homogenate is rich in lipid, with a thick layer 
visible at top of the supernatant.  To obtain the supernatant, whilst avoiding the fat 
layer, a needle attached to a syringe was used to carefully transfer the protein fraction 
to a clean microcentrifuge tube.  During transfer, inclusion of a small amount of fat is 
inevitable.  Therefore, to further dilute out the fat from the sample, two more spins 
were conducted.  Samples were spun for 5 minutes at 12,000 g, 4 °C to separate the 
lipid layer and a needled syringe was again used to transfer the supernatant whilst 
avoiding the fat.  This was repeated for a total of two times, after which a 5-minute 
spin formed no visible lipid layer.   
 
2.4.1.3  Faecal and Colonic Samples 
Faecal or colonic samples were place on ice and 30-60 mg of matter was immersed in 
1 mL aliquots of ice-cold Triton lysis buffer (1% Triton X-100, 140 mM NaCl, 10 
mM Tris pH8, 1 mM EDTA, 1 mM PMSF) containing Halt™ Protease and 
Phosphatase Inhibitor Cocktail (Thermo Scientific).  A 5 mm stainless steel bead was 
placed into each sample and tubes were loaded into the Tissue Lyser II (Qiagen).  
Samples were homogenised at 25 Hz for 30 seconds, left to cool on ice for 1 minute 
and homogenised for a further 30 seconds at 25 Hz.  To ensure complete 
homogenisation, samples were rotated on a spinning wheel at 4 °C for 40 minutes.   
Homogenates were then spun in a microcentrifuge for 20 minutes at 12,000 g, 4 °C.  
As the resultant pellet was very soft and prone to resuspend, the supernatant was 
quickly transferred into a clean microcentrifuge tube and the pellet was discarded.   
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2.4.2 Protein Precipitation 
When probing for certain targets in biological samples, it was necessary to first 
precipitate the protein.  Pelleted protein can then be resuspended in a small volume of 
compatible buffer, resulting in a more concentrated solution of the original proteins 
present.   
After protein isolation (see 2.4.1), the equivalent volume of ice-cold 20 % 
trichloroacetic acid was added to homogenates to a final concentration of 10 % (v/v).  
Samples were incubated at 4 °C for 10 minutes and centrifuged for 5 minutes at 
14,000 g, 4 °C.  The supernatant was removed and discarded, leaving the protein 
pellet intact.  The pellet was then washed in 200 µL ice-cold acetone, tubes were 
vortexed for 10 seconds so as to disturb, but not dissolve, the pellet.  Samples were 
then centrifuged for 5 minutes at 14,000 g, 4 °C.  Taking precaution to not disturb the 
resultant pellet, the supernatant was removed and discarded.  A further acetone wash 
was conducted; 200 µL ice-cold acetone was added and the tubes were briefly 
vortexed before a 5 minute centrifuge at 14,000 g, 4 °C.   Samples were then heated at 
95 °C for 5 minutes to evaporate the majority of the acetone, whilst not completely 
drying the pellet.  When all that remained was a wet pellet (~ 10 µL residual acetone), 
50 µL of resuspension buffer (6 M urea, 0.5 % SDS, 50 mM TrisHCL pH6.8, 5 mM 
EDTA) was added.  To resuspend the pellet, the samples were heated for 10 minutes 
at 95 °C and briefly vortexed and centrifuged.  A further 7-minute heat, followed by a 
vortex resulted in resuspension.   
 
2.4.3 Protein Determination by BCA assay 
The bicinchoninic acid (BCA) assay couples the reduction of Cu2+ to Cu1+ by protein, 
with the specific colorimetric detection of the cuprous cation (Cu1+) by BCA.  BCA is 
a chromogenic compound: chelation of reduced copper atoms produces a colour 
change, which can be measured photometrically at 562 nm.  Absorbance at 562 nm is 
therefore linearly related to the protein concentration of the sample.  A set of bovine 
serum albumin standards, of known concentrations, is used to generate a standard 
curve from which the concentration of unknown samples can be interpolated.   
The Pierce® BCA Protein Assay Kit (Thermo Scientific) was used for measurement 
and the manufacturer’s instructions were followed.  Standards and samples to be 
measured were applied to a microtiter plate in duplicate.  A solution containing 
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bicinchoninic acid and cupric sulphate was then added to all reactions and the plate 
was incubated at 37 °C for 30 minutes.  Absorbance was read at 562 nm and the 
concentrations of the unknowns were calculated.   
2.4.4 Protein Determination by Coomassie Protein Assay 
For protein determination of samples originating from adipose tissue, the BCA assay 
(see 2.4.3) was found to be inappropriate.  Although care was taken to eliminate the 
maximum amount of lipid possible, residual fat in the samples interfered with the 
method of detection resulting in variable and invalid protein concentration readings.  
Instead, a coomassie-based assay was used for adipose tissue homogenates.   
The Pierce Coomassie Protein Assay (Thermo Scientific) is a stable solution of the 
Bradford assay reagent, used to measure protein concentration at 595 nm.  The 
Bradford assay reagent, acidic Coomassie Brilliant Blue G-250, changes maximum 
absorbance from 465 nm to 595 nm upon binding to protein.  A set of bovine serum 
albumin standards, of known concentrations, is used to generate a standard curve from 
which the concentration of unknown samples can be interpolated. 
1 mL of the coomassie reagent was dispensed into the required number of cuvettes.  1 
µL of standard or sample was dispensed into each cuvette and the reactions were 
mixed by inversion.  Absorbance was read at 595 nm and the concentrations of the 
unknowns were determined.    
 
2.4.5 Sample Preparation for Electrophoresis 
Correct sample volumes required for a defined amount of protein were calculated 
using results of the BCA (see 2.4.3) or Coomassie Protein Assay (see 2.4.4).  Sample 
volumes were then normalised using distilled, deionised water, and mixed with 4X 
sample buffer to a final concentration of 1X.  Samples were heated for 6 minutes at 95 
°C. 
All samples prepared for electrophoresis were denatured and, depending on the 
protein target, either reduced on non-reduced.  For reducing conditions the samples 
were mixed with a 4X sample buffer containing a reducing agent (200 mM Tris pH 
6.8, 40 % (v/v) glycerol, 8 % (w/v) SDS, 1 % (w/v) bromophenol blue, 400 mM 
DTT) and for non-reducing conditions 4X sample buffer without reducing agent was 
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used (200 mM Tris pH 6.8, 40 % (v/v) glycerol, 8 % (w/v) SDS, 1  % (w/v) 
bromophenol blue). 
2.4.6 Electrophoresis 
The Mini-PROTEAN® Tetra Cell System from BioRad was used for sodium dodecyl 
sulphate polyacrylamide gel electrophoresis (SDS-PAGE).  Proteins were separated 
by the mini-vertical electrophoresis system and the manufacturer’s instructions were 
followed.  Briefly, precast gels (Mini-PROTEAN® TGX™ gels, BioRad) were 
securely fixed into the inner cell and immersed in running buffer (0.1 % (w/v) SDS, 
25 mM Tris, 192 mM glycine).   The bottom of the tank was also filled with running 
buffer, ensuring electrodes are too immersed in buffer.  Precision Plus Protein™ Dual 
Colour Standards (BioRad) and MagicMark™ XP Western Protein Standard 
(Invitrogen) were loaded to allow visual and chemiluminescent detection of protein 
size respectively.  Prepared samples (see 2.4.5) were then loaded into the appropriate 
wells.  Application of the tank lid locks the mini-cell and connects the system to a 
power pack.  The gel was run at 150 V for 50 minutes.  Depending on the size of the 
target protein, different percentage gels were selected.  For proteins larger than 30 
kDa, 10 % precast gels were used, however for the separation of smaller proteins (<20 
kDa), samples were run on 4- 12 % gradient gels.   
 
2.4.7 Protein Transfer 
The presence of SDS in sample and running buffers during electrophoresis imparts a 
negative charge to separated proteins.  Charged, immobilised proteins can therefore 
be transferred from the gel to a membrane with the application of an electric current.   
The Trans-Blot® Turbo™ Transfer System (BioRad) was used for transfer.  The gel 
to be analysed was freed from the electrophoresis equipment and the manufacturer’s 
instructions were followed.  A Trans-Blot® Turbo™ Transfer pack was loaded into 
the cassette; a nitrocellulose membrane on top of soaked filter paper was placed into 
the Trans-Blot® cell and the gel was carefully placed on top, ensuring complete 
contact with the membrane and no bubbles.  A further layer of soaked filter paper was 
placed on top, the cassette was closed and loaded into the transfer system.  The 
transfer was run at 1.3 A, 25 V for 7 minutes.   
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2.4.8 Blocking of the Membrane 
Membranes have a high affinity for protein binding.   Therefore it is necessary to first 
block non-specific interactions between the membrane and detection antibodies.  This 
is achieved by incubating the membrane in a dilute solution of protein, which will 
cover the unbound membrane however leave transferred proteins unmasked.   
Without letting the membrane dry, immediately after transfer, the membrane was 
placed in blocking buffer.  Depending on the following method of detection, the 
membrane was blocked in the appropriate buffer.   
 
2.4.8.1  Bovine Serum Albumin 
For chemiluminescent detection of proteins with polyclonal antibodies raised against 
proteins, membranes were blocked with bovine serum albumin (BSA).  A 5 % (w/v) 
solution of BSA was prepared in Tris-buffered saline (TBS) (150 mM NaCl, 10 mM 
Tris-Cl pH 7.5) with 0.1% Tween20 (TBS-T).  In a clean vessel, the membrane was 
immersed in 5 % (w/v) BSA and incubated for 1 hour at room temperature.   
 
2.4.8.2  Non- Fat Dried Milk 
For chemiluminescent detection of RELMβ with the polyclonal antibody raised 
against the peptide sequence (Abcam® ab11429), 5 % (w/v) BSA was found to be 
insufficient and membranes were instead blocked with non-fat dried milk (NFDM).  
A 5 % (w/v) solution of NFDM was prepared in TBS-T and the membrane was 
incubated for 1 hour at room temperature.   
 
2.4.8.3  Odyssey® Blocking Buffer  
For fluorescent detection of proteins with antibodies conjugated to fluorophores, a 
commercially available blocking buffer, Odyssey® Blocking Buffer (LI-COR), was 
used.  The membrane was immersed in solution and incubated for 1 hour at room 
temperature.   
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2.4.9 Incubation with Primary Antibody 
After sufficient blocking, the membrane was washed in TBS-T.  In a clean vessel, the 
membrane was immersed in TBS-T and rocked at room temperature for 5 minutes.  
Three quick rinses in TBS-T followed and this was repeated twice, for a total of three 
washes.  Using manufacturer’s instructions for guidance, primary antibody was 
diluted in the specific blocking buffer used in the previous step (see 2.4.8).  In 
accordance with manufacturer’s instruction, for dilution of the primary antibody, the 
Odyssey® Blocking Buffer was supplemented with 0.1 % Tween20. 
 
Antigen (Manufacturer, Catalogue No.) Sample Analysed Dilution 
Complement Component 3 (Calbiochem®, 204869) 
Epididymal adipose tissue 
 
1:1,000 
 
Enolase (Santa Cruz Biotechnology®, sc-15343) 
 
Epididymal adipose tissue 
 
1:200 
  
Faecal sample 
 
1:1,500 
 
FMO5 (Proteintech™, 16864-1-AP) 
 
Liver 
 
1:4,500 
 
Phospho-Akt (Ser473) (Cell Signalling Technology®, 9271) 
 
Epididymal adipose tissue 
 
1:1000 
 
 
 
Colon contents 
 
1:10,000 
 
RELMβ (Abcam®, ab11429) 
 
Faecal sample 
 
1:10,000 
 
 
 
Colon contents 
 
1:15,000 
 
RELMβ (QED Bioscience, 20805) 
 
Faecal sample 
 
1:1,500 
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Membranes were immersed in the appropriate dilution of primary antibody and 
incubated overnight (16 hours) at 4 °C with gentle rocking.   
 
2.4.10 Incubations with Secondary Antibody 
Following primary antibody incubation, the membranes were first washed to remove 
any unbound antibody.  The membrane was immersed in TBS-T and rocked at room 
temperature for 10 minutes.  Three quick rinses in TBS-T followed and this was 
repeated twice, for a total of three washes.   
All primary antibodies used were raised in rabbit.  Therefore, dependent on the 
method of detection to follow, either fluorescently labeled or horseradish peroxidase 
conjugated anti-rabbit secondary antibodies were used.   
 
2.4.10.1 Fluorescent Secondary Antibody 
An anti-rabbit antibody coupled to a fluorescent dye (Alexa Fluor® 790 Goat Anti-
Rabbit IgG (H+L), Invitrogen) was diluted 1:5000 in Odyssey® Blocking Buffer 
supplemented with 0.1% Tween20.  Membranes were immersed in secondary 
antibody and incubated for 1 hour at room temperature with rocking.   
 
2.4.10.2 Horseradish Peroxidase Conjugated Antibody 
An anti-rabbit antibody conjugated to horseradish peroxidase (HRP) (Donkey Anti-
Rabbit IgG H+L (HRP), Abcam) was diluted 1:15,000 in TBS-T.  Membranes were 
immersed in secondary antibody and incubated for 1 hour at room temperature with 
rocking.   
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2.4.11 Detection Methods 
After incubation with secondary antibody, the membranes were washed to remove 
any unbound antibody.  The membrane was immersed in TBS-T and rocked at room 
temperature for 10 minutes.  Three quick rinses in TBS-T followed and this was 
repeated twice, for a total of three washes.   
 
2.4.11.1 Fluorescent Antibody Detection 
A fluorescent dye label allows the rapid detection of an antibody-antigen complex on 
the membrane.  After washing the blot was scanned, at the appropriate wavelength, 
using the LiCor® Odyssey® Fc Dual-Mode Imaging System. 
 
2.4.11.2 Enhanced Chemiluminescence  
For detection of HRP antibody conjugates, enhanced chemiluminescence (ECL) was 
used.  Enzyme immobilised to the membrane, mediated by the antigen-antibody 
complex, catalyses the oxidation of luminol emitting light at 428 nm.  The addition of 
an enhancer further amplifies the light emitted and this enables detection of antigen-
antibody interactions on the membrane. 
Equivalent volumes of ECL reagent 1 (1.25 mM luminol, 2 mM 4-iodophenylboronic 
acid, 100 mM Tris-HCL pH 8.5) and ECL reagent 2 (5.3 mM H2O2, 100 mM Tris-
HCL pH 8.5) were mixed.  Enough solution was used to cover the membrane evenly 
and the reaction was left to develop for 1 minute, protected from light.  The blot was 
then exposed and the image captured using the LiCor® Odyssey® Fc Dual-Mode 
Imaging System.   
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2.5 HISTOLOGY AND IMMUNOHISTOCHEMISTRY 
 
2.5.1 Embedding and Cutting 
Fixed tissues (see 2.1.10) were sent to the Medical Research Council Anatomical 
Pathology Group in Harwell, where they were embedded and cut.  The Shandon 
Pathcentre™ tissue processor was used to embed tissues.  A programme gave five 
changes of graded alcohol over 6 hours, four changes of SubX (Leica Biosystems) 
clearing over 5.5 hours and four changes of wax over 4 hours.  Sections were then cut 
on a Shandon™ Finesse™ Microtome™ at 3 µm and collected from a water bath onto 
plain slides.  Slides were dried overnight at 37 °C.   
 
2.5.2 Hematoxylin and Eosin Staining 
Nucleic acid stain hematoxylin and protein stain eosin are used together to investigate 
cell and tissue morphology, staining the nucleus blue and cytoplasm pink 
respectively. Hematoxylin and eosin staining was conducted at the Medical Research 
Council Anatomical Pathology Group, Harwell.  Slides were stained on a Sakura® 
Tissue-Tek® DRS™ Slide Stainer using Shandon™ Gill™ 3 Hematoxylin and 
Shandon™ Eosin Y.   
 
2.5.3 Alcian Blue Staining 
Alcian blue stains acidic mucin of secretory granules and is therefore used as a goblet 
cell specific dye.  Alcian blue staining was conducted at the Department of 
Histopathology, University College London Hospital.  Sections were dewaxed 
through xylene and graded alcohols and stained with 1% (w/v) Alcian Blue for 10 
minutes.  Slides were washed in water, counterstained with 0.5 % (v/v) Neutral Red 
and dehydrated through graded alcohols and xylene.   
 
2.5.4 Immunohistochemistry 
Immunohistochemistry allows the tissue- and cell- specific detection of proteins.  
Antibodies applied to a fixed section of tissue will bind to their specific antigen, and 
the antibody-interaction is visualised by conjugating the complex to a colorimetric, 
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enzyme-catalysed reaction.  Immunohistochemistry of sliced and mounted sections of 
the murine skin and gut was performed at UCL Advanced Diagnostics.   
Sections underwent automated dewaxing and endogenous peroxidase activity was 
blocked using 3-4% (v/v) hydrogen peroxide.  Heat/enzyme induced epitope retrieval 
is described for each protein of interest below.  Diluted antibodies, also described 
below, were then applied to the slides and incubated at ambient temperature for 15 
minutes.  Signal visualization was performed using Bond™ Polymer Refine Detection 
Kit (Leica Biosytems) with Bond™ DAB Enhancer (Leica Biosytems). Cell nuclei 
were counterstained with hematoxylin (Leica Biosytems) Leica Bond-III and Leica 
Bond Max automated systems (Leica Biosystems) were used.   
 
 
Antibody (Manufacturer, Catalogue No.) 
 
Antigen Retrieval 
 
Dilutio
n 
 
Diluent 
 
FMO5 (ProteinTech™, 16864-1-AP) 
 
Bond™ Epitope 
Retrieval Solution 1 
(Leica Biosystems): 
30 minutes, 100 °C 
 
1:100 
 
Antibody Diluent, 
Background 
Reducing (Dako) 
 
RELMβ (Abcam, ab11429) 
 
Bond™ Epitope 
Retrieval Solution 1: 
10 minutes, ambient 
temperature 
 
1:400 
 
Bond™ Primary 
Antibody Diluent 
(Leica Biosystems) 
2.5.5 Slide Scanning 
Slides were scanned using the Axio Scan.Z1 (ZEISS) with a 20 X magnification.   
 
2.5.6 Goblet Cell Quantification 
Photomicrographs of alcian blue stained sections of the colon (see 2.5.3) were used to 
quantify colonic crypt length and number of goblet cells per crypt.  Using a method 
previously described, regions of interest containing at least three contiguous crypts 
were selected and six regions were sampled per photomicrograph.  Three crypts per 
region of interest were analysed.  For each crypt, crypt length was measured and 
number of goblet cells (alcian blue stained bodies) per crypt was counted (de Oliveira 
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Mello et al., 2012).  For both WT and FMO5 KO, three photomicrographs, each from 
different animals, were used for quantification.   
 
2.6 STATISTICAL ANALYSIS 
 
 
Data is expressed as mean ± standard error of the mean (SEM).  Statistical 
significance was determined using Student’s t-test.  The following symbols were used 
throughout all figures and text to indicate the significance value:  
* = p<0.05, ** = p<0.01, *** = p<0.001, **** = p<0.0001. 
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Chapter 3: The FMO5 KO Mouse
	   59 
3.1 INTRODUCTION 
3.1.1 Mouse Knockout Models 
To further investigate the role of FMOs in both xenobiotic and endogenous 
metabolism, it is necessary to utilise knockout mouse lines lacking the specific 
isoforms.  There are no known specific inhibitors of family members and antibodies 
only weakly inhibit catalytic activity.  In addition, the thermal sensitivity of the 
enzyme family, and the difficulty in measuring enzyme products, makes determining 
the particular activity of FMOs problematic (Shephard and Phillips, 2010).   
 
A mouse model was first created with the aim of humanising the mouse liver and 
lung, by deleting Fmo1 and Fmo2 respectively (Hernandez et al., 2006a).  Using 
Cre/LoxP technology, Fmo1, Fmo2 and Fmo4 were deleted from chromosome 1, 
creating a Fmo1,2,4(-/-) mouse (FMO1,2,4 KO).  Due to the attenuation of Fmo3 
expression during development in males, the male knockout mice are subsequently 
null for all FMOs known to be involved in drug metabolism and this mouse model has 
helped us better understand the role of the specific FMOs in drug metabolism.  In 
particular, the FMO1,2,4 KO model revealed the importance of FMO1 in the 
metabolism of an anti-depressant, imipramine.  The mice showed exaggerated and 
prolonged effects to the drug, maintaining higher plasma concentrations of the parent 
compound with a reduction in appearance of the N-oxide (Hernandez et al., 2009). 
 
This mouse line also has revealed a dual functionality of FMO1; further 
characterisation of the FMO1,2,4 KO mouse has shown FMO1 to  participate in 
endogenous, as well as xenobiotic, metabolism.  When compared to the WT controls, 
the knockout animal weighs less, is leaner and has less fat. Specifically, an increased 
capacity for exercise and higher levels of fatty acid oxidation in soleus muscle results 
in less fat stored in the knockout.  Together with a higher resting energy expenditure, 
due to the activation of a futile cycle in white adipose tissue, this results in an 
enhanced total energy expenditure in the knockout, which is not accompanied by an 
increase in calorific intake.  Unlike FMO2 and FMO4, FMO1 is highly expressed in 
the metabolic tissues investigated, therefore the altered phenotype of the knockout is 
likely to be due to the absence of specifically FMO1.  FMO1 can subsequently be 
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considered as a regulator of energy homeostasis, as well as a drug metabolising 
enzyme (Veeravalli et al., 2014).   
 
3.1.2 The FMO5 Knockout Mouse 
Employing a slightly different method of homologous recombination, a mouse model 
deficient in Fmo5 (FMO5 KO) was also generated.  Using a linearized vector, exon 
two of the Fmo5 gene was replaced with the neomycin resistance gene (neor).  
Embryonic stem cells from the 129 mouse strain (yellow coat) were injected with a 
targeting construct consisting of neor flanked by exon 1 and 3 of the Fmo5 gene, with 
the thymidine kinase (tk) gene downstream of exon 3.  If homologous recombination 
with exon 1 and 3 of the Fmo5 gene locus occurs, the clones will have replaced exon 
2 of the gene with neor, without incorporating the tk gene.  These clones will therefore 
be resistant to neomycin (neor +) and resistant to ganciclovir (tk-) (Hernandez et al., 
2006b).  Successful clones were selected, injected into C57BL/6 (black coat) 
blastocysts and blastocysts were injected into foster mothers.  Black and brown 
spotted coat colour indicates chimeric offspring, with DNA from both the C57BL/6 
blastocyst and 129 embryonic stem cell (Hernandez et al., 2006c).  Genotyping was 
confirmed by PCR of the Fmo5 allele and heterozygous mice were back-crossed with 
the wild-type C57BL/6 animals for eight generations.  Male and female mice 
heterozygous for the mutation were then bred to produce a congenic Fmo5 knockout 
line and mice homozygous for the altered allele (Figure 3.1).   
 
  
	   61 
  
neo
NsiI HpaIBglIINsiI
4.5 kb
1 kb
8.9 kb
c d 3’ probe5’ probe
vector probe
targeting
construct
Fmo5
locus
A
NsiI HpaIBglIINsiI
5.5 kb
2 kb
9.6 kb
c d
3’ probe
5’ probe
Fmo5
targeted
allele
neo probe
2.26 kb
neo
a b
1 2 3
31
C
B
23 kb
6 kb
5.5 kb
reddal
enolc
NsiIi)
SE
W
T 
enolc
NsiIii)
neo probe 5’ internal
probe
5.9 kb
4.7 kb
SE enolc
BglII/HpaIiii)
3’ internal
probe
9.6 kb
8.9 kb
2 kb
1 kb
Het WT WT Het KO D WT KO
W
T
1 3
Figure 3.1 – Generation of the FMO5 KO mouse. A – Recombination between 
homologous regions (thick black lines) of the targeting construct and the Fmo5 locus 
leads to the generation of a targeted Fmo5 allele, in which exon 2 is replaced by the 
neo
r
 cassette.  Black arrows: Primers used for screening of G418
r
 ES clones.  White 
arrows: Primers used for identifying WT and targeted alleles.  Probes and restriction 
sites used for Southern blot genotyping are also indicated.  B – Southern blot analysis 
with i) a neo
r
 specific probe, ii) a 5’-internal probe and iii) 3’-external probe verify 
the correct integration of the targeted allele.  C – Mice were genotyped by PCR 
analysis of tail DNA with primers c and d (see A).  Het, Heterozygous knockout; WT, 
wild-type; KO, homozygous knockout.  D – Western blot analysis of protein isolated 
from liver of wild-type (WT) and homozygous knockout (KO) mice.  The KO do not 
express FMO5 (Hernandez et al., 2006b).   
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Similar to the FMO1,2,4 KO in the characterisation of FMO1, the FMO5 KO has also 
implicated a role of FMO5 in endogenous metabolism (Gonzalez Malagon 2011).  
When compared to the WT, the inactivation of Fmo5 results in an attenuation of age-
related weight gain (Figure 3.2).  The use of knockout mouse lines has therefore 
revealed unsuspected roles of both these isoforms in energy metabolism. 
 
Studies by Gonzalez Malagon revealed up until 20 weeks of age, weight gain in the 
WT and FMO5 KO is comparable.   From 20-weeks however, even though the KO 
consume more chow per g of body weight and are not more active than the WT, 
weight gain in the FMO5 KO is reduced (Figure 3.2-A). The weight phenotype 
becomes more pronounced by 30 weeks of age, where a significant difference in 
weight of the two animals is observed (Figure3.2-B).   
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Figure 3.2 – Difference in age-related weight gain.  A. WT (n=8) and FMO5 KO (n=7) male 
mice, fed a standard chow diet ad libitum, were weighed once a week for 30 weeks.  Data is 
expressed as mean ± SEM.  B. Body weight comparison of 15-week (WT, n=10; FMO5, n=7) 
and 30-week (WT, n=27; FMO5 n=24) old male mice fed a standard chow diet ad libitum.  Data 
is expressed as mean ± SEM (**: p<0.01, ****: p<0.0001). 
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The older FMO5 KO mice were also found to have less fat relative to their total body 
weight at 30-weeks, with reductions in all fat depot sizes when compared with WT 
mice.  Histological analysis of white adipose tissue revealed the decrease in fat depot 
size of the FMO5 KO could be attributed to a decrease in adipocyte cell volume.  The 
discovery of this difference in weight and fat storage in the FMO5 KO mice led to 
further investigations of energy metabolism in these mice. 
 
Similar to the difference in weight, plasma glucose was also found to be different in 
the 30-week WT and FMO5 KO animals, whereas levels are comparable at 15 weeks 
of age (Figure 3.3).  Between time points 15- and 30-weeks, the WT plasma glucose 
is significantly increased.  However, the plasma glucose of the KO does not change 
with age, this therefore results in a significant difference between the WT and FMO5 
KO at 30 weeks.   
 
 
  
Figure 3.3 – Differences in plasma glucose at 15 and 30 weeks.  
Plasma glucose was measured between 9-11 am in fed 15-week (WT, 
n=18; FMO5 KO, n=23) and 30-week (WT, n=22; FMO5 KO, n=21) 
old male mice.  Data is expressed as mean ± SEM (***: p<0.001). 
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Another key difference observed in the FMO5 KO mouse is lower plasma cholesterol 
as early as 15 weeks (Figure 3.4).  This change, precedes the difference in weight and 
glucose observed at 30-weeks of age in the FMO5 KO mice. By the age of 30-weeks, 
the FMO5 KO mouse therefore presents with significantly lower weight gain, plasma 
glucose, total, HDL and LDL cholesterol. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
At 30-weeks of age total energy expenditure, measured by oxygen consumption, was 
found to be significantly higher in the FMO5 KO when compared to the WT in both 
the light (WT, 0.416 ± 0.005 kcal.day-1.g-1; FMO5 KO, 0.458  ± kcal.day-1.g-1) and 
dark (WT, 0.448 ± 0.006 kcal.day-1.g-1; FMO5 KO, 0.500 ± 0.006 kcal.day-1.g-1) 
phase (p<0.0001).  A higher energy expenditure of the KO animal suggests the 
oxidation of fuel substrates is continuously higher.  Furthermore, the resting energy 
expenditure (a measure of basal metabolic rate plus energy expended in processing 
food) was found to be higher in the KO (0.321 ± 0.009 kcal.day-1.g-1) when compared 
to the WT animal (0.283 ± 0.007 kcal.day-1.g-1) at this age (p<0.01).   
 
 
 
Figure 3.4 – Plasma cholesterol measurements of 15-week old mice.  
Total (WT, n = 6; FMO5 KO, n = 10), HDL (WT, n = 8; FMO5 KO,  n = 
10) and  LDL (WT,  n = 3; FMO5 KO, n = 8) cholesterol was measured 
in fed 15-week old male mice. Data is expressed as mean ± SEM (*: 
p<0.05, **: p<0.01, ***: p<0.001).   
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The respiratory exchange ratio (RER) is a measure of the relative contributions of 
carbohydrate and fat oxidation to total energy expenditure.  During the light period, 
RER measurements indicate the animals have a similar utilisation of fuel (WT, 0.950 
± 0.006; FMO5 KO, 0.943 ± 0.007).  During the dark phase (active period), the 
average RER value remains the same for the WT, however the RER value of the 
FMO5 KO increases to 0.989 ± 0.006.  This value is significantly higher than the 
RER value of the FMO5 KO in the light phase (p<0.001), and the WT average RER 
during the dark phase (p<0.001).  These measurements therefore indicate the FMO5 
KO animal uses more carbohydrate than the WT in the active period (Gonzalez 
Malagon 2011).   
 
The differences recorded by Gonzalez Malagon et. al in weight, plasma glucose and 
plasma cholesterol in the WT and FMO5 KO mouse are apparent in both and male 
and female cohorts.  My analysis herein will therefore focus solely on the male WT 
and FMO5 KO mouse.   
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3.2 EXPERIMENTAL QUESTIONS AND AIMS 
 
I. The phenotype suggests that the FMO5 KO mice will be more insulin sensitive 
than WT mice. Aim I was to further characterise the glucose phenotype 
observed in the WT and FMO5 KO animals with ageing.  Measurement of 
plasma insulin, glucose tolerance and insulin sensitivity at different ages of the 
two mouse lines will further elucidate the changes in the phenotype with age.    
 
II. To investigate the influence of a high-fat diet in the WT and FMO5 KO animals.  
Measurement of weight, glucose and insulin levels and glucose tolerance in 
animals subjected to a high-fat diet will identify any differences in diet-induced 
changes in glucose homeostasis and weight gain.   
 
III. To examine of the role of the intestinal microbiota in the glucose profile of the 
WT and FMO5 KO animal.  Use of a low-dose course of antibiotics to reduce 
the bacterial load in the intestine, will clarify the influence of the microbiota in 
glucose homeostasis. 
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3.3 RESULTS 
 
3.3.1 The Glucose Phenotype of the FMO5 KO mice in Ageing 
 
3.3.1.1  Glucose Tolerance Test 
The glucose tolerance test is a measure of how effectively an individual can clear 
glucose from the blood.  By injecting an animal with a defined, exogenous amount of 
glucose, the subsequent rise in blood glucose can be measured.  By then taking blood 
glucose measurements at incremental time points post glucose bolus, the ability of the 
individual to return glucose levels back to baseline can be assessed.  The test was first 
performed on 15 week-old animals.  
 
In agreement with the plasma glucose measurements at this age (see Figure 3.3), the 
glucose tolerance of 15-week old WT and FMO5 KO animals is also similar (Figure 
3.5-A).  There was no difference in AUC values of the WT (596.3 ± 105.7 mmol.L-
1.min-1, n=5) and FMO5 KO (526.5 ± 40.6 mmol.L-1.min-1, n=7) animals tested.   
 
The test was then performed on 30-week old WT and FMO5 KO animals (Figure 3.5-
B).  At this age point, there is a measurable difference in glucose tolerance.  The 
glucose bolus results in a higher and more sustained glucose peak in the WT animal.  
Furthermore, the FMO5 KO is able to clear glucose faster, and to a much greater 
extent, than the WT.  The WT animal fails to return to basal blood glucose in the 120-
minute time course.  Together, this results in a significant difference between the 
AUC values of the WT (1278.3 ± 124.7 mmol.L-1.min-1, n=5) and the FMO5 KO 
(594.0 ± 124.5 mmol.L-1.min-1, n=5) animals (p<0.01).   
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The difference in glucose tolerance reported at 30 weeks, and absent in 15-week old 
animals, is due to changes in the WT AUC values with age (15 week, 596.3 ± 105.7 
mmol.L-1.min-1; 30 week, 1278.3 ± 124.7 mmol.L-1.min-1) (p<0.01), whilst FMO5 KO 
values remain unchanged (15 week, 526.5 ± 40.60 mmol.L-1.min-1; 30 week, 594.0 ± 
124.5 mmol.L-1.min-1).  This is consistent with the phenotype observed in plasma 
glucose; the difference between genotypes appearing at 30 weeks is due specifically 
to an increase in plasma glucose and glucose tolerance in the WT, whereas KO values 
remain unchanged.  Therefore, both plasma glucose and glucose tolerance worsens 
with age in the WT animal, however the FMO5 KO is able to retain the healthier 
profile; lower blood glucose and a better glucose tolerance, through ageing.   
 
Figure 3.5 – Glucose tolerance of 15- and 30- week old animals.  Glucose tolerance was 
measured in A. 15-week (WT, n=6; FMO5 KO, n=5) and B. 30-week (WT, n=4; FMO5 KO, n=4) 
old male mice.  Left – Plasma glucose levels following a glucose bolus.  Right – Area under the 
curve (AUC) analysis.  Data is expressed as mean ± SEM (**: p<0.01). 
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3.3.1.2  Plasma Insulin Measurement 
Insulin is a hormone released by pancreatic beta cells in response to elevated blood 
glucose.  Amongst other roles, this signal then drives glucose uptake in tissues such as 
adipose tissue and muscle.  Measurement of plasma insulin is used to indicate any 
changes in the hormone function in states of perturbed glucose homeostasis.  Plasma 
insulin of WT and FMO5 KO animals was measured by ELISA.  Measurements were 
conducted at both 15 and 30 weeks  (Figure 3.6).   
 
 
Contrary to blood glucose and glucose tolerance measurements, as early as 15 weeks 
there is a significant difference in plasma insulin of the WT (1.36 ± 0.17 ng.ml-1, n=4) 
and FMO5 KO (0.72 ± 0.08 ng.ml-1, n=4) animals (p<0.05).  This difference becomes 
more pronounced, and significant, at 30 weeks of age (WT: 1.92 ± 0.13 ng.ml-1 n=3, 
FMO5 KO: 0.63 ± 0.08 ng.ml-1, n=3) (p=<0.01).  In a similar pattern observed in the 
glucose parameters tested, the greater difference in plasma insulin at 30 weeks is due 
to an increase in the WT animal in ageing (15 week, 1.36 ± 0.17 ng.ml-1; 30 week, 
1.92 ± 0.13 ng.ml-1), whilst the FMO5 KO levels remain unchanged (15 week, 0.72 ± 
0.08 ng.ml-1; 30 week, 0.72 ± 0.08 ng.ml-1).   
 
At 15 weeks, the KO animals have lower circulating levels of insulin whereas there is 
no difference in the plasma glucose measurements of the two animals.  This suggests 
the knockout animal is more insulin sensitive; they need lower levels of the hormone 
Figure 3.6 – Plasma insulin of 15- and 30-week old animals. Plasma 
insulin was measured between 9-11 am in fed 15-week (WT, n=4; 
FMO5 KO, n=4) and 30-week (WT, n=3; FMO5 KO, n=3) old male 
mice.  Data is expressed as mean ± SEM (*: p<0.05, **: p<0.01). 
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to maintain glycaemia.  At 30 weeks, even though circulating insulin remains higher 
in the WT when compared to the FMO5 KO, WT animals now also present with 
higher levels of plasma glucose and worsened glucose tolerance.  Therefore, along 
with having a greater insulin sensitivity from young, the FMO5 KO mouse appears to 
be resistant to the age-related decline in insulin sensitivity seen in the WT.   
 
3.3.1.3  Insulin Sensitivity Test 
To further define the insulin sensitivity of the WT and FMO5 KO animal, the insulin 
sensitivity test was performed.  Insulin sensitivity of an individual can be 
experimentally determined by injecting a defined amount of exogenous insulin.  
Measuring the decline in plasma glucose at incremental time points following the 
injection gives a measure of the hormone’s function.  As early as 10 weeks of age, the 
FMO5 KO animal is more insulin sensitive than the WT (Figure 3.7).  
 
 
 
The 10-week old FMO5 KO animal has a greater response to the same dose of 
insulin; over the 120-minute time course the animals cleared glucose faster, and to a 
greater extent than the WT.  Subsequently, iAUC values of FMO5 KO animals tested 
(425.1 ± 23.7 mmol.L-1.min-1, n=4) are significantly greater than that of the WT 
(151.1 ± 28.5 mmol.L-1.min-1, n=4) (p<0.001).   Measurements were also conducted 
in 15- and 30-week old animals (data not shown) and the insulin sensitivity of the 
FMO5 KO remains higher than that of the WT throughout ageing.   
Figure 3.7 –Insulin sensitivity of 10-week old animals.  A. Insulin sensitivity was measured in 
10-week old male mice (WT, n=4; FMO5 KO, n=4).  Left – Plasma glucose following an insulin 
bolus.  Right – Inverse area under the curve (iAUC) analysis.  Data is expressed as mean  ± SEM 
(***: p<0.001). 
0 60 12
0
0
4
8
12
G
lu
co
se
 (m
m
ol
/L
)
Time (minutes)
WT
FMO5 KO
iA
U
C
 (m
m
ol
.L
-1
.m
in
)
0
250
500
WT
FMO5
KO
***
	   71 
At 10 weeks of age, the WT and FMO5 KO animals show no difference in weight, 
plasma insulin, glucose and cholesterol (Figure 3.8).  Therefore, preceding all other 
observed phenotypes, the first measured difference in the FMO5 KO animal is an 
enhanced insulin sensitivity; inactivation of the Fmo5 gene results in a greater 
response to an exogenous dose of insulin.  The absence of FMO5 protein further 
protects the animal from an age-related decline in insulin sensitivity seen in the WT.  
An elevation in plasma glucose and worsening of glucose tolerance observed in 
ageing of the WT is not evident in the FMO5 KO, which may therefore explain the 
attenuation in age-related weight gain.   
 
A. B. 
Figure 3.8 – Plasma measurements of 10-week old mice - A. Plasma glucose (WT, 
n=23; FMO5, n=27), B. Plasma insulin (WT, n=4; FMO5, n=4) and C. Plasma cholesterol 
(WT, n=11; FMO5 KO, n=8) was measured between 9-11 am in 10-week old male mice.  
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In addition, as the differences seen in cholesterol also occur secondary to the 
difference in insulin sensitivity of the animals, it is tempting to speculate the higher 
levels of cholesterol in the WT is a consequence of the changes in insulin, whether it 
be the loss of sensitivity or increase in circulating levels.  A wealth of human studies 
has provided evidence for disturbances in insulin signaling conferring a detrimental 
influence on cholesterol metabolism. Whole-body cholesterol homeostasis is achieved 
by the well-governed interplay of endogenous cholesterol synthesis, intestinal 
absorption and cholesterol clearance (Taverne et al., 2013).  Insulin levels, insulin 
resistance and diabetes are positively associated with an increase in cholesterol 
synthesis and consequent decrease in intestinal absorption (Simonen et al., 2002a; 
Pihlajamäki et al., 2004; Gylling et al., 2010; Hoenig and Sellke, 2010; Simonen et 
al., 2011; Paramsothy et al., 2011).  Higher fasting glucose levels alone were 
sufficient to disrupt the balance of synthesis and absorption (Stranberg et al., 1996; 
Gylling et al., 2010), and coronary heart disease events are shown to have a greater 
dependency on insulin resistance and diabetes than baseline HDL cholesterol and 
triglycerides (Robins et al., 2003).   
 
Currently the mechanism of this cross talk remains unclear.  It has been postulated 
hepatic insulin resistance and/or accompanying hyperinsulinaemia may activate the 
transcription factor sterol regulatory element binding protein 2 (SREBP-2) resulting in 
the upregulation of cholesterol synthesis genes, or intestinal insulin resistance would 
modify transporter expression hence decreasing cholesterol transport (Stranberg et al., 
1996; Gylling et al., 2010; Simonen et al., 2011).  However, Pihlajamaki et al. suggest 
the observed decrease in absorption is likely to be merely secondary to the insulin-
mediated increase in cholesterol synthesis (Pihlajamäki et al., 2004).  An alternative 
explanation is insulin resistant adipocytes secrete more free fatty acids, which would 
increase hepatic very low density lipoprotein production, however whether this is 
capable of concomitantly inducing cholesterol production remains unclear (Simonen 
et al., 2002a; Pihlajamäki et al., 2004).   
 
Body weight (Simonen et al., 2002b) and specifically visceral fat (Peltola et al., 2006) 
are also considered catalysts for unregulated cholesterol metabolism.  Several of the 
studies mentioned above state the relationship between insulin resistance and 
perturbed cholesterol metabolism is obesity independent by virtue of body weight and 
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BMI measurements, however the measurement of abdominal or visceral adiposity and 
its contribution is lacking.  The role of abdominal fat in the aetiology of insulin 
resistance is indisputable and it may in fact be a common component of the insulin 
resistance states used to describe the correlation with cholesterol metabolism in these 
studies.  Therefore, the specific delineation of insulin resistance and obesity in 
cholesterol homeostasis remains elusive as the latter often accompanies the former.  
Interestingly however, in comparisons of the WT and FMO5 KO mouse, we observe a 
difference in insulin sensitivity followed by an increase in cholesterol, prior to any 
difference in body weight and visceral fat.   
 	    
	   74 
3.3.2 The FMO5 KO Animal is Resistant to High-fat Diet Induced Weight Gain 
 
3.3.2.1  Body Weight Analysis 
In light of the FMO5 KO mice, fed a standard chow diet, exhibiting reduced weight 
gain post 20 weeks of age (see Figure 3.2), the effect of a high-fat diet on these 
animals was investigated (Figure 3.9).  At 33 weeks of age, WT and FMO5 KO 
animals were fed either a standard chow or a high-fat diet.   
Figure 3.9 – Body weight measurements of mice fed standard chow (A) or a high-fat diet (B). 
Male mice were fed either a standard chow (WT, n=4; FMO5, n=4) (A) or a high-fat diet (WT, 
n=7; FMO5, n=7) (B).  Mice were placed on the high-fat diet from 33- to 39-weeks of age.  
Animals were weighed twice weekly during the 6 week diet intervention. Data is expressed as mean  
± SEM. 
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When fed a standard chow diet, neither cohort of animals gained a significant amount 
of weight between 33 and 39 weeks of age (figure 3.9-A).  When fed a high-fat diet, 
the weight of the FMO5 KO animal also remains stable; they did not respond to the 
change in diet.  However, high-fat feeding resulted in a substantial increase in body 
weight in the WT animal (figure 3.9-B).  Over the 6-week diet intervention the WT 
mouse gained, on average, 8.6 ± 0.4 g; over 20 % of their original starting body 
weight.  This resulted in a remarkable disparity in the body weight of the WT and 
FMO5 KO animal at the end of the study (WT, 46.2 ± 0.9 g, n=7; FMO5 KO, 33.7 ± 
1 g, n=7) (p<0.0001); with a difference of more than 25 %.  Therefore, as well as 
curtailing weight gain in the older mouse, absence of FMO5 also protects the mouse 
from diet-induced weight gain.   
 
3.3.2.2  Plasma Glucose Measurement 
Plasma glucose was measured in WT and FMO5 KO animals following the 6-week 
high-fat feeding period (Figure 3.10).  High concentration of lipids in the blood 
(lipaemia), resulting from the high-fat diet, can interfere with biochemical analyses.  
Animals were therefore starved overnight prior to blood collection.  For comparison, 
both WT and FMO5 KO animals fed both the standard chow and high-fat diet were 
starved overnight.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.10 – Plasma glucose of mice fed a standard chow or high-
fat diet (HFD).  Plasma glucose was measured between 9-11 am in 
overnight-starved male mice fed a standard chow (WT, n=10; FMO5 
KO, n=10) or a high-fat diet (WT HFD, n=9; FMO5 KO HFD, n=7).  
Data is expressed as mean ± SEM (**: p<0.01). 
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WT animals fed a high-fat diet (WT HFD) had significantly higher starved plasma 
glucose than those fed standard chow (WT) (WT, 8.21 ± 0.42 mmol.L-1, n=10; WT 
HFD, 10.01 ± 0.40 mmol.L-1, n=9) (p<0.01).  Plasma glucose concentration of FMO5 
KO mice fed either the standard chow (FMO5 KO) or high-fat diet (FMO5 KO HFD) 
was however similar (FMO5 KO, 7.38 ± 0.32 mmol.L-1, n=10; FMO5 KO HFD, 7.57 
± 0.56 mmol.L-1, n=7).  Subsequently, there is a significant difference in the starved 
plasma glucose values of the WT and FMO5 KO animals fed a high-fat diet (WT 
HFD, 10.01 ± 0.40 mmol.L-1; FMO5 KO HFD, 7.57 ± 0.56 mmol.L-1) (p<0.01).  
Therefore, as well as protecting the animal from diet-induced weight gain, the absence 
of FMO5 also prevents elevations in blood glucose in response to high-fat feeding.   
 
3.3.2.3  Glucose Tolerance Measurement 
To further investigate the diet-induced changes in glucose metabolism, the glucose 
tolerance test was performed on WT and FMO5 KO animals fed either the standard 
chow or high-fat diet (Figure 3.11).   
 
Accompanying the rise in plasma glucose, WT animals fed the high-fat diet (WT 
HFD) had impaired glucose tolerance compared with mice fed standard chow (WT).  
A higher, and more sustained, glucose peak resulted in a significant difference in 
calculated AUC values (WT, 1278.3 ± 124.7 mmol.L-1.min-1, n=5; WT HFD, 1901.4 
± 97.0 mmol.L-1.min-1, n=4) (p<0.01).  The glucose tolerance of the FMO5 KO mice 
however, was similar on the standard chow (FMO5 KO) and high-fat diets (FMO5 
KO HFD) (FMO5 KO, 594.0 ± 124.5 mmol.L-1.min-1, n=5; FMO5 KO HFD, 811.7 ± 
88.8 mmol.L-1.min-1, n=4).  A pronounced difference is therefore observed in the 
glucose tolerance of WT and FMO5 KO animals fed a high-fat diet (WT HFD, 1901.4 
± 97.0 mmol.L-1.min-1, n=4; FMO5 KO HFD, 811.7 ± 88.8 mmol.L-1.min-1, n=4) 
(p<0.001). 
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Figure 3.11 –Glucose tolerance of animals fed a standard chow or high-fat diet (HFD).  
Glucose tolerance was measured in male mice fed standard chow (WT, n=5; FMO5 KO, n=5) or a 
high-fat diet (WT HFD, n=4; FMO5 KO HFD, n=4).  Above – Plasma glucose levels following a 
glucose bolus.  Below – Area under the curve (AUC) analysis.  Data is expressed as mean ± SEM 
(**: p<0.01, ***: p<0.001). 
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3.3.2.4  Plasma Insulin Measurement 
The effect of high-fat feeding on plasma insulin levels was also determined (Figure 
3.12).  Insulin was measured in plasma of high-fat diet fed animals, which had not 
been starved, and compared to those fed standard chow.   
 
 
The high-fat diet (HFD) resulted in a great increase in plasma insulin levels in the WT 
mice (WT, 1.92 ± 0.13 ng.ml-1, n=3; WT HFD, 18.45 ± 0.13 ng.ml-1, n=3) (p<0.05).  
After high-fat feeding, the WT insulin level exceeds 10 ng/ml; the value of the highest 
point of the standard curve permissible with the chosen method of ELISA 
quantification.  These values are therefore not precise, but instead in excess of 10 
ng/ml.  The insulin concentration value of >10 ng.ml-1 indicates a greater than five-
fold increase in plasma insulin is needed to regulate glycaemia in the high-fat fed WT 
mice.  The plasma insulin concentration of the FMO5 KO animal is also elevated in 
high-fat feeding (FMO5 KO, 0.63 ± 0.08 ng.ml-1 n=3; FMO5 KO HFD, 2.03 ± 0.33 
ng.ml-1, n=4) (p<0.05).  The increase is however much lower when compared to that 
seen in the high-fat fed WT mouse and, in high-fat feeding, levels are still 
significantly lower in the FMO5 KO mouse (WT HFD, 18.45 ± 0.13 ng.ml-1, n=3; 
FMO5 KO HFD, 2.03 ± 0.33 ng.ml-1, n=4;) (p<0.01),  
 
Figure 3.12 – Plasma insulin of animals fed standard chow or a 
high-fat diet.  Plasma insulin was measured between 9-11 am in male 
mice fed standard chow (WT, n=3; FMO5 KO, n=3) or a high-fat diet 
(WT HFD, n=3; FMO5 KO HFD, n=4).  Data is expressed as mean  ± 
SEM (*: p<0.05, **: p<0.01). 
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High-fat feeding results in further loss of glycaemic control in the WT animal due to 
the development of insulin resistance.  In spite of raised circulating insulin, the animal 
is no longer responding to the hormone effectively and has higher starved plasma 
glucose than WT mice fed a standard chow.  Conversely, the knockout animal is 
protected.  During high-fat feeding, the FMO5 KO mouse maintains glucose 
homeostasis due to a sustained, higher insulin sensitivity compared to the WT.   
 
3.3.2.5  Plasma Cholesterol Measurement   
 
Measurements of plasma cholesterol also indicate the protective effect of the absence 
of FMO5 when mice are fed a high-fat diet (Figure 3.13).  Measurements were 
conducted in plasma of starved animals to avoid lipaemia interference with the assays 
in high-fat diet treated cohorts.   
 
As discussed above, as early as 15 weeks, total, HDL and LDL cholesterol is lower in 
the FMO5 KO (see Figure 3.4).  However, when measurements are conducted in 
plasma of starved animals to avoid lipaemia interference, there is no difference in 
values of total, HDL and LDL cholesterol in the WT and FMO5 KO animals fed a 
standard chow diet.  Yet, when compared to animals fed standard chow (WT), WT 
animals fed a high-fat diet (WT HFD) have significantly higher total cholesterol (WT, 
3.78 ± 0.08 mmol.L-1, n=4: WT HFD: 5.53 ± 0.18 mmol.L-1 n=4) (p<0.0001), HDL 
cholesterol (WT, 2.77 ± 0.08 mmol.L-1, n=4; WT HFD, 4.03 ± 0.15 mmol.L-1, n=5) 
(p<0.001) and LDL cholesterol (WT, 0.59 ± 0.01 mmol.L-1, n=4; WT HFD, 0.91 ± 
0.05 mmol.L-1, n=5) (p<0.001).  The plasma cholesterol levels of the FMO5 KO mice 
however remain unchanged in high-fat feeding.   
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Figure 3.13 – Plasma cholesterol measurements of animals 
fed a standard chow or high-fat diet (HFD).  Total, HDL 
and LDL cholesterol was measured in overnight-starved male 
mice fed a standard chow (WT, n=4; FMO5, n=4) or high-fat 
diet (WT HFD, n=5; FMO5 KO HFD, n=4). Data is expressed 
as mean  ± SEM (***: p<0.001, ****: p<0.0001).   
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The WT animal has shown the canonical response to a high-fat diet; a loss in the 
control of glycaemia due to insulin resistance, increase in plasma cholesterol and 
excessive weight gain.  The absence of FMO5, however, results in a protective 
phenotype.  Throughout the period of high-fat diet feeding, the FMO5 KO mouse 
remains lean with unaltered glucose and cholesterol profiles and only a small increase 
in plasma insulin.  We propose this to be due to the heightened insulin sensitivity of 
the FMO5 KO.    
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3.3.3 The Effect of an Antibiotic Treatment in the WT and FMO5 KO Animal 
 
The gut microbiota is considered an environmental factor, capable of modulating host 
insulin signaling and energy storage (Bäckhed et al., 2004).  To explore a role of the 
intestinal bacteria in the differing phenotypes of the WT and FMO5 KO animal, both 
mouse lines were subjected to a 4-week antibiotic treatment.  Low doses of ampicillin 
(gram negative) and neomycin (gram positive) antibiotics were co-administered in 
drinking water, with the aim of reducing the bacterial load of the intestine.  These 
antibiotics were selected based on previous reports of treatment targeting the 
intestinal microbiota alone.  A sustained, low dose treatment ensures poor absorption 
of the antibiotics from the gut and avoids a systemic, off-target effect in the animal 
(Vijay-Kumar et al., 2007; Cani et al., 2008a; Membrez et al., 2008).  In agreement 
with previous observations of antibiotic treated animals (Vijay-Kumar et al., 2007), 
WT and FMO5 KO mice that underwent treatment presented with an enlarged cecum.  
This is indicative of an elimination of the intestinal microbiota.  Furthermore, in 
plasma analysis of antibiotic treated animals, circulating bacterial metabolites were 
reduced when compared to control treated animals (data not shown).   
 
3.3.3.1  Plasma Glucose Measurement 
 
After 2 weeks of treatment, plasma glucose was measured in WT and FMO5 KO 
animals treated with antibiotics (Figure 3.14).  Antibiotic treated WT animals (WT 
AB) have significantly lower plasma glucose compared to untreated WT mice (WT) 
(WT, 10.82 ± 0.16 mmol.L-1, n=22; WT AB, 7.78 ± 0.41 mmol.L-1, n=4) (p<0.0001).  
Plasma glucose of FMO5 KO mice treated with antibiotics (FMO5 KO AB) was 
found to be slightly lower than untreated animals (FMO5 KO) (FMO5 KO: 9.46 ± 
0.28 mmol.L-1 n=21, FMO5 KO AB: 8.30 ± 0.45 mmol.L-1 n=6), however the 
reduction was not as great as that seen in the WT and was not significant.  Antibiotic 
treatment, and a reduced microbial load in the intestine, reduces plasma glucose in the 
WT.  Levels of treated WT animals are subsequently similar to those of FMO5 KO 
animals, which are comparatively unaffected in treatment.  
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3.3.3.2  Glucose Tolerance Test 
To further analyse glucose homeostasis in response to antibiotic treatment, the 
glucose tolerance of the treated animals was also measured (Figure 3.15).  Antibiotic 
treatment improves glucose tolerance of WT animals.  Treatment resulted in a smaller 
glucose peak, and faster and more efficient clearance of blood glucose.  Together, this 
results in significantly lower calculated AUC values of treated WT animals (WT AB, 
331.0 ± 17.5 mmol.L-1.min-1, n=3) compared to untreated controls (WT, 1278.3 ± 
124.7 mmol.L-1.min-1, n=5;) (p<0.05).  No difference in glucose tolerance was 
observed in antibiotic treatment of FMO5 KO animals (FMO5 KO, 594.0 ± 124.5 
mmol.L-1.min-1, n=5; FMO5 KO AB, 501.5 ± 55.2 mmol.L-1.min-1, n=5).  Therefore, 
a reduction of the intestinal microbiota in response to antibiotic treatment results in 
improved glucose tolerance of WT animals, and a tolerance that is similar to the 
untreated FMO5 KO animals.  Strikingly however, the glucose tolerance of antibiotic-
treated FMO5 KO animals is the same as that of non-antibiotic treated animals. 
 	    
Fig. 3.14 – Plasma glucose of control and antibiotic treated (AB) 
animals.  Plasma glucose was measured between 9-11 am in 30-week old 
control treated (WT, n=3; FMO5 KO, n=3) and antibiotic treated (WT 
AB, n=3; FMO5 KO AB, n=3) male mice.  Data is expressed as mean  ± 
SEM (***: p<0.001, ****: p<0.0001). 
G
lu
co
se
 (m
m
ol
/L
)
0
4
8
12
WT
FMO5
KO
WT
AB
FMO5
KO
AB
****
***
	   84 
 
 	    
Figure 3.15 –Glucose tolerance of control and antibiotic treated (AB) animals.  Glucose 
tolerance was measured in 30-week old control treated (WT, n=5; FMO5 KO, n=5) or antibiotic 
treated (WT AB, n=3; FMO5 KO AB, n=5) male mice.  Above – plasma glucose levels following 
a glucose bolus.  Below – Area under the curve (AUC) analysis.  Data is represented as mean ± 
SEM (**: p<0.01). 
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3.3.3.3  Plasma Insulin Measurement 
Plasma insulin was also measured following the antibiotic treatment (Figure 3.16).  
Similar to the effect on plasma glucose, antibiotic treatment also reduces plasma 
insulin in the WT animal (WT, 1.92 ± 0.13 ng.ml-1, n=3; WT AB, 0.31 ± 0.08 ng.ml-1, 
n=3) (p<0.001).  There was however no difference in plasma insulin after antibiotic 
treatment of the FMO5 KO animal (FMO5 KO, 0.63 ± 0.07 ng.ml-1, n=3; FMO5 KO 
AB, 0.55 ± 0.13 ng.ml-1, n=3).  These results demonstrate that microbiota modulation, 
through treatment with antibiotics, reduces circulating insulin in the WT animals. 
However, this is not the case in the FMO5 KO animal.  Along with plasma glucose 
and glucose tolerance, plasma insulin of the antibiotic-treated WT animals therefore 
becomes similar to that of the FMO5 KO. 
 
 
 
  
Figure 3.16 – Plasma insulin of control and antibiotic treated (AB) 
animals. Plasma insulin was measured between 9-11 am in 30-week old 
control treated (WT, n=3; FMO5 KO, n=3) and antibiotic treated (WT 
AB, n=3; FMO5 KO AB, n=3) male mice.  Data is expressed as mean ± 
SEM (**: p<0.01, ***: p<0.001). 
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3.4 CONCLUSIONS 
 
Inactivation of Fmo5 results in a heightened insulin sensitivity from young and 
protection from the age-related decline in insulin signaling.  The FMO5 KO therefore 
remains leaner in old age and has improved parameters of glucose homeostasis and 
cholesterol metabolism.  Furthermore, the KO are protected from the diet-induced 
obesity and disruptions in glucose homeostasis observed in WT animals upon high-fat 
feeding.   
 
In response to microbiota modulation, there is an improvement in insulin sensitivity 
of the WT animal.  A sustained, low-dose antibiotic treatment designed to specifically 
target the intestinal microbiota has reduced circulating insulin and improved glucose 
homeostasis of the WT.  As a consequence, the glucose profile of the antibiotic-
treated WT now resembles that of the FMO5 KO animal.  The improved metabolic 
phenotype of specifically the WT animal in antibiotic treatment is in support of 
previous studies of germ-free and conventionally raised animals, indicating the 
intestinal microbiota’s influence in insulin signaling (see 1.2.2).  The failure of 
treatment to produce a comparable response in the FMO5 KO points towards a role of 
this protein in the host response to the commensal bacteria of the intestine.  The 
phenotype of the untreated KO is similar to a germ-free WT; in the absence of FMO5 
the animal is “pseudo germ-free”.   	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Chapter 4 – The Intestine and the Commensal 
Microbiota 
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Modulation of the intestinal microbiota had a great effect on the metabolic phenotype 
of the WT animal.  The same treatment did not however result in any consequence in 
the FMO5 KO.  This led investigations into the intestine of the WT and FMO5 KO 
animals.  Previous investigations into the function of FMO5 have focused on its 
primary site of expression; the liver (Janmohamed et al., 2004; Zhang and Cashman, 
2005).  However, FMO5 is also expressed in the digestive tract, where its role is also 
unclear.   
 
4.1 INTRODUCTION 
 
4.1.1  Intestinal Epithelial Cells 	  
The role of the intestine is the digestion and absorption of ingested food.  The 
intestine is also the major site of bacterial colonisation of the human; with over a 100 
trillion microorganisms present, it is one of the most extensively populated microbial 
communities on earth (Ley et al., 2006a).  The other essential role of the intestine is 
therefore the elimination of microbes and microbial products along with undigested 
dietary components.  Intestinal epithelial cells (IECs) constitute the interface between 
the host and this luminal environment; they serve as the first line of defense against 
potential pathogens.  Not only a physical barrier, allowing the selective absorption of 
nutrients and denial of antigenic compounds, IECs are also a vital component of the 
innate immunity of the intestine.  They are able to recognise pathogens, activate the 
host immune system and secrete antimicrobials and cytokines accordingly.  A 
protective mucus layer, intercellular tight junctions and the adaptive and innate 
immune system of the host synergistically regulate the integrity of IECs.  Therefore, 
the precise interaction between the commensal bacteria of the intestine, the mucus 
layer, the epithelia and host immunity is fundamental in maintaining intestinal 
homeostasis.  Disruptions or dysregulation in this cross talk leads to a 
compromisation of the protective barrier, with increased permeability having the 
potential to lead to chronic inflammation and systemic deleterious consequences in 
the host (Strober et al., 2002; Kim and Ho, 2010; Pastorelli et al., 2013).   
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4.1.2 The Intestinal Microbiota 
 
4.1.2.1  Intestinal Microbiota and Inflammation 
The persistence and proximity of the intestinal microbiota to the mucosal barrier              
almost makes them self-antigens in the digestive tract.  Consequently, the appropriate 
reaction of the host immune response in the intestine could be considered a form of 
autoimmunity.  The presence of the microbiota is indeed the stimulus for intestinal 
inflammation and specific species (or an altered population) appear to be more 
important than others.  Consequently, microbial classification of the intestinal lumen 
has undergone extensive investigation in pathophysiologies such as inflammatory 
bowel disease (IBD) and Crohn’s disease.  However, these inflammatory disorders are 
more likely to be a result of the inappropriate activation of the host immune system 
rather than dysbiosis itself.  Both IBD and Crohn’s disease are a result of several 
genetic abnormalities, both presenting as a loss in tolerance to commensal bacteria 
required for the functional integrity of the intestine (Specian and Oliver, 1991; Kim 
and Ho, 2010; Hooper and Macpherson, 2010; Pastorelli et al., 2013). 
 
Correct recognition of commensal bacteria is therefore required for intestinal 
homeostasis.  IECs expressing toll like receptors (TLRs) have been shown to be of 
critical importance.  Deletion of TLR5 led to the development of spontaneous colitis 
in mice due to a higher microbial burden in the intestine (Vijay-Kumar et al., 2007).  
This specific knockout also went on to develop a phenotype resembling human 
metabolic syndrome (higher body mass, hyperglycaemia and insulin resistance), 
indicating the possible role of intestinal inflammation in systemic metabolic 
phenotypes (Vijay-Kumar et al., 2010).  
 
Several genetic polymorphisms of TLRs have been associated with inflammatory 
disorders and further mouse knockout studies have strengthened the link between 
defective TLR function and intestinal infection (Pastorelli et al., 2013).  However, 
reduced TLR5 function is also suggested to be protective.  Heterozygote carriers of a 
TLR5 polymorphism, resulting in a premature stop codon, have reduced TLR5 
activity which results in a dampened response to the bacterial antigen flagellin, and 
was also negatively associated with the incidence of Crohn’s disease (Gewirtz, 2006).  
Therefore, although it is clear detection of the microbiota is vital, in this example 
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where an individual is not completely deficient in TLR5 function, a perhaps “less 
active” immune response can be beneficial.   
 
4.1.2.2  Dysbiosis in Metabolic Disorders 
Along with a hand in the instigation of inflammation, the intestinal microbiota has 
also been linked with the incidence of obesity in an individual.  Dysbiosis, 
specifically the increase in Firmicutes and concomitant decrease in Bacteroidetes 
phyla, has been reported in both obese animals and humans (Ley et al., 2005; 
Turnbaugh et al., 2009a).  This change is reversed when obese subjects were 
subjected to a low calorie diet.   Following weight loss, the obese subjects’ microbiota 
began to resemble that of a lean subject (Ley et al., 2006b).  What remains unclear 
however, is whether changes in the microbiota composition is a cause or simply an 
effect of an obesogenic state.  In fact, extensive studies have, perhaps unsurprisingly, 
indicated the extent to which the diet can affect the microbiota (Turnbaugh et al., 
2009b; Hildebrandt et al., 2009; Koropatkin et al., 2012; Tachon et al., 2012; 
Sahasakul et al., 2012), and the speed of response of the host to dietary changes 
(Burcelin et al., 2011; Angelakis et al., 2012). 
 
Nevertheless, the population of bacteria residing in the gut became to be regarded as 
an important factor in the cause and contribution of obesity.  The microbiota was 
considered as a modulator of how an individual is able to harvest energy from their 
diet (Turnbaugh et al., 2006).  Indeed, changes in metabolism upon 
conventionalisation illustrate how the presence of the microbiota alone is a powerful 
influence (see 1.2.2).  However, given it is host cells of the intestine which recognise 
the commensal bacteria, it is now regarded as a much more complicated paradigm.  In 
fact, again it is the host-genetic component, influencing how these intestinal cells 
function, which is now regarded as paramount in intestinal homeostasis and 
subsequent energy storage.  Discussed herein is one such intestinal cell lineage, the 
goblet cell.   
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4.1.3 Goblet Cells 
 
Along with absorptive enterocytes, Paneth cells and enteroendocrine cells, goblet cells 
make up the intestinal mucosal epithelium.  Goblet cells function to secrete bioactive 
molecules into the lumen of the intestine and goblet cell differentiation is a hallmark 
of intestinal inflammation. Goblet cells originate from stem cells in the lower regions 
of colonic crypts and very rapidly begin to synthesise mucins.    Mature goblet cells 
are located on the upper region of the crypt, where they are polarized and specialised 
in unidirectional secretion of mucin granules.    Upon secretion, along with other 
factors, mucins form the mucus layer; a physical separation between the apical IEC 
membrane and the luminal bacteria.  This layer serves as a lubricant; allowing the 
passage of organisms and molecules down the digestive tract, and as a molecular 
sieve; the penetrative capacity of a molecule is governed by its molecular weight 
(Nimmerfall and Rosenthaler, 1980; Smithson et al., 1981; Specian and Oliver, 1991).   
 
The mucin matrix serves as a diffusion gradient of IEC-secreted factors and the 
mucus layer can be further divided into two distinct zones.  Antimicrobials secreted 
by IECs are high in concentration close to the apical epithelial cell surface, creating a 
relatively sterile environment.  The outer layer, devoid of antimicrobials, is however 
rich in bacteria as mucin oligosaccharides provide a site of adherence and a source of 
energy for invading microbes.  This ‘mucosal trapping’, along with the secretion of 
IgA, is thought to limit the association of bacteria with the epithelial cell membrane, 
hence preventing bacterial invasion of host tissue.  It is apparent that defects in this 
mucosal protection allows bacterial penetration and consequent inflammation; IBD 
patients have more bacteria associated with the epithelial cell surface (Rozee et al., 
1982; Hooper and Macpherson, 2010). 
 
A necessary balance of synthesis, secretion and degradation of the mucus layer is 
achieved by bacterial breakdown and the mechanical force of peristalsis.  However, 
quantitative and qualitative changes are seen in mucus production in certain 
pathologies.  Normally, many mucin granules lie beneath the apical membrane of a 
goblet cell, and the baseline mucus layer is maintained by the continuous exocytosis 
of just one granule.  However when challenged physically or chemically, the goblet 
cell is able to rapidly secrete its entire granule mass.  Mucin is then quickly 
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resynthesized and the cell is refilled with granules during an acute phase of infection 
(Specian and Oliver, 1991; Kim and Ho, 2010).  However, in chronic infection, hence 
sustained increased secretion of mucins, goblet cells are depleted and the mucus 
barrier is weakened due to altered synthesis and impaired secretion of mucins (Kim 
and Ho, 2010).   
 
MUC2 is the main structural component of the mucus layer.  It is clear mucins of the 
mucus layer have a critical role in epithelial protection, as knockouts and genetic 
polymorphisms in the MUC2 gene lead to spontaneous colitis due to a poorer barrier 
function of the intestinal lumen (Van der Sluis et al., 2006; Heazlewood et al., 2008).   
However, mucin overproduction can also be pathogenic.  A mouse line defective in 
IEC signaling (Pofut1(-/-) ) exhibits goblet cell hyperplasia and hypertrophy leading to  
the overproduction of mucus.  As early as four weeks, these mice display colonic 
inflammation thought to be a result of a change in the bacteria associated with the 
colonic mucosa (Guilmeau et al. 2008).   
 
Therefore, mucins appear to be tightly regulated in the homeostasis of the epithelial 
barrier, with pathologies being associated with both under and over production.  This 
is further confounded by goblet cell ablation experiments.  Unexpectedly, mice with a 
60% reduction of goblet cells in the large intestine were protected from intestinal 
injury.  Despite goblet cell depletion, MUC2 expression was comparable to the 
control mice, suggesting a compensatory overproduction of MUC2 (Itoh et al., 1999; 
Van der Sluis et al., 2006; Guilmeau et al., 2008; Heazlewood et al., 2008).  The 
protection mediated by fewer goblet cells therefore indicates the significance of other 
goblet cell secreted factors in the protection from inflammation.  A goblet cell 
secreted factor that has been extensively studied in intestinal homeostasis is resistin 
like molecule β.   
 
4.1.4 Resistin Like Molecule β 
 
Murine resistin is an adipose tissue derived hormone, which antagonises the action of 
insulin in the liver (Steppan et al., 2001a; Youn et al., 2004).  The expression of 
resistin in human adipose tissue is much lower and the biological relevance of the 
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human orthologue however remains unclear (Yang et al., 2003).  More recently, a 
family of resistin-like molecules (RELMs), or molecules found in inflammatory zones 
(FIZZ), were concomitantly characterised in the mouse.  Subsequently, resistin and 
the three structurally related RELMs, RELMα, RELMβ and RELMγ, constitute a 
family of proteins with isoform specific tissue expression.    
 
Murine RELMα (FIZZ1) mRNA was located to several tissues including white 
adipose tissue and the lungs, where it is induced upon epithelial injury.  RELMβ 
(FIZZ2) was however found exclusively in goblet cells of the murine digestive tract, 
most abundant in the colon and to a lesser extent in the small intestine.  RELMγ 
(FIZZ3) was expressed in the white adipose tissue of many of the organs tested.  
RELM proteins are secreted and, unlike the family founder resistin, are all induced in 
type 2 infection.  Human orthologues of RELMα and RELMγ have not been 
identified, however human and mouse RELMβ are very highly conserved and display 
similar expression profiles.  Subsequently RELMβ has received much more attention 
in the investigation of colonisation and infection of the gastrointestinal tract, in which 
it is shown to be apically secreted into the lumen exclusively by colonic goblet cells 
(Holcomb et al., 2000; Steppan et al., 2001b; Yang et al., 2003; He et al., 2003; 
Shojima et al., 2005; Hogan et al., 2006). 
 
RELMs contain an N-terminal signal sequence, a variable middle portion and a highly 
conserved C-terminal region containing 10 invariantly spaced cysteine residues.  Like 
resistin, human and murine RELMβ also contain an additional cysteine residue in the 
N-terminal domain.  Whilst the 10 conserved cysteine residues are thought to mediate 
intramolecular disulphide bonds, the 11th residue mediates the formation of dimers of 
resistin and RELMβ, identified both in vitro and in vivo.  The biological significance 
of dimer formation is unknown, however studies of resistin indicate the monomer is 
the bioactive form.  The conservation in vertebrates and absence in lower organisms 
of RELMβ suggest its expression in the intestine is a result of host-defense evolution 
against gastrointestinal infections (Banerjee and Lazar, 2001; Patel, 2004; Artis et al., 
2004; Nair et al., 2006). 
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4.1.4.1  RELMβ in Parasitic Infection 
Gastrointestinal (GI) nematode parasites pose a threat to health, infecting more than 
one billion people worldwide, and burden the economy in areas of infected livestock.  
Infection is characterised by goblet cell hyperplasia and a heightened helper T cell-2 
(Th2) cytokine response required for worm expulsion (Cliffe and Grencis, 2004).   
 
Whilst Th2 cytokines are considered to have an anti-inflammatory role, Th1 cytokines 
are associated with proinflammatory effects and perpetuating the autoimmune 
response.  The two distinct sets of cytokines are reciprocally regulated dependent on 
the type of immune assault and ideally, a correct balance of Th1 and Th2 activation 
will result in the appropriate response when challenged.  In a specific example of 
parasite infection, Th2 cytokines are required for the expulsion of Trichuris muris and 
resistance to infection.  However, Th1 cytokines such as INFγ, are associated with 
chronic infection and the development of severe intestinal inflammation (Cliffe and 
Grencis, 2004; Zaph et al., 2007).   Different levels of infection of this parasite 
produce polarised immune responses, hence giving rise to resistant or susceptible 
phenotypes.  At low levels of infection, Trichuris muris promotes a Th1 mediated 
response leading to chronic infection, whereas at higher levels of infection, the release 
of Th2 cytokines results in worm expulsion.  Trichuris muris infection has therefore 
been employed as an experimental system to investigate the two host responses to 
intestinal infection.   
 
RELMβ was originally shown to be coincident with the production of Th2 cytokines 
IL-4 and IL-13 during parasitic infection and in studies of the RELMβ knockout 
(RELMβ	   KO) mouse, the protein was shown to be required for parasite expulsion 
(Artis et al., 2004; Herbert et al., 2009).  Conversely, when investigating ‘low-dose’ 
infection, the RELMβ	   KO mouse was protected against intestinal inflammation.  
Infected RELMβ	  KO mice had lower levels of Th1 proinflammatory cytokines TNFα 
and INFγ and subsequently less intestinal inflammation than WT controls (Nair et al., 
2008).  Therefore, along with its identified anti-parasitic effect in the Th2 response, 
RELMβ also has a critical role in the development of severe intestinal inflammation 
in the chronic Th1 response.  This was further explained by the capability of RELMβ 
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to activate macrophages leading to the increased production of INFγ in cellular 
experiments (Nair et al., 2008). 
 
4.1.4.2  RELMβ in Models of Colonic Injury 
Models of experimentally induced colonic injury further corroborate a role of RELMβ 
in intestinal inflammation.  Dextran sulphate sodium (DSS) is a common agent used 
to induce epithelial injury.  Treatment leads to a reduced epithelial barrier function 
and infiltration of antigenic luminal components into the lamina propria beneath the 
epithelium.  Here, microbial components making contact with the host immune 
system have the potential to lead to chronic inflammation.  The RELMβ	  KO mouse 
was protected against intestinal inflammation in DSS treatment when compared to a 
WT control, even though intestinal permeability was present and comparable in both 
groups.  McVay et al. therefore hypothesise that once the epithelial barrier is breached, 
RELMβ is able to permeate and activate host immune cells.  In vitro and in vivo 
experiments revealed macrophages are activated by recombinant RELMβ, resulting in 
the release of inflammatory cytokine TNF-α.  In agreement, the RELMβ	  KO mouse 
has lower colonic levels of TNF-α (McVay et al., 2006).   
 
The protection from DSS treatment in the RELMβ	  KO mouse is further supported by 
additional investigations by Hogen et al.  DSS treatment resulted in a marked increase 
in RELMβ mRNA in the colon of WT mice and in agreement with previous 
observations, the knockout animals showed less weight loss, diarrhea-rectal bleeding 
and importantly higher survival rates when treated with the agent.  However, an 
additional observation was made; the permeability of the intestinal membrane, 
measured by tissue resistance, of untreated mice was higher in the knockout (Hogan et 
al., 2006).  This paradoxically implicates RELMβ to have a positive role in normal 
barrier physiology.  Indeed, the animals were more susceptible to inflammation when 
another agent, trinitrobenzene sulphonate (TNBS) co-administered with ethanol, was 
used to induce epithelial damage.  TNBS functions in a distinct mechanism to DSS 
and is not accompanied by an increase in RELMβ expression (Wirtz et al., 2007).  
The disparity in the two models of inflammation again presents RELMβ as a molecule 
of conflicting function.  In normal physiology, hence ‘basal’ expression, RELMβ is 
protective and contributes to barrier integrity.  However, if induced in models such as 
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DSS exposure, the protein has a role in disease pathogenesis, contributing to the 
severity of inflammation.   
 
4.1.4.3  RELMβ in Bacterial Colonisation 
Along with its role in parasitic infection, a relationship between RELMβ and the 
bacterial colonisation of the intestine has also been identified.  Commensal bacteria of 
the intestine has the potential to modify host gene expression and, using germ-free 
models or antibiotic treatment, has been implicated in several inflammatory disorders 
of the intestine such as IBD and cystic fibrosis (Norkina et al., 2004a; Wang et al., 
2005; Hooper and Macpherson, 2010).  RELMβ has been characterised as a factor, 
which is strongly influenced by the presence of the microbiota and the composition of 
diet, and is also capable of modifying the luminal environment. 
 
He et al. first showed RELMβ exists in murine and human stool samples, where it is 
present as a dimer.  RELMβ protein expression was markedly reduced in samples 
from germ-free animals and expression could be recovered by the reintroduction of 
bacteria into the intestine (conventionalisation). The induction of RELMβ expression 
upon conventionalisation was comparable in severe-combined immunodeficient mice, 
indicating bacterial mediated RELMβ expression is not dependent on the adaptive 
immune system.  Immunohistochemistry instead revealed colonisation of germ-free 
animals influenced the proliferation and maturation of goblet cells; changing the size, 
frequency and location of this particular cell lineage and subsequently RELMβ 
expression (He et al., 2003; Wang et al., 2005). 
 
Hildebrandt et al. further confirmed the microbiota-mediated induction of RELMβ 
mRNA and went on to show RELMβ protein is robustly induced in stool in response 
to high-fat feeding. This is supported by colonic mRNA and serum protein 
measurements conducted by Fujio et al., who also showed feeding alone induces 
colonic RELMβ.  Along with increased colonic mRNA, higher levels of epididymal 
fat were reported after the two-week high-fat diet.  Conversely diets high in protein 
and carbohydrate, diets associated with reduced diabetes incidence and improved 
waist circumference, led to reduced epididymal fat and lower RELMβ expression.  
Therefore, it is clear RELMβ responds to dietary stimuli and levels appear to correlate 
with changes epididymal fat (Fujio et al., 2008; Hildebrandt et al., 2009). 
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Analysis of the intestinal bacteria of a RELMβ KO mouse also revealed this apically 
secreted protein modifies the commensal bacteria.  When compared to the WT animal, 
differences in the Bacteroidetes and Firmicutes phyla were reported in the RELMβ 
KO.  The same investigation showed the RELMβ KO mouse to be protected from 
diet-induced weight gain (and increase in fat mass) in response to high-fat feeding.  
When WT and RELMβ KO animals were fed a high-fat diet, weight gain was only 
observed in the WT.  Moreover, this protection was mediated independently to 
changes in the microbial population.  In high-fat feeding both animals made the 
transition to a population well associated with weight gain and increased adiposity, a 
higher abundance of the Firmicutes phylum with a concomitant decrease in 
Bacteroidetes (Ley et al., 2005; Turnbaugh et al., 2009a), whereas only the WT 
controls developed the metabolic phenotype (Hildebrandt et al., 2009).   
 
Collectively these studies implicate RELMβ as a microbial sensor in the intestine, 
susceptible to changes upon conventionalisation and microbial shifts associated with 
diet.  Furthermore, expression is associated with the development of an unfavourable 
metabolic phenotype in response to dietary changes.  However, in the absence of the 
protein, KO animals do not respond to the high-fat diet and accompanied microbial 
shift.     
 
Wang et al. went on to show the presence of bacteria specifically upregulates RELMβ 
mRNA in the colon, with levels of family members RELMα and RELMγ remaining 
unchanged.    This is different to parasitic induction of the RELM family, where it is 
reported all three isoforms are upregulated in the colon and suggests a disparity in 
bacterial-mediated and infection-induced regulation of RELMβ.   
 
4.1.4.4  RELMβ in Other Inflammatory Disorders 
Cystic fibrosis (CF) is a result of mutations in the CFTR gene.  The CTFR protein 
controls ion transport across epithelia, hence fluid secretion and the pH of affected 
organs.  CF is consequently characterised by mucus aggregation, due to the poor 
solubility of secreted mucins and glycoproteins, and inflammation in airways and 
intestines of sufferers.  The cystic fibrosis mouse model presents with an increase in 
immune cells of the intestine and, along with other genes of the innate immune 
system, RELMβ was shown to be upregulated.  Norkina et al. went on to suggest 
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bacterial overgrowth in the small intestine, mediated by mucus aggregation, could 
explain intestinal inflammation.  Indeed, antibiotic treatment ameliorated the CF 
phenotype and resulted in a concomitant decrease in RELMβ expression (Norkina et 
al., 2004a; 2004b).  
 
Asthma is another chronic inflammatory disease of the airways.  Overproduction of 
mucus in the mucosa is a hallmark of asthma and other obstructive airway disorders.  
A marked overexpression of RELMβ was reported in the bronchial mucosa of 
asthmatics, which correlated with impaired lung function and epithelial mucin 
production.  Furthermore, expression was shown to increase with severity of asthma 
and is further induced upon inhalation challenges (Mishra et al., 2007; Grainge et al., 
2012).   
 
In these pathologies ectopic RELMβ expression appears to be linked with detrimental 
over production of mucus.  Recently using human colonic cell lines, RELMβ was 
proposed to act as a mucosecretagogue, specifically increasing the production and 
secretion of mucin MUC2 when applied apically.  RELMβ mediated MUC2 release 
was further confirmed by immunohistochemical analysis of colons of mice after 
receiving intrarectal RELMβ infusion (Krimi et al., 2008).  This positive regulation of 
mucin release and mucus formation could very well explain the pathogenicity of the 
induction of RELMβ in disorders of mucosal sites.  RELMβ over expression at 
affected sites leads to an overproduction of mucus, which is involved in disease 
pathogenesis.   
 
A mucosecretory function of RELMβ would also explain observations of the RELMβ 
KO mouse.  As described previously (see 4.1.3), a tight balance of mucin secretion is 
required, as pathologies are associated with both under and over production.  
Likewise, a similar control of RELMβ expression seems necessary for intestinal 
homeostasis. In the absence of RELMβ, mice have increased permeability of the 
intestinal epithelium and are more susceptible to certain noxious agents, indicating a 
requirement for a basal expression of the hormone.  However, in conditions of 
intestinal stress, induction of RELMβ participates in disease development.  In both 
DSS treatment and high-fat feeding the RELMβ KO mouse is protected from 
intestinal inflammation and diet-induced weight gain respectively.    
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4.1.4.5  RELMβ in Insulin Signaling 
As resistin is secreted by adipocytes and reported to inhibit insulin action and 
adipocyte differentiation, a role of RELMβ in insulin signaling has also been 
investigated.  Initially it was demonstrated an intra-arterial bolus of RELMβ worsened 
insulin sensitivity in mice.  During pancreatic insulin clamp experiments, lower levels 
of glucose and higher levels of insulin were required to maintain glycaemia in the 
RELMβ infused animals.   An increase in glucose production, resulted by higher 
levels of glycogenolysis, gluconeogenesis and glucose turnover, indicate an increase 
in circulating RELMβ reduces hepatic insulin sensitivity (Rajala et al., 2003).  
Although the physiological relevance of the RELMβ infusion used in experiments is 
unclear; as actual RELMβ levels entering the portal venous circulation is unknown, 
these results present an attractive link between a gut-derived hormone and hepatic 
metabolism.  
  
Kushiyama et al. went on to show hepatic overexpression of RELMβ had deleterious 
consequences in mice challenged with a high-fat diet.  Transgenic mice, the livers of 
which express RELMβ, were compared to WT animals in standard chow and high- fat 
feeding conditions. Only once challenged with a high-fat diet, transgenic animals 
became glucose intolerant, insulin resistant and displayed insufficient suppression of 
hepatic gluconeogenesis.  This was accompanied by increased serum glucose, insulin 
and lipids and hepatic triglycerides.  In cellular experiments, treatment of cultured 
hepatocytes with RELMβ resulted in activation of JNK, ERK and p38 kinases, all 
known to inhibit insulin receptor activity, and a subsequent decrease in cellular 
insulin signaling was observed (Kushiyama et al., 2005).  Therefore, although it is 
clear RELMβ has the potential to influence hepatic insulin resistance via MAPKs, the 
hepatic overexpression of RELMβ alone is not sufficient to mediate the progression 
of systemic insulin resistance; transgenic and control animals in standard chow 
conditions were comparable.  Furthermore the physiological relevance of hepatic 
overexpression is unclear.  The development of insulin resistance is evidently a more 
complicated event, likely to be influenced by several different extra-hepatic sites.   
In a more physiological context, without exogenous doses and overexpression, 
RELMβ and RELMγ were shown to be upregulated in serum of WT (C57BL/6J) mice 
in response to high-fat feeding.  Serum levels were in agreement with an increase in 
colonic RELMβ mRNA and protein, and correlate with body weight and serum 
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glucose and insulin.  This study begins to validate the previously mentioned 
investigations, indicating RELMβ is indeed able to enter circulation from the 
intestine.  However, the disparity in methods of investigation employed makes 
comparisons of actual levels of resultant circulating RELMβ between studies very 
difficult.   RELMβ and RELMγ isoforms were also increased in sera and colons of 
genetically obese (db/db) mice.  Interestingly, here, RELMβ and RELMγ correlated 
with weight and insulin but not glucose (Shojima et al., 2005).  RELMβ was therefore 
proposed as a diagnostic marker for obesity and diabetes, however measurement in 
human plasma has proved problematic (Neilson et al., 2011).   
 
Krimi et al. have suggested a functional role of RELMβ in the jejunum.  Experiments 
using isolated jejunal tissue show a decrease in glucose transport via the Na+/glucose 
cotransporter-1 (SGLT-1) and an increase in the translocation of GLUT2 to the brush 
border membrane in response to RELMβ stimulation (Krimi et al., 2009).  The 
inverse regulation of these two transporters results in the more rapid uptake of glucose 
in the jejunum tissue, a characteristic response of inflamed tissue due to increased 
metabolic demand.   Although corroborating a role of the protein in inflammation, the 
relevance of these investigations is again questionable as the jejunum is not the 
primary site of RELMβ expression, and the experiments are conducted ex vivo on 
processed tissue.  Moreover, no differences are observed in the plasma glucose of the 
RELMβ KO mouse and elevated RELMβ expression is not always associated with 
elevated serum glucose  (Shojima et al., 2005; Hogan et al., 2006).   
 
Whilst the area of research is evidently under debate, we can conclude RELMβ has 
the potential to influence insulin signaling and possibly glucose transport in the 
instance of inflammation.  Indeed, the mechanism of function for RELMβ seems be 
site specific and therefore the molecule more likely acts as a signal or cytokine, 
mediating subsequent cellular events, rather than a specific metabolic hormone.   
 
To conclude, a tight balance of RELMβ expression in the colon maintains intestinal 
homeostasis.   Basal expression has been indicated to have a positive role in barrier 
morphology and an anti parasitic function of the protein has been suggested.  
However, it is also evident the chronic, ectopic or excessive production of such a 
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factor in sustained infection, high-fat feeding and disease can contribute to the 
severity of inflammation.   
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4.2 EXPERIMENTAL QUESTIONS AND AIMS 
 
I. The intestinal microbiota has been proposed as a modulator of host energy 
storage (see 1.2.2).  To further characterise the luminal environment of the WT 
and FMO5 KO animal and its potential role in the metabolic phenotype, the 
intestinal microbiotas of the two mouse lines, fed either a standard chow or 
high-fat diet, will be investigated.   
 
II. To further clarify the expression of FMO5 in the digestive tract, investigations 
will aim to confirm the presence of the protein and investigate specific 
localisation in the murine gut.  The influence of a high-fat diet in intestinal 
expression of FMO5 will also be investigated.   
 
III. Similarities have been observed in the phenotype of the FMO5 KO and RELMβ 
KO mice; both animals are resistant to diet induced obesity.  To explore the 
potential link between the two intestinal proteins, the expression and function of 
RELMβ will be compared between the WT and FMO5 KO animal.   
 
IV. Furthermore, following the vast improvement in the metabolic phenotype of the 
WT animal in antibiotic treatment, I will also consider the effect of antibiotic 
treatment on the expression of proteins of interest, FMO5 and RELMβ.   
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4.3 RESULTS 
	  
4.3.1 A Perturbed Intestinal Microbiota in the FMO5 KO Animal 
 
A dysbiosis of the intestinal microbiota has been linked with the occurrence of obesity 
in an individual (Ley et al., 2005; Turnbaugh et al., 2009a).  It was proposed a change 
in the representation of the different phyla, in particular a rise in Firmicutes and 
decrease in Bacteroidetes, has the potential to alter the capacity of the host to harvest 
energy from the diet.  To investigate a potential role of the intestinal microbiota in the 
altered energy phenotype of the FMO5 KO, the commensal bacteria of the intestine 
was profiled in the WT and FMO5 KO animal.  DNA was isolated from faecal pellets 
of WT and FMO5 KO animals, bacterial 16S rRNA genes were selectively amplified, 
cloned and sequenced.  Using the online tool, The Ribosomal Database Project, 16S 
rRNA sequences were aligned and matched to 16S rRNA sequences of known 
bacterial origin (Wang et al., 2007; Cole et al., 2009).  Initially, the phyla composition 
was compared between the WT and FMO5 KO microbiota at 7, 10 and 30 weeks of 
age (Figure 4.1, Table 4.1).   
 
 
 
  
	   104 
 
  
Figure 4.1 – Phyla level analysis of the intestinal microbiota of 7-week, 10-week and 30-week old male WT and 
FMO5 KO male mice.  Sequence reads were pooled from faecal samples of triplicate cages (housing 3-4 mice) for 
each age point.  Analysis was conducted on samples from 7-week (WT, n=79; FMO5 KO; n=70),  10-week  (WT, 
n=156; FMO5 KO, n=73)   and 30-week (WT, n=172; FMO5 KO, n=180) old male mice.  Data is expressed as a 
percentage of total sequence reads. 
Table 4.1 – Phyla level analysis of the intestinal microbiota of 7-week, 10-week 
and 30-week old WT and FMO5 KO male mice.  Sequence reads were pooled from 
faecal samples of triplicate cages (housing 3-4 mice) for each age point. Analysis was 
conducted on samples from 7-week (WT, n=79; FMO5 KO; n=70),  10-week  (WT, 
n=156; FMO5 KO, n=73)   and 30-week (WT, n=172; FMO5 KO, n=180) old male 
mice.  Data is expressed as percent of total sequence reads. 
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Five phyla were identified in the digestive tract of the WT and FMO5 animal; 
Actinobacteria, Proteobacteria, Deferribacteres, Firmicutes and Bacteroidetes.  This is 
in agreement with previous investigations indicating only few bacterial divisions are 
present in the gastrointestinal tract, with the Bacteroidetes and Firmicutes phyla 
dominating (Bäckhed et al., 2005; Ley et al., 2006a; Arumugam et al., 2011).  As the 
representation of the three less abundant phyla; Actinobacteria, Proteobacteria, 
Deferribacteres, remained unchanged between animals and age groups they will be 
referred to herein as Other and analysis will focus on the abundance of the 
Bacteroidetes and Firmicutes phyla.  Unclassified refers to bacterial sequences that 
were not assigned at the phyla or family level with >80 % confidence.   
 
In the 7-week old animals, the representation of Bacteroidetes and Firmicutes is 
similar in both the WT and FMO5 KO animal (Figure 4.1, Table 4.1).  However, from 
7 to 10 weeks there is a rise in Firmicutes detected in the WT (7 week, 18 %; 10 
week, 40 %), which is accompanied by a decrease in Bacteroidetes (7 week, 73 %; 10 
week, 50 %).  The microbiota of the FMO5 KO however remains comparatively 
stable between 7 and 10 weeks, which results in a marked difference observed 
between the two animal lines at 10 weeks.  The ratio of Bacteroidetes to Firmicutes 
shifts further in the WT animals between 10 and 30 weeks; where detected levels of 
the two phyla almost become equivalent.  However, even though there is also a shift 
in the same direction observed in the FMO5 KO animal between 10 and 30 weeks, 
Bacteroidetes still outnumber the Firmicutes to a ratio of around 2:1 (Figure 4.1, 
Table 4.1).   
 
Taking a closer look at the changes in family representation of each phyla, we observe 
the change in abundance of Firmicutes through ageing is specifically due to a bloom 
in the Erysipelotrichaceae family (Table 4.2).  In the WT animal it is undetectable at 7 
weeks, however this family accounts for 26 % of the bacterial composition at 10 
weeks.  The bloom in the Erysipelotrichaceae family is accompanied by a specific 
decrease in counts of the Porphyromonadaceae family of the Bacteroidetes phylum (7 
week, 56 %; 10 week, 34 %).  Furthermore, when considering the less dramatic shift 
in Bacteroidetes and Firmicutes in the FMO5 KO between 10 and 30 weeks, it is 
again due to the concomitant rise in Erysipelotrichaceae and fall in 
Porphyromonadaceae families of the Firmicutes and Bacteroidetes phyla respectively.   
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In summary, at 7 weeks the FMO5 KO and WT animals present with similar phyla 
composition.  The levels of Bacteroidetes and Firmicutes in the two sets of mice are 
comparable, however the Bacteroidetes phylum is slightly more diverse in the FMO5 
KO at this age.  Through ageing in the WT animal, we report a marked increase in the 
abundance of the Firmicutes phylum with a reciprocal decrease in Bacteroidetes, a 
shift well associated with an obesogenic state.  Although this shift occurs in the 
FMO5 KO animal, it is to a much lesser extent and occurs later in ageing.  Our 
Table 4.2 – Family level analysis of the intestinal bacteria of 7-week, 10-week and 30-week 
old WT and FMO5 KO male mice. Sequence reads were pooled from faecal samples of 
triplicate cages (housing 3-4 mice) for each age point.  Analysis was conducted on samples from 
7-week (WT, n=79; FMO5 KO; n=70),  10-week  (WT, n=156; FMO5 KO, n=73)   and 30-week 
(WT, n=172; FMO5 KO, n=180) old male mice. Data is expressed as a percentage of total 
sequence reads. 
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observations are in part agreement with what is currently thought of the microbiota; a 
higher Firmicutes to Bacteroidetes ratio is observed in the WT animal, who gain more 
weight with ageing than do the FMO5 KO animals.  However, the difference in 
bacteria representation between WT and FMO5 KO mice is observed as early as 10 
weeks, whereas the weight phenotype difference between the two sets of animals does 
not present until the animals are 20 weeks and older (see Figure 3.2). 
 
4.3.2 The Response of the Intestinal Microbiota To High-Fat Feeding 
 
High-fat feeding is a remarkable modulator of the intestinal bacteria.  Through diet 
intervention studies in mice, a high-fat diet has been extensively shown to increase the 
abundance of Firmicutes and decrease the abundance of Bacteroidetes (Kim et al., 
2012; Turnbaugh et al., 2008; Lam et al., 2012; Hildebrandt et al., 2009; Turnbaugh et 
al., 2009b).  The microbial shift is thought to propagate the deleterious affects of 
high-fat feeding, further worsening the metabolic outcome of the individual.  
The FMO5 KO animal is resistant to the canonical metabolic response to high-fat 
feeding; they remain lean and their plasma glucose and insulin are unaffected (see 
section 3.3.2).  To assess a potential role of the microbiota in this protection, the 
intestinal bacteria of high-fat diet fed WT and FMO5 KO animals was also 
investigated (Figure 4.2, Table 4.3).   
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Figure 4.2 – Phyla level analysis of the intestinal microbiota of 30-week WT and 
FMO5 KO male mice fed a standard chow or a high fat diet.  Sequence reads were 
pooled from faecal samples of triplicate cages (housing 3-4 mice) for standard chow and 
duplicate cages for high fat diet conditions.  Standard chow (WT, n=172; FMO5 KO, 
n=180).  High Fat Diet (WT, n=212; FMO5 KO, n=214).  Data is expressed as a 
percentage of total sequence reads. 
Table 4.3 – Phyla level analysis of the intestinal microbiota of 30-
week old WT and FMO5 KO male mice fed standard chow or a 
high fat diet. Sequence reads were pooled from faecal samples of 
triplicate cages (housing 3-4 mice) for standard chow and duplicate 
cages for high fat diet conditions.  Standard chow (WT, n=172; FMO5 
KO; n=180).  High fat diet  (WT, n=212; FMO5 KO, n=214).  Data is 
expressed as percent of total sequence reads. 
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The microbiota of WT and FMO5 KO respond to the high-fat diet in the expected 
manner; Firmicutes becomes the most abundant phylum, with an accompanied 
decrease in Bacteroidetes levels.  In fact, the shift in composition is much more severe 
in the FMO5 KO animal, the Firmicutes now greatly outnumber the Bacteroidetes 
(Figure 4.2, Table 4.3).  Again, the rise in Firmicutes and fall in Bacteroidetes can be 
specifically attributed to the bloom in the Erysipelotrichaceae family and depletion of 
the Porphyromonadaceae family respectively (Table 4.4).   
 
 
Table 4.4 – Family level analysis of the intestinal bacteria of 30-week old WT and FMO5 
KO male mice fed standard chow or a high fat diet. Sequence reads were pooled from faecal 
samples of triplicate cages (housing 3-4 mice) for standard chow and duplicate cages for high fat 
diet conditions.  Standard Chow – WT; n=172, FMO5 KO; n=180.  High Fat Diet– WT; 
n=212, FMO5 KO; n=214.  Data is expressed as a percentage of total sequence reads. 
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Therefore, in high-fat feeding, both animals now harbor an intestinal microbiota that 
has been linked to excessive weight gain.  During the 6-week high-fat feeding 
experiment, the FMO5 KO animals did not however gain weight (see Figure 3.9).  
Taken together with the original observed microbiota differences at 10 weeks far 
predating the weight phenotype, the intestinal microbiota profile in both standard 
chow and high-fat feeding conditions does not correlate with the differences in body 
weight observed in the WT and FMO5 KO animal.   
 
Our results are not alone in disputing the change in the Bacteroidetes and Firmicutes 
phyla to be responsible for a change in energy storage of the host.  First and foremost, 
there are contradictory results regarding the change in the Bacteroidetes:Firmicutes 
ratio between obese and lean subjects; researchers report an obese microbiota exhibits 
no change at all, and either higher representation of the Firmicutes or Bacteroidetes 
phyla (Venema, 2010; Harris et al., 2012).  Taken with the findings that microbiota 
monitoring during weight loss also produces polarized results (Ley, 2010), it is clear 
the relationship is not always universally true and therefore a direct causative link is 
in dispute.  Although microbiota transplant experiments provide a convincing 
argument; germ-free mice that receive microbiota from obese donors gain more 
weight than those who receive a transplant from lean animals (Turnbaugh et al., 
2006), it has been questioned whether the modest change in energy harvest, mediated 
by a change in the representation of bacterial genes, would be great enough to elicit an 
immediate, observable change in the hosts gross phenotype.  Furthermore, a 
microbiome deemed more efficient in energy harvest is not always associated with an 
increase in weight gain and fat mass (Cani et al., 2008b). 
 
In the studies of the WT and FMO5 KO animal, we have however identified FMO5 as 
a novel regulator of the intestinal bacteria.  WT and FMO5 KO animals housed in the 
same animal holding room and fed the same standard chow present with different 
microbiotas.  Furthermore, we have shown the effect of a high-fat diet on the 
microbiota supersedes the genetic influence.  The diet intervention remodeled the 
commensal bacteria so that both WT and FMO5 KO animals present with similar 
microbiotas.  However, in the FMO5 KO the diet induced microbial shift is not 
accompanied by the once proposed related incidence of excessive weight gain.  
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In support of our findings, the colonic host protein RELMβ also modulates the 
intestinal microbiota when animals are fed a standard chow.  Similar to the FMO5 
KO, the RELMβ KO presents with a microbiota depleted in Firmicutes and enriched 
in Bacteroidetes.  The switch to a high-fat diet results in the canonical bloom in 
Firmicutes in both the WT and RELMβ KO, however, like the FMO5 KO, the 
RELMβ KO animal is protected from the diet induced obesity that is observed in the 
WT.  Akin to the FMO5 KO, the RELMβ KO mouse line is therefore further evidence 
of high-fat diet modulation of the intestinal microbiota occurring independently to 
obesity (Hildebrandt et al., 2009).  The protection from high-fat diet induced obesity, 
mediated by the absence of these two host proteins, highlights the complicated cross-
talk of host genetics and the microbiota in the response to diet. The hosts recognition, 
and subsequent reaction to the commensal bacteria and the luminal environment of 
the gut is now regarded to be just as, if not more, important than the microbiota itself.   
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4.3.3 FMO5 is Expressed in the Murine Digestive Tract 
 
When compared to the WT, the FMO5 KO has an altered intestinal microbiota.  
Although this disparity does not correlate with the observed metabolic phenotype, this 
led to further exploration into a role of FMO5 in the intestine.  FMO5 expression in 
the murine digestive tract was initially characterised.   
 
4.3.3.1  FMO5 detection in faecal contents 
To first confirm the presence of FMO5 in the murine digestive tract, protein isolated 
from faecal matter of WT animals was probed for FMO5.  Protein was isolated from 
faecal homogenates, acetone-precipitated and electrophoresed before transfer onto a 
nitrocellulose membrane (Figure 4.3).  A band migrating between the 50 and 60 kDa 
molecular weight marker was present in the WT samples and absent from the faecal 
matter proteins extracted from FMO5 KO mice.   
 
 
The detection of FMO5 in faeces indicates the protein is present in the digestive tract 
of WT mice.  The detection of FMO5 could be a result of the protein being secreted 
into the intestinal lumen.  Alternatively, FMO5 expression in epithelial cells, which 
are sloughed in excretion, would also result in the protein appearing in faeces.  
 
Figure 4.3 – FMO5 expression in the murine digestive 
tract.  Western blot analysis of protein isolated from faecal 
pellets of WT (n=2) and FMO5 KO (n=1) animals.  The 
membrane was probed for FMO5 (A) and total protein stain 
amido black was used to confirm equal loading (B).   
WT
FMO5
KO
A
B
60 kDa
50 kDa
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To further clarify the localisation of FMO5, immunohistochemical analysis was 
conducted on sections of the murine digestive tract (Figure 4.4 – 4.6).   
 
4.3.3.2  FMO5 expression in stomach mucosa 
Immunohistochemistry (IHC) of WT stomach mucosa (Figure 4.4-A and B) suggests 
FMO5 immunodetectection (brown) in both the lamina propria, at the base of the 
mucosa, and the columnar epithelial cells, at the luminal surface of the tissue.  FMO5 
KO tissue was stained for a negative control (Figure 4.4-C).  KO tissue had similar 
staining at the base of the lamina propria, indicating this signal is not a result of 
FMO5 expression and due to non-specific antibody binding.  The absence of the 
columnar epithelium staining in KO tissue would however indicate this is specific to 
WT tissue, therefore a result of FMO5 expression.   
 
 	    
Figure 4.4 – Immunohistochemical detection of FMO5 in stomach mucosa.  Butterflied section of WT stomach 
stained for FMO5 (A).  Higher magnifications of WT mucosa (B) and, for negative control, FMO5 KO mucosa (C).  
Scale bar: A, 500 µm; B and C, 100 µm.  M, mucosa; L, lumen; LP, lamina propria; CE, columnar epithelium.  
Photomicrographs are a representative of four WT and FMO5 KO male mice. 
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4.3.3.3  FMO5 expression in small intestine mucosa 
IHC was also performed on transverse sections of WT and FMO5 KO small intestine 
(Figure 4.5).  Sections of WT duodenum (Figure 4.5-A and D), jejunum (4.5-B and E) 
and ileum (Figure 4.5-C and F) stained for FMO5 (brown) also indicate the prevalent 
expression of the enzyme in the intestinal mucosa.   
 
Figure 4.5 – Immunohistochemical detection of FMO5 in small intestine mucosa.  Transverse sections 
of WT duodenum (A), jejunum (B) and ileum (C) stained for FMO5.  Higher magnifications of villi from 
WT duodenum (D), WT jejunum (E) and WT ileum (F) are shown in middle panels.   For negative controls, 
villi of corresponding FMO5 KO sections are shown in furthest right panels (G, H and I).  Scale bar: A - C, 
500 µm; D - I, 100 µm.  Mus, muscle; V, villi; L, lumen; CE, columnar epithelium; LP, lamina propria; GC 
goblet cell.  Photomicrographs are a representative of four WT and FMO5 KO male mice. 
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FMO5 is again expressed in the columnar epithelium of the mucosa, at the luminal 
surface of the tissue.  Higher magnifications of the intestinal villi (projections of the 
mucosa) (Figure 4.5-D, E and F) show the pervasive expression of FMO5 in the 
epithelial cell layer, including the specialised goblet cell; a cell type discussed in more 
detail in the introduction to this chapter (see 4.1.3).  The visible secretory granule, 
devoid of any staining, distinguishes the goblet cell from other epithelial cells.  FMO5 
is not expressed in the secretory granule itself, but is detected in the corresponding 
cell cytoplasm and expression seems most concentrated at the periphery of the 
granule.  Analogous staining of FMO5 KO duodenal (Figure 4.5-G), jejunal (Figure 
4.5-H) and ileal tissue (Figure 4.5-I) resulted in no signal, indicating the described 
staining of WT tissue is FMO5 specific.  Swiss rolls of WT intestine also show FMO5 
is expressed throughout the length of the small intestine (data not shown).   
 
4.3.3.4  FMO5 expression in colonic mucosa 
Colonic FMO5 expression was also confirmed with IHC (Figure 4.6).  Unlike the 
villi-projections seen in the small intestine, the mucosa of the colon is arranged in to 
rows of tubular glands (crypts of Lieberkühn or crypts).  The colonic mucosa may 
also further fold on itself forming a projection distinct to a villus; a mucosal fold.  
Similar to the mucosa of the small intestine however, FMO5 (brown) is highly 
expressed at the luminal surface of colonic mucosa (Figure 4.6-A).  Further 
magnification of WT colonic crypts (Figure 4.6-B) shows a gradient of FMO5 
expression from the base to the luminal opening of the crypt, and expression of FMO5 
is again throughout the columnar epithelium, including the prevalent goblet cells.  
FMO5 is not packaged within the secretory granule of the goblet cell, however 
staining is again clear in the cytoplasm and expression appears to be focused 
surrounding the granules.  FMO5 staining was also conducted in FMO5 KO colonic 
tissue for a negative control (Figure 4.6-C).  Staining is only observed in WT tissue 
and is therefore considered FMO5 specific.  Colonic Swiss rolls again reveal FMO5 
to be expressed throughout the entire colon 
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Figure 4.6 – Immunohistochemical detection of FMO5 in mucosal crypts of the colon. Transverse section of WT 
colon stained for FMO5 (A). Higher magnifications of WT mucosa (B) and, for negative control, FMO5 KO mucosa 
(C).  Scale bar: A, 200 µm; B and C, 50 µm.  MF, mucosal fold; M, mucosa; L, Lumen; GC, goblet cell; Cr, crypt; LP, 
lamina propria. Photomicrographs are a representative of four WT and FMO5 KO male mice. 
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4.3.4 No Gross Morphological Differences in the WT and FMO5 KO Digestive 
Tract  	  
Following the detection of FMO5 expression throughout the digestive tract, general 
histology was conducted to compare the gross morphology of WT and FMO5 KO 
tissues (Figures 4.7 – 4.9).  Nucleic acid stain hematoxylin and protein stain eosin 
were used together to investigate cell and tissue morphology, staining the nucleus 
blue and cytoplasm pink respectively.   
 
Hematoxylin and eosin staining of WT and FMO5 KO stomach (Figure 4.7) revealed 
no difference in mucosal thickness or tissue structure.   
 
  
 
  
Figure 4.7 – Gross morphology of WT and FMO5 KO stomach.  Butterflied 
sections of WT (A) and FMO5 KO (B) stomach stained with hematoxylin and 
eosin.  Scale bar: 500 µm. M, mucosa; L, lumen. Photomicrographs are a 
representative of four WT and FMO5 KO male mice. 
	   118 
Likewise, when comparing hematoxylin and eosin stained sections of WT and FMO5 
KO duodenum (Figure 4.8-A and D), jejunum (Figure 4.8-B and E) and ileum (Figure 
4.8-C and F) no difference is observed in the muscle layer or luminal arrangement of 
the small intestine.   
 
Figure 4.8 – Gross morphology of WT and FMO5 KO small intestine.  Transverse 
sections of WT duodenum (A), WT jejunum (B) and WT ileum (C) and FMO5 KO 
duodenum (D), FMO5 KO jejunum (E) and FMO5 KO ileum (F) stained with 
hematoxylin and eosin.  Scale bar: 500 µm.  V, villi; L, lumen; Mus, muscle.  
Photomicrographs are a representative of four WT and FMO5 KO male mice. 
 
	   119 
Furthermore, staining also shows no difference in the mucosal arrangement or muscle 
layer thickness of colon tissue of the WT and FMO5 KO mice (Figure 4.9).   
 
  
Immunohistochemical analysis of WT tissue reveals the prevalent expression of 
FMO5 throughout the murine digestive tract, in particular epithelial cells at the 
luminal surface of tissue.  However, in comparison of the WT and FMO5 KO tissue, 
no gross morphological differences are observed in the protein’s absence.  No 
epithelial damage or reduction in barrier integrity was recorded for either genotype in 
any intestinal section.   
 	    
Figure 4.9 – Gross morphology of WT and FMO5 KO colon.  Transverse sections 
of WT (A) and FMO5 KO (B) colon stained with hematoxylin and eosin.  Scale bar: 
500 µm.  Mus, muscle; MF, mucosal fold; L, lumen; M, mucosa.  Photomicrographs 
are a representative of four WT and FMO5 KO male mice. 
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4.3.5 FMO5 Expression is Induced in Response to the High-Fat Diet 	  
The disparity in the metabolic phenotype of the WT and FMO5 KO animal becomes 
more pronounced in response to a high-fat diet (see 3.3.2).  High-fat feeding resulted 
in further weight gain and increases in plasma glucose and plasma insulin in the WT 
animal, whereas the FMO5 KO remained lean with low plasma glucose and insulin.  
The worsening of the metabolic phenotype in the WT, and protection in the FMO5 
KO, suggests FMO5 may have a role in the response of an animal to their diet.  
Intestinal expression of FMO5 following high-fat diet feeding was therefore 
investigated.   Protein isolated from faecal samples of WT animals fed either a control 
or high-fat diet was concentrated by acetone precipitation, electrophoresed and 
Western blot analysis was performed with an FMO5 antibody. 
 
FMO5 expression in the digestive tract is robustly induced in response to high-fat 
feeding (Figure 4.10), indeed suggesting an involvement in an animal’s response to 
high-fat feeding. The analysis was conducted in faecal samples, a gross, and non-
specific representative of the digestive tract.  
 
 	    
Figure 4.10 – Faecal FMO5 expression following high fat feeding.  
Western blot analysis of protein isolated from faecal samples of WT 
animals fed a standard chow (WT, n=4) or a high fat diet (WT-HFD, 
n=4).  The membrane was probed for FMO5 (A) and total protein stain, 
amido black was used to confirm equal loading (B).   
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4.3.6 A Disparity in RELMβ Expression in the WT and FMO5 KO Animal 
 
This study shows that FMO5 is expressed throughout the murine digestive tract and is 
induced in high-fat feeding.  RELMβ is a goblet cell secreted factor described in more 
detail in the introduction to this chapter (see 4.1.4).  RELMβ is highly expressed in 
the colon and is also induced in high-fat feeding.  Like the FMO5 KO (see Figure 
3.9), the RELMβ KO is protected from diet-induced obesity (Hildebrandt et al., 
2009).  The common colonic expression of both proteins, and the similarity in the 
phenotypes of the FMO5 and RELMβ KO mice, led to the investigation of the of 
colonic expression of RELMβ in the presence (WT mice) and absence (FMO5 KO 
mice) of FMO5.   
 
4.3.6.1  Western Blot Analysis of Colon Contents 
RELMβ expression was initially investigated in the luminal content of the colon. 
Protein was isolated from colon contents of the WT and FMO5 KO mouse and 
electrophoresed.  Western blot analysis was conducted using an antibody against full-
length RELMβ (Abcam®) (Figure 4.11).   
 
 
  
Figure 4.11 – Expression of RELMβ in colon contents of WT and FMO5 KO 
animals.  Immunoblot analysis of protein isolated from colon contents of WT (n=4) and 
FMO5 KO (n=3) male mice.  MM: molecular weight marker.  The membrane was probed 
for RELMβ (A) and total protein stain amido black was used to check protein loading (B). 
M, monomer; D, dimer. 
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RELMβ was first shown to exist in stool contents of the murine colon by He et al. (He 
et al., 2003).  The protein exists as a dimer under non-reducing conditions, migrating 
just above a 17 kDa marker.  In both the WT and FMO5 KO samples, we also detect a 
band, migrating just below the 20 kDa molecular weight marker, likely to correspond 
to the dimer.  In all WT samples analysed, there is also an additional band migrating 
just below the proposed dimer.  In the WT colon, RELMβ also appears to exist as a 
monomer of approximately 8 kDa.   
 
He et al. detected the RELMβ monomer (6-8 kDa) when the SDS-PAGE was run 
under reducing conditions.  In my investigations the gel was not run under stringent 
reducing conditions, this is clear from the presence of the dimer.  Although 
dithiothreitol was used as a reducing agent in the sample buffer used to prepare 
samples for SDS-PAGE, subsequent observations revealed the agent must also be 
added to running buffers used in the electrophoresis system due to the small size and 
high cysteine content of the protein.  Regardless, under the ‘partial’ reducing 
condition used for both WT and FMO5 KO samples, there is disparity in the RELMβ 
species present.  In the WT and FMO5 KO colon the dimer is detected, however I also 
propose the smaller molecular weight species, found exclusively in the WT, to be the 
monomer.   
 
4.3.6.2  Immunohistochemistry of Colon Tissue 
Following Western blot analysis of colon contents, immunohistochemistry compared 
expression of RELMβ in WT and FMO5 KO colonic tissue (Figure 4.12).  Transverse 
sections of WT (Figure 4.12-A) and FMO5 KO (Figure 4.12-B) colon stained for 
RELMβ (brown) show protein expression is localised to the crypts of the colonic 
mucosa.  Higher magnifications of WT (Figure 4.12-C) and FMO5 KO crypts (Figure 
4.12-D) further show RELMβ expression is concentrated in the secretory granules of 
goblet cells and, similar to colonic staining for FMO5, a gradient of expression from 
the base of the crypt to the luminal opening is observed. This is in agreement with 
previous investigations into RELMβ expression (He et al., 2003; Hogan et al., 2006; 
McVay et al., 2006) and the absence of RELMβ staining in extra-colonic sections of 
the intestine further confirms RELMβ to be a colon specific protein (data not shown).  
Immunohistochemistry does not provide information on the dimerisation state of 
RELMβ however, in agreement with the Western blot analysis of colon contents, both 
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the WT and FMO5 KO produce RELMβ.  Furthermore, localisation of the colonic 
hormone is unchanged in the genotypes.   
 
 	    
Figure 4.12 – Goblet cell expression of RELMβ in WT and FMO5 KO colon.  
Transverse sections of WT (A) and FMO5 KO (B) colon stained for RELMβ.  Higher 
magnifications of WT mucosa (C) and FMO5 mucosa (D) are shown below.  Scale bar: A 
and B, 500 µm; C and D, 50 µm.  M, mucosa; L, lumen; MF, mucosal fold; Cr, crypt; GC, 
goblet cell; LP, lamina propria.  Photomicrographs are a representative of four WT and 
FMO5 KO male mice. 
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4.3.6.3  Western Blot Analysis of Faecal Contents 
To further explore the difference in RELMβ expression, protein isolates from the 
faeces of WT and FMO5 KO animals were assayed.  Western blot analysis of faecal 
proteins, using an antibody against full-length RELMβ, show that the dimer of 
RELMβ is the only species detected, and the amount of dimer is higher in the FMO5 
KO (Figure 4.13).   
 
By investigating protein levels in faecal samples, we can deduce what the animal is 
excreting.  Although colonic amounts of the dimer species in WT and FMO5 KO 
animals are comparable (see Figure 4.11), the FMO5 KO animals excrete more of the 
RELMβ dimer in their faeces than do WT mice. We may speculate this is due to the 
difference in the amount of the monomeric and dimeric state of RELMβ in the two 
animals.  In functional studies of resistin, the closely related family member of 
RELMβ, the monomer species was shown to be the active form of the hormone 
(Patel, 2004).  Therefore, in the colon of the FMO5 KO mouse, we propose that 
RELMβ exists as an inactive dimer, which is subsequently excreted and therefore 
detected in high amounts in the faeces.  Whereas in the WT animal the dimer is 
processed to the monomeric, or active, form of RELMβ, which results in less of the 
dimeric protein being excreted.   
 
 
 
 
 
 
 
 	    
Figure 4.13 – Faecal expression of RELMβ in the WT and FMO5 KO 
mouse.  Immunoblot analysis of protein isolated from faecal pellets of WT 
(n=3) and FMO5 KO (n=3) male mice.  The membrane was probed for 
RELMβ and equal loading was confirmed using Colloidal Gold Total Protein 
Stain (Bio-Rad) (not shown).  D, dimer. 
20 kDa
WT FMO5 KO
D
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4.3.7 RELMβ Expression is Induced in Response to the High-Fat Diet 
 
It is well known that RELMβ is induced in response to a high-fat diet.  Both colonic 
mRNA and serum protein levels were found to be elevated in high-fat diet fed animals 
(Shojima et al., 2005; Fujio et al., 2008; Hildebrandt et al., 2009).  To determine 
whether the presence of FMO5 influences the ability of an animal to induce RELMβ, 
WT and FMO5 KO animals fed either standard chow or a high-fat diet were 
monitored for RELMβ expression.  Protein was isolated from faecal samples and 
Western blot analysis was conducted with an antibody against a synthetic peptide 
corresponding the amino acids 2-46 of mouse RELMβ (QED Bioscience) (Figure 
4.14).   
 
Using this peptide antibody, instead of the monomer and dimer species, a larger band 
migrating between the 30 and 40 kDa molecular weight marker is detected.  This is 
however the only band detected and it may therefore be that this antibody 
preferentially recognises a higher oligomeric state of RELMβ.  In studies of resistin, a 
closely related family member, Patel et al. describe the detection of a hexamer 
species.  Taking the detected size of the RELMβ  monomer described by He et al. as 6 
kDa, it is possible that with this antibody we are detecting the RELMβ hexamer of 36 
kDa.   
 
  
Figure 4.14 – Faecal RELMβ expression following high fat feeding.  Western blot 
analysis of protein isolated from faecal samples of WT and FMO5 KO animals fed a 
standard chow (WT, n=2; FMO5 KO, n=2) or a high fat diet (WT HFD, n=2; FMO5 
KO HFD, n=2).  The membrane was probed for RELMβ (A) and total stain Colloidal 
Gold Total Protein Stain (Bio-Rad) was used to confirm equal loading (B).   
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Faecal pellets of WT and FMO5 KO animals fed either a standard chow or high-fat 
diet were analysed and conditions were run in duplicate.  One isolation from WT 
animals fed a high-fat diet (WT HFD) failed; no RELMβ is detected and the total 
protein stain for the corresponding lane is weaker than other samples.  The single 
successful isolation from the WT HFD condition does however indicate RELMβ is 
induced in high-fat feeding; more RELMβ is detected in the faeces of the WT animal 
fed a high-fat diet (WT HFD) than those from WT animals fed standard chow (WT).  
Furthermore, this is apparent in the FMO5 KO condition.  Higher levels of RELMβ 
are also detected in faeces of FMO5 KO animals fed a high-fat diet (FMO5 KO HFD) 
than those fed standard chow (FMO5 KO).  Therefore, both animals respond in the 
canonical way to the high-fat diet, in the induction of RELMβ.   
 
The higher amount of RELMβ detected in the faeces of FMO5 KO animals fed a 
normal chow diet (see figure 4.13) is also observed in high-fat feeding.  In both 
circumstances the absence of FMO5 leads to more of the RELMβ protein being 
excreted. Therefore, in both basal expression and high-fat diet induction, it seems the 
absence of FMO5 is no hindrance to the production of the RELMβ in the colon. The 
protein is produced, but more is excreted in the FMO5 KO animal. 
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4.3.8 A difference in Colonic Goblet Cells in the FMO5 KO Animal 
 
As discussed in the introduction to this chapter (see 4.1.4), RELMβ is proposed to act 
as a mucosecretagogue (Krimi et al., 2008).  When applied apically to human colonic 
cells, RELMβ induced the secretion of mucin protein MUC2.  MUC2 is a goblet cell-
secreted factor and is a major structural component of the mucus layer (Kim and Ho, 
2010).  Mucin proteins are packaged into the secretory granules of the goblet cell and 
basal exocytosis is necessary for the formation of the protective mucus layer.   
 
This study has shown RELMβ to exist as both a monomer and dimer in the WT colon.  
Conversely, the dimer is the only form observed in the FMO5 KO.  To investigate the 
functional consequence of the difference observed in RELMβ, mucosecretory 
function was measured in the WT and FMO5 KO mouse.  Sections of WT and FMO5 
KO colon were stained with alcian blue (Figure 4.15).  Alcian blue stains the mucin 
polysaccharides of secretory granules and is used to identify and quantify secretory 
goblet cells.  Higher magnifications of WT (Figure 4.15-C) and FMO5 KO (Figure 
4.15-D) colonic mucosa shown below indicated a difference in goblet cell number; 
alcian staining appears less frequent in the FMO5 KO colonic crypts.   
	   128 
Subsequently, a method previously described by Mello et al. was used to quantify 
goblet cell number in the WT and FMO5 KO colon (de Oliveira Mello et al., 2012).  
Photomicrographs of alcian blue-stained colon sections of WT and FMO5 KO 
animals were used for analysis.  Six regions of interest, containing at least 3 
contiguous crypts, were sampled per photomicrograph and 18 crypts were analysed 
per biological repeat.  Crypt length was measured and the number of goblet cells 
(alcian blue stained bodies) was recorded for each crypt analysed.  
 
Figure 4.15 – Goblet cell staining of WT and FMO5 KO colonic mucosa.  Transverse 
sections of WT (A) and FMO5 KO (B) colon are stained with alcian blue for goblet cell 
detection and counter-stained with neutral red.  Higher magnifications of WT (C) and 
FMO5 KO (D) mucosa are shown below.  Scale bar: A and B, 500 µm; C and D, 100 µm.  
MF, mucosal fold; M, mucosa; L, lumen; Cr, crypt; GC, goblet cell.  Photomicrographs are 
a representative of four WT and FMO5 KO male mice. 
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In measurement of crypt length, no difference was observed in the WT and FMO5 
KO colon crypts (WT, 151.7 ± 3.6 µm, n=57; FMO5 KO, 162.1 ± 5.0 µm, n=54) 
(Figure 4.16).   
 
The number of goblet cells per crypt was however found to be higher in the WT colon 
(WT, 18.5 ±  0.8, n=57; FMO5 KO, 15.4 ±  0.7, n=54) (p<0.01) (Figure 4.17)   
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Figure 4.16 – Measurement of colon crypt length in 
WT and FMO5 KO mice.  Colon photomicrographs 
of WT (n=3) and FMO5 KO (n=3) male mice were 
used for quantification.  At least 18 crypts per 
photomicrograph were sampled.  Crypt lengths of WT 
(n=57) and FMO5 KO (n=54) crypts were measured.  
Data is expressed as mean ± SEM.   
Figure 4.17 – Goblet cell quantification 
in WT and FMO5 KO colonic crypts.  
Colon photomicrographs of WT (n=3) and 
FMO5 KO (n=3) male mice were used for 
quantification.  At least 18 crypts per 
photomicrograph were sampled. Counts of 
goblet cells per crypt for WT (n=57) and 
FMO5 KO (n=54) crypts were recorded.  
Data is expressed as mean ± SEM (**: 
p<0.01) 
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Furthermore, when goblet cell number is expressed over crypt length, thus giving a 
measure of goblet cell number per unit of crypt length (Figure 4.18), the difference in 
the WT and FMO5 KO becomes more pronounced.  Normalised for crypt length, the 
WT colonic crypt contains more goblet cells (WT, 12.2 ± 0.4 cells.100µm-1, n=57; 
FMO5 KO, 9.5 ± 0.3 cells.100µm-1, n=54) (p<0.0001).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In the absence of FMO5, we observe a difference in the processing of colonic 
hormone RELMβ.  The monomer, and proposed active form of RELMβ, is absent in 
the FMO5 KO colon.  In line with RELMβ acting as a mucosecretagogue, in 
investigations of the colon mucosa, the absence of the monomer is accompanied by a 
decrease in goblet cell number in KO crypts.   
 
Goblet cell secretion is necessary for the formation of the mucus layer and secretion is 
upregulated when the cell is physically or chemically challenged.  However, as 
described in more detail in the introduction to this chapter (see 4.1.3), a tight 
regulation of MUC2 production and mucin secretion is necessary as pathologies are 
associated with over, as well as under, production.  RELMβ has been described as a 
mucosecretagogue (Krimi et al., 2008), and the upregulation of RELMβ and 
overproduction of mucus is a hallmark of several inflammatory disorders of  mucosal 
sites (see 4.1.4).  A moderate suppression of mucosecretion, mediated by an 
attenuation of RELMβ activation, in the FMO5 KO mouse may therefore be 
Figure 4.18 – Goblet cell number normalised to 
colon crypt length in WT and FMO5 KO mice.  
Colon photomicrographs of WT (n=3) and FMO5 
KO (n=3) male mice were used for quantification.  
At least 18 crypts per photomicrograph were 
sampled.  Goblet cell number is divided by crypt 
length for WT (n=57) and FMO5 KO (n=54) 
crypts analysed.  Data is expressed as mean ± SEM 
(*:p<0.0001).   
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protective.  Of note, the absence of FMO5 does result in detrimental goblet cell 
ablation (see Figure 4.17) and subsequently no gross morphological differences are 
seen in the luminal integrity of intestinal tissue (see 4.3.4), however a small decrease 
in goblet cell activity when compared to the WT animal may be beneficial to the 
FMO5 KO.   
 
The RELMβ KO mouse is protected from diet induced obesity, also indicating a key 
role for this protein in the response to a high-fat diet (Hildebrandt et al., 2009).  In 
high-fat feeding the induction of RELMβ is observed in both animals, however we 
deduce that an attenuation in processing, and lack of activity, of RELMβ in the FMO5 
KO animal leads to the proteins excretion in faeces (see Figure 4.14).  Therefore, in 
addition to maintaining a beneficial intestinal environment in the standard chow 
condition, the absence of FMO5, and proposed inactivity of RELMβ, also serves to 
protect the FMO5 KO animal from diet induced obesity.  
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4.3.9 RELMβ and FMO5 Expression Following Antibiotic Treatment 
 
To investigate the role of the intestinal microbiota, WT and FMO5 KO animals were 
treated with low-dose, broad-spectrum antibiotics to reduce the bacterial load of the 
intestine (see 3.3.3).  Metabolic profiling following treatment revealed, although the 
FMO5 KO remained unaffected, antibiotic treatment improved glucose tolerance and 
lowered plasma insulin and glucose in the WT mouse.  Consequently, the phenotype 
of the antibiotic treated WT animals resembled that of the FMO5 KO.  To further 
understand the convergence in phenotype, intestinal expression of proteins of interest 
FMO5 and RELMβ were measured following treatment.   
 
4.3.9.1  Ablation of RELMβ Expression in Antibiotic Treatment 
RELMβ has been well characterised as a goblet cell secreted factor and expression is 
heavily dependent on the presence of the microbiota.   Colonic RELMβ protein and 
mRNA measurements are markedly reduced in germ-free animals and both can be 
recovered upon conventionalisation (He et al., 2003; Wang et al., 2005).  Protein was 
isolated from faeces of WT animals and WT animals treated with antibiotics.  
Previously RELMβ was detected in WT faeces at very low levels (see Figure 4.13), 
therefore protein samples were first concentrated by acetone-precipitation before 
being electrophoresed and transferred onto nitrocellulose membrane.  Western blot 
analysis was performed with the peptide RELMβ antibody and subsequently the 
proposed RELMβ hexamer was detected (Figure 4.19). 
 
 
Figure 4.19 – Faecal RELMβ expression following antibiotic 
treatment.  Western blot analysis of protein isolated from 
faecal samples of WT animals (WT) (n=3) and WT animals 
treated with antibiotics (WT antibiotic) (n=3).  The membrane 
was probed for RELMβ (A) and total protein stain amido black 
was used to confirm equal loading (B).   
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In agreement with previous studies of RELMβ, antibiotic treatment experiments were 
found to attenuate RELMβ expression.  The response of RELMβ, a protein known to 
be potently induced by the presence of the microbiota, validates the antibiotic 
treatment used and the proposed reduction in microbial load of treated animals.   
 
4.3.9.2  FMO5 Expression is Unchanged in Antibiotic Treatment 
Concentrated protein samples of faecal pellets from WT and antibiotic-treated WT 
animals were also used to investigate the response of FMO5 to the antibiotic 
treatment (figure 4.20). 
 
 
Though there is high variation in the samples, it seems FMO5 expression is 
unchanged in treatment, indicating expression is not so heavily dependent on the 
microbiota.   
 
  
Figure 4.20 – Faecal FMO5 expression following antibiotic 
treatment.  Western blot analysis of protein isolated from faecal 
samples of WT animals (WT) (n=3) and WT animals treated with 
antibiotics (WT antibiotic) (n=3).  The membrane was probed for 
FMO5 (A) and total protein stain amido black was used to confirm 
equal loading (B).   
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4.4 CONCLUSIONS 	  
FMO5 was found to be expressed in epithelial cells in all sections of the digestive 
tract analysed.  Although no difference was observed in the gross morphology of WT 
and FMO5 KO intestinal tissue, in microbiota analysis we demonstrate FMO5 
expression modifies the commensal bacterial of the intestine.  However, further 
characterisation of the intestinal microbiota in high-fat feeding experiments dispute 
this to be the cause of the altered energy phenotype of the WT and FMO5 KO.  
Similar to the RELMβ KO mouse, the FMO5 KO is protected from diet-induced 
obesity independent to the intestinal dysbiosis.   
 
As discussed in chapter 3 (see 3.3.3), the antibiotic treatment of the WT animal elicits 
the expected response in the elimination of the intestinal microbiota; an overall 
improvement in insulin sensitivity and glucose homeostasis.  However, the metabolic 
phenotype of the FMO5 KO remained unchanged in treatment.  In addition, similar to 
a germ-free model, the KO animal presents with a heightened insulin sensitivity from 
a young age.  We therefore propose the FMO5 KO as a ‘pseudo germ-free’ model; 
impervious to the presence of the commensal microbes of the intestine.   
 
From investigations into the intestine of WT and FMO5 KO mice, we further propose 
the absence of FMO5 mimics a germ-free environment by attenuating the necessary 
processing of RELMβ, the microbial sensor of the intestine.  In the absence of FMO5, 
RELMβ remains as an inactive dimer resulting in a modest, beneficial reduction in 
mucosecretion.  In high-fat feeding RELMβ is induced, however remains as an 
inactive dimer in the KO.  Analogous to the RELMβ KO, the FMO5 KO animal is 
therefore protected from diet induced obesity.  In antibiotic treatment, and subsequent 
attenuation in RELMβ expression, the WT animal adopts the pseudo germ-free profile 
of the FMO5 KO.   
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Chapter 5 - Low-grade Inflammation in 
Metabolic Disorders 
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Chapter 3 describes a heightened insulin sensitivity of the FMO5 KO and its 
subsequent influence on the gross metabolic phenotype of the animal.  Following 
investigations into the intestine of the WT and FMO5 KO mice, in Chapter 4 we 
report a disparity in the luminal environment of the two mouse lines.  There is a 
difference in the dimerization state of the colonic hormone RELMβ.  Only the WT 
expresses the active monomer and mucosecretion, known to be induced by RELMβ, 
was found to be higher in the WT.  In addition to a mucosecretagogue, RELMβ is also 
regarded as an inflammatory mediator.  RELMβ-activation of macrophages results in 
inflammatory TNFα release (Hogan et al., 2006; McVay et al., 2006; Krimi et al., 
2008).  In this chapter a potential link between intestinal inflammation and systemic 
insulin resistance will be explored.   
 
5.1 INTRODUCTION 	  
5.1.1 Inflammation and Metabolism 
Both the metabolic and immune systems are fundamental to the survival of a 
multicellular organism.  The signaling networks have evolved to be closely linked; 
many bioactive molecules including cytokines, hormones and lipids function in both 
immune and metabolic roles, and the interplay of the two pathways is now a well-
established mediator of an individual’s homeostasis.  The regulation of metabolism in 
immunity is clear; in the extremes of obesity the immune system is activated and 
malnutrition results in immunosuppression, however the reverse is also the case.  
Immunity relies on metabolic support; the mobilisation of stored lipid helps fight 
infection, and hence basic inflammation promotes a catabolic state, suppressing 
anabolic processes including the function of insulin.  Therefore, a delicate balance 
must exist between inflammatory and metabolic signaling in the maintenance of good 
health, as disorder in one will lead to the imbalance of the other (Hotamisligil, 2006; 
Shoelson et al., 2007).  	  
 
Inflammation is the response of an organism to a harmful stimulus, normally resulting 
in the delivery of plasma components to the site of injury, facilitating the return to a 
homeostatic state.  More recently a distinct, mild inflammatory state has been linked 
to metabolic disorders.  This inflammation occurs in the absence of gross tissue injury 
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or infection, and the subclinical state has subsequently been referred to as  ‘metabolic’ 
or ‘low-grade’ inflammation.  Although mild, the chronic, low-grade inflammatory 
state has become heavily implicated in the disturbance of energy distribution seen in 
several metabolic pathologies including diabetes and obesity (Wellen and 
Hotamisligil, 2005; Monteiro and Azevedo, 2010).   
 
5.1.2 Adipose Tissue  
In addition to adipocytes, adipose tissue contains a connective tissue matrix and 
several immune cells.  Whereas brown adipose tissue functions mainly to produce 
heat through the uncoupling of oxidative phosphorylation in hibernating mammals, 
white adipose tissue (WAT) is responsible for triglyceride storage when energy is 
available and the mobilisation of lipids in times of energy deficit.  In addition, WAT 
also secretes bioactive molecules, such as adiponectin and cytokines IL-1β, IL-6 and 
TNFα, enabling the organ to communicate with the other metabolically active tissues 
of the body.  Subsequently WAT is now considered to be much more than a passive 
site of energy storage, with the capacity to regulate food intake, energy homeostasis 
and insulin signaling (Shoelson et al., 2007; Park et al., 2014).   
 
WAT can be further subdivided into visceral and subcutaneous depots, specifically 
the former being implicated in the instigation and propagation of metabolic low-grade 
inflammation.  Visceral adipose tissue (VAT) secretion of chemokines, in particular 
monocyte chemoattractant protein 1, induces macrophage infiltration of adipose 
tissue.   Due to the secretion of their own inflammatory molecules, infiltration of 
macrophages further propagates the inflammatory response.  The resulting interaction 
between endothelial cells, adipocytes and macrophages potentially leads to the 
originally local inflammation resulting in a systemic state of low-grade inflammation 
(Shoelson et al., 2006; Monteiro and Azevedo, 2010; Lam et al., 2011; Kwon and 
Pessin, 2013; Park et al., 2014). 
 
Insulin signaling is suppressed in the inflammatory state.  An increase in adiposity, 
and resultant increase in inflammatory tone is subsequently now regarded as a prime 
contributor to the pathogenesis of type 2 diabetes (T2D).  The size of specifically 
VAT depots correlates with inflammatory markers and in cross studies of healthy and 
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diabetic individuals, markers of inflammation are heavily associated with and actually 
predict the development of insulin resistance and occurrence of T2D (Duncan et al., 
2003; Herder et al., 2007; Sam et al., 2009). 
 
Although elevated fatty acids in circulation alone is known to have an inhibitory 
effect on insulin signaling, when Miyazaki et al. further investigated the role of 
visceral fat in peripheral insulin resistance (i.e. muscle and liver), it was not correlated 
with plasma free fatty acid (FFA) levels.  This suggests the relationship is not simply 
due to an increase in circulating FFA and further corroborates another role of adipose 
tissue and its association with the development of insulin resistance (Miyazaki et al., 
2002).  In using conditioned media from human VAT, Lam et al. again demonstrated 
the inhibitory action of VAT on the insulin pathway of a cultured rat muscle cell line.  
The inhibition was partly restored when IL-6 was neutralised, implicating a role of 
adipose tissue derived cytokines in adipose tissue induced diminished insulin 
signaling (Lam et al., 2011).  In addition, several other studies have described the 
detrimental effect of adipose tissue derived TNFα on insulin sensitivity and the 
efficacy of TNFα blocking as a therapeutic in humans with inflammatory linked 
metabolic disorders (Kwon and Pessin, 2013).   
 
Furthermore, even in the absence of full disease development, the associated increase 
in cytokines with greater adiposity in ageing is proposed to explain the age-related 
decline in insulin sensitivity.  Indeed, anti-inflammatory agents, which decrease 
inflammatory tone, reduce the risk of development and improve control in already 
established diabetes (Pickup, 2004; Park et al., 2014). The mechanism of cytokine 
induced insulin resistance will be discussed further in the following section.   
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5.1.3 Inflammation and Insulin Signaling 
 
5.1.2.1  Insulin Signaling 
Production of insulin from pancreatic islets is enhanced in response to elevated blood 
glucose.  Circulating insulin then binds to the α subunit of the insulin receptor, which 
is arranged as a α2β2 heterodimer on the cell surface.  Binding of an insulin molecule 
permits the tyrosine kinase activity of the intracellular β subunit, resulting in 
autophosphorylation of the dimer.  The conformational change further amplifies the 
intrinsic tyrosine kinase activity of the receptor, which is now able to phosphorylate 
proximal adaptor molecules, such as insulin receptor substrates 1 and 2 (IRS-1 and 
IRS-2).  IRS1/2 tyrosine phosphorylation activates the phosphatidylinositol-3-kinase 
(PI3K) and mitogen activated protein kinase (MAPK) pathways.  Amongst other 
cellular effects, the PI3K pathway functions to stimulate glucose uptake in muscle and 
adipose tissue by the translocation of glucose transporter 4 (GLUT4) into the 
membrane, the induction of glycogen synthesis in muscle and liver by the activation 
of glycogen synthase, and inhibition of liver gluconeogenesis by suppressing the 
expression of the required enzymes (Wellen and Hotamisligil, 2005; Hotamisligil et 
al., 2006; Kwon and Pessin, 2013; Park et al., 2014).  
 
5.1.2.2  Insulin Resistance 
A decrease in insulin sensitivity, or increase in insulin resistance, can be defined as a 
smaller than expected biological response of insulin-sensitive organs to a defined dose 
of insulin.  In the first instance, the pancreatic beta cells respond by producing more 
insulin.  Hyperinsulinaemia, as well as causing metabolic stress, eventually becomes 
insufficient and a state of hyperglycaemia ensues.  The constant activation of the beta 
cells, due to unresolved hyperglycaemia, causes cellular stress and apoptosis.  
Additive to the original insulin resistance, the subsequent reduced function of 
pancreatic beta cells further worsens the physiological state, resulting in T2D. (Kwon 
and Pessin, 2013) 
 
Insulin resistance is characterised at the cellular level by the interruption of the IRS-
PI3K pathway.  IRS-1 tyrosine phosphorylation, mediated by the insulin receptor, 
permits the activation of PI3K and MAPK pathways, however there are also several 
serine residues of the IRS-1 that can be phosphorylated.  Serine phosphorylation 
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conversely disrupts binding between the insulin receptor and IRS-1 and subsequently 
decreases the activity of the downstream PI3K and MAPK cascades.  As well as its 
tyrosine kinase activity, the insulin receptor also activates certain serine/threonine 
kinases capable of catalysing the inhibitory phosphorylation of the receptor itself or 
IRS-1.  Serine phosphorylation may therefore have developed as a negative feedback 
loop if insulin signaling is overactive or insulin is in excess (Aguirre et al., 2002; 
Werner et al., 2004; Kwon and Pessin, 2013). 
 
Cytokines 
Inhibitory serine phosphorylation of IRS-1 is induced by inflammatory cytokines.  
Cytokines such as TNFα and IL-6 activate kinases c-Jun N-terminal kinase 1 (JNK) 
and IκKB kinase (IKK).  JNK and IKK are well characterised in diminishing the 
activity of the insulin pathway, either by direct serine phosphorylation of substrates or 
by activating genes of the inflammatory response.  Since its detection in adipose 
tissue, a cytokine that has received particular attention in the progression of insulin 
resistance is TNFα.  TNFα is elevated in adipose tissue in obesity, hyperinsulinaemia 
and in response to high-fat feeding.  The cytokine is experimentally shown to induce 
serine phosphorylation, hence reducing tyrosine phosphorylation and downstream 
activity of the insulin receptor and IRS-1.  As well as lowering whole body insulin 
and glucose levels, TNFα neutralization specifically restores diminished tyrosine 
phosphorylation of adipose tissue and muscle tissue in obesity induced insulin 
resistance. Muscle tissue does not directly produce the cytokine, therefore further 
highlighting an endocrine/paracrine function of the cytokine.  TNFα infusions alone 
have been shown to reduce insulin sensitivity and gain of function mutations in the 
TNFα, as well as IL-6, genes are associated with a higher risk of diabetes 
(Hotamisligil et al., 1993; 1994; Moller, 2000; Gao et al., 2002; Dandona et al., 2004; 
Pickup, 2004; Hotamisligil et al., 2006). 
 
Higher circulating lipids, ER and mitochondrial stress also activate JNK and IKK and 
genetic loss-of-function mutations in the two pathways are associated with higher 
insulin sensitivity and the protection from diet induced insulin resistance (Wellen and 
Hotamisligil, 2005; Hotamisligil et al., 2006; Shoelson et al., 2007; Monteiro and 
Azevedo, 2010).  
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Obesity and Insulin Resistance 
A sustained positive energy balance, resulting from over nutrition and a sedentary 
lifestyle, results in the accumulation of lipid and pathogenesis of obesity.   The 
increase in adipose tissue, and its associated secreted factors, in obesity, makes the 
obese state itself a prime cause of T2D.  Indeed, obesity is characterised by a higher 
inflammatory tone and inflammatory genes represent one of the most abundantly 
affected sets in the obesogenic state.  Subsequently, obesity is well regarded as an 
activator of the immune response and consistent with this, weight loss and calorific 
restriction improves the inflammatory tone of obese individuals.  Likewise, the use of 
anti-inflammatory therapeutics improve the outcome of obesity induced insulin 
resistance (Wellen and Hotamisligil, 2005; Shoelson et al., 2007; Hotamisligil et al., 
1993) 
 
Obesity-induced low-grade inflammation is now well regarded to be the transmitting 
signal between obesity and the development of insulin resistance.  In fact, it is the 
discriminating factor of the not always uniform relationship between obesity and 
diabetes.  Although a strong link exists between the two pathologies, the former does 
not always result in the latter.  In both animals and humans, inflammatory markers are 
elevated in specifically obese subjects with accompanying insulin resistance.  Those 
who are obese, yet protected from the development of insulin resistance, do not have 
an accompanying increase in inflammatory tone. Furthermore, a genetic mutation 
impairing TNFα synthesis uncouples obesity and diabetes and the TNFα null mouse is 
protected from obesity induced glucose intolerance and hyperinsulinaemia 
(Hotamisligil et al., 1993; Moller, 2000; Barbarroja et al., 2010; Kwon and Pessin, 
2013).     
 
The activation of inflammatory cellular kinases, mediated by excess lipids and 
cytokines, therefore dictates a pathogenic feed forward loop in obesity.  Larger 
adipose deposits, and an increase in associated cytokines, initiates insulin resistance 
which further propagates excessive lipid storage.  However, it is clear inflammation 
induced insulin resistance can also happen independently of obesity.  The infusion of 
inflammatory mediators, in the absence of obesity, is alone effectual in the instigation 
of insulin resistance.  Along with the increased incidence of T2D in other 
inflammatory diseases, it is clear insulin resistance is also a consequence of the 
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inflammatory response alone (Wellen and Hotamisligil, 2005).  Therefore, in addition 
to the very well characterised, canonical pathway of obesity-induced inflammation 
mediating insulin resistance, another loop may exist whereby inflammation, in the 
absence of obesity, first provides a stimulus for reduced insulin sensitivity.  
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5.1.4 The Intestine and Metabolic Endotoxaemia 
 
There are pronounced differences in the phenotype of the germ-free and 
conventionalized mouse.  Specifically, conventionalisation of the murine digestive 
tract results in reduced insulin sensitivity and a coincident increase in plasma glucose 
(see 1.2.2).   Because of this, research has focused on the intestine and its resident 
microbes as a potential source of low-grade inflammation, capable of influencing 
insulin signaling.   
 
Using mouse models, Ding et al. showed ileal TNFα to correlate with obesity and 
insulin resistance during high-fat feeding and intestinal markers of inflammation 
predated the development of metabolic syndrome (Ding et al., 2010).  Subsequent 
investigations of high-fat fed mice agreed that the colon tissue itself is more inflamed 
and intestinal inflammation was identified as an early response to the diet, which 
could participate in systemic inflammation and whole body insulin resistance (Lam et 
al., 2012; Kim et al., 2012). 
 
In parallel, Lipopolysaccharide (LPS), a component of gram-negative bacterial cell 
walls, was also proposed to be a gut-derived trigger for a low-grade inflammatory 
state.  Bacterial-derived LPS can be transported from the lumen into intestinal 
epithelial cells.  Here, chylomicron formation facilitates entry into circulation, and 
transport of LPS to peripheral tissues.  Contact of the antigen with innate immune 
cells of the host has the potential to evoke the production of inflammatory cytokines.  
Subsequent activation of kinases JNK and IKK leads to the serine phosphorylation 
and downregulation of the insulin pathway.  Cani et al. demonstrated high-fat feeding 
increased circulating LPS (or endotoxaemia) in the mouse.  This moderate increase in 
LPS is much lower than that observed in the severe instance of septic shock, and was 
therefore referred to as “metabolic endotoxaemia”.  An LPS infusion alone was able 
to mimic the increase in inflammatory tone observed in high-fat feeding, along with 
associated hyperinsulinaemia, hyperglycaemia and increased body weight.  
Furthermore, the LPS receptor (CD14) knockout was protected from the development 
of associated inflammation and insulin resistance in response to a high-fat diet. LPS 
was therefore postulated to be involved in the gut-insulin signaling axis, transmitting 
the signal of a high-fat diet to the systemic phenotype.  Even when fed normal chow, 
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the CD14 knockout is more insulin responsive, indicating LPS may also be a mediator 
of insulin sensitivity in physiological conditions.  (Cani et al., 2007a)  
 
High-fat feeding is thought to increase the uptake of LPS by upregulating the 
incorporation into chylomicrons and also by simply increasing gut permeability.  
Specifically a high-fat diet has been shown to reduce the intestinal epithelial 
expression of tight junction proteins ZO-1 and Occludin.  Thus a ‘leaky gut’ would be 
more permissive to LPS entering circulation and further worsening the inflammatory 
tone (Erridge et al., 2007; Cani et al., 2008a; Delzenne and Cani, 2011; Raybould, 
2012; Boroni Moreira and de Cássia Gonçalves Alfenas, 2012).  
 
Human studies have further corroborated a role of LPS, as a high-fat diet increased 
plasma LPS and elevated LPS is associated with insulin resistance and insulin levels 
in healthy individuals and is higher in T2D patients.  Low doses of LPS induced 
adipocyte-derived cytokines such as TNFα and IL-6 at both the whole body and 
cellular level.  LPS is now therefore regarded as a bacterial mediator, capable of 
infiltrating host circulation and instigating the subclinical inflammation seen in the 
development of insulin resistance (Creely et al., 2006; Cani et al., 2007a; Anderson et 
al., 2007; Amar et al., 2008; Serino et al., 2011; Hawkesworth et al., 2013). 
 
Intestinal inflammation and/or the infiltration of LPS in the instigation of systemic 
inflammation is thought to be a potential determinant in whether an individual is 
prone or resistant to diet-induced insulin sensitivity.  As described previously, both 
humans and mice display different responses to obesity, with only some developing 
impaired insulin signaling.  Although an increased inflammatory tone is known to be 
key in the development of obesity induced insulin resistance, Serino et al. further 
implicated gut permeability and circulating LPS in determining the polarised response 
to a high fat diet.  In addition, in patients that underwent gastric bypass surgery to 
alleviate the obese and diabetic state, T2D resolved itself far before the obesogenic 
state was improved.  This further supports the intestine as a significant site of 
inflammation, in addition to adipose tissue, in the pathogenesis of acquired diabetes 
(Serino et al., 2011; Kemp, 2013). 
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Consequently, the source of LPS generation, the intestinal bacteria, has been the focus 
of efforts to relieve the stress of metabolic endotoxaemia.  Indeed, antibiotic treatment 
or prebiotic feeding of high-fat diet fed animals reduced intestinal permeability, 
plasma LPS and improved peripheral inflammation and associated metabolic 
parameters (Cani et al., 2007b; 2008a; 2009).  Caution must however be taken when 
postulating a causative role in specifically the changes in the microbiota upon high-fat 
feeding in the instigation of inflammation.  The diet associated microbial shift does 
not always correlate with the susceptibility to diet-induced insulin resistance.  In 
addition, there are several evidences of a high-fat diet induced dysbiosis occurring 
independently of obesity.  Therefore, although the significance of the presence of the 
microbiota cannot be argued, it is clear the transmission of the signal from the gut to 
host immunity also involves a host-genetic component (Hildebrandt et al., 2009; La 
Serre et al., 2010; Boroni Moreira and de Cássia Gonçalves Alfenas, 2012).   
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5.1.5 Complement Component 3 
 
The complement pathway is a component of the innate immune system.  Briefly, 
activation of the three complement pathways; alternative, classical and lectin, leads to 
the activation and cleavage of complement component 3 (C3), subsequent production 
of C3a and C3b and activation of the terminal pathway.  Membrane attack complexes 
formed in the terminal pathway insert themselves into cell membranes, disturb 
cellular integrity and eventually promote cell lysis.  The complement system is 
ubiquitous and therefore a tight balance of activation and inhibition is necessary in 
preventing immune dysregulation (Hertle et al., 2014). 
 
C3 is an acute phase reactant (a factor induced in acute inflammation) and production 
was originally solely attributed to the liver.  Since however, C3 synthesis has also 
been demonstrated in macrophages and adipocytes, where all other components of 
specifically the alternative pathway are produced, and it is considered an important 
immune mediator.  C3-derived anaphylatoxins C3a and C5a serve to promote initial 
immune cell infiltration, macrophage proliferation and cytokine release.  A further 
product of C3 cleavage, acylation stimulating protein (ASP), also contributes to the 
activation of adipocyte inflammatory mechanisms, such as the increased gene 
expression of inflammatory kinases JNK1 and IKK.  Along with being one of the 
major plasma proteins of the immune complement system, C3 production in adipose 
tissue in response to local inflammation is postulated to link tissue inflammation with 
systemic pathologies, such as low-grade chronic inflammation and accompanying 
insulin resistance (Muscari et al., 2000; Cianflone et al., 2003; Engström et al., 2005; 
Onat et al., 2011; Wlazlo et al., 2012; Munkonda et al., 2012; Hertle et al., 2014). 
 
Indeed changes in levels of C3, and its cleavage products, are a now well-established 
marker of inflammatory disorders such as T2D and obesity.  Circulating C3 correlates 
with high-fat feeding, obesity and insulin resistance where it is also associated with 
systemic low-grade inflammation.  C3 levels are actually found to be predictive of 
impaired glucose tolerance, diabetes and weight gain and subsequently are considered 
to be not just a marker, but also a mediator of immune disorder development.  In 
support of this, the C3 knockout has lower plasma glucose and C3a and C5a receptor 
knockout models have ameliorated inflammation and maintained insulin sensitivity 
	   147 
during high-fat feeding (Muscari et al., 2000; Engström et al., 2005; Samaras et al., 
2010; Onat et al., 2011; Hertle et al., 2014). 
 
Being a product of adipose tissue, it is unsurprising C3 is found to be elevated in 
times of increased adiposity such as high-fat feeding and obesity.  However, a 
magnitude of epidemiological studies has specifically shown C3 to be predictive of 
insulin resistance and T2D independently of obesity and metabolic syndrome.  In fact, 
ASP was found to be elevated in lean T2D subjects, suggesting C3 activation 
participates in inflammatory insulin resistance even in the absence of increased 
adiposity (Engström et al., 2005; Onat et al., 2011; Phillips et al., 2012; Wlazlo et al., 
2012; Hertle et al., 2014).  
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5.2 RESEARCH  QUESTIONS AND AIMS 
 
 
I. Complement component 3 (C3) is used as an inflammatory marker in the 
pathogenesis of insulin resistance.  In C3 measurement, inflammation of WT 
and FMO5 KO adipose tissue will be determined. 
 
II. Following the observed increase in whole-body insulin sensitivity of the FMO5 
KO, insulin sensitivity will be measured in specifically the adipose tissue of the 
WT and FMO5 KO animal. 
 
III. LPS is a bacterial product of the intestine thought to be involved in the 
progression of low-grade inflammation in the host (see 5.1.4).  To investigate 
the ‘leaky gut’ hypothesis and subsequent infiltration of luminal LPS, plasma 
LPS (endotoxin) will be measured in the WT and FMO5 KO animal.   
 
IV. Differences in colonic expression of RELMβ indicate an altered processing of 
the hormone in the WT and FMO5 KO animal (see 4.3.6).  To clarify whether 
this results in a difference in how much hormone enters circulation, plasma 
RELMβ will be measured.  
 
V. Finally, to characterise any differences in systemic inflammation of the WT and 
FMO5 KO animal, inflammatory cytokine TNFα will be measured in plasma of 
the two mouse lines.  	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5.3 RESULTS 	  
5.3.1 Adipose tissue C3 expression is reduced in the FMO5 KO Mouse 
 
Adipose tissue produces C3 in response to acute infection.  Levels are associated with 
the development of inflammatory-linked metabolic disorders and specifically visceral 
adipose tissue (VAT) C3 expression is shown to influence insulin function (Engström 
et al., 2005; Samaras et al., 2010; Hertle et al., 2014).  VAT from 10-week old WT 
and FMO5 KO animals was harvested and probed for C3 (Figure 5.1).   
 
Consistent with a size of ~185 kDa , a single band for C3 was detected in Western 
blot analysis.  FMO5 KO mice have reduced amounts of adipose tissue C3 when 
compared to the WT, indicating the FMO5 KO adipose tissue has a lower 
inflammatory tone.  Enolase was used as a loading control and variation in sample 
loading is evident.  Protein determination of adipose tissue lysates is challenging, due 
to the high lipid content of samples interfering with the protein assay.  Regardless, the 
genotype-related difference in C3 is clearly not an artifact of the imperfect protein 
loading. 
 
Moreover, there was no difference in liver C3 expression in the WT and FMO5 KO 
mice (data not shown).  The difference in C3 expression is therefore paradoxically 
detected in adipose tissue, where FMO5 is not expressed, and not evident in the liver; 
the primary site of FMO5 expression.  This suggests the difference observed in C3 is 
not a direct result of FMO5 mediated catalysis, the action we are seeing is a 
consequence of its expression in a discrete location.   
Figure 5.1 – Adipose tissue levels of complement component 3 
(C3) in the WT and FMO5 KO animal.   Western blot analysis of 
visceral epididymal adipose tissue of 10-week old WT (n=4) and 
FMO5 KO (n=4) male mice.  The membrane was probed for C3 (A) 
and enolase was used as a loading control (B)   
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5.3.2 FMO5 KO Adipose Tissue is more Insulin Sensitive  
As early as 10 weeks of age, whole-body measurements revealed the FMO5 KO to be 
insulin hypersensitive (see 3.3.1).   A decline in insulin sensitivity of specifically 
VAT, in response to low-grade inflammation, has been postulated as the mediator of 
whole-body insulin resistance (Shoelson et al., 2006).  Insulin sensitivity was 
subsequently measured in VAT of WT and FMO5 KO mice.  Insulin resistance is 
characterised by the interruption of the IRS-PI3K pathway, hence phosphorylation of 
the PI3K substrate; Akt, generating phospho-Akt (pAkt), is a measurable indicator of 
pathway activation.  10 minutes post insulin stimulation, WT and FMO5 KO mice 
were culled and VAT was harvested and probed for pAkt (Figure 5.2).    
 
 
At a low dose of insulin (0.5U/Kg), FMO5 KO adipose tissue was more responsive.  
FMO5 KO insulin treated animals (+) show a consistent increase in pAkt compared to 
the untreated animal (-).  However, in measurements of the WT animal, insulin 
stimulation did not result in any great deviation from the basal pAkt level.   
 
A low dose of insulin was used, 4 times lower than what is generally used in the study 
of control versus obese or diabetic groups.  We are not measuring obese nor diabetic 
mice and the dose was selected to be just great enough to instigate a response, 
however not too great to mask the very slight difference between a control and 
hyperinsulinsensitive animal.  This explains why, in our analyses, the WT mice do not 
show any response to the stimulation, whereas the hypersensitive FMO5 KO does.   
Figure 5.2 – Adipose tissue insulin sensitivity measurement in WT 
and FMO5 KO animals.   Western blot analysis of visceral 
epididymal adipose tissue from control (-) and insulin stimulated (+) 
WT and FMO5 KO male mice at 10-weeks of age.  The membrane 
was probed for pAkt (A) and total protein stain amido black was used 
to confirm equal loading (B).   
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Out of the insulin sensitive organs, VAT has gained the most attention in the 
investigation of inflammation-induced insulin resistance.  In fact, there is 
disagreement as to whether insulin signaling of muscle and liver is affected in 
response to low-grade inflammation (Hotamisligil et al., 1993; Moller, 2000; 
Shoelson et al., 2006; Serino et al., 2011).  Nevertheless, future insulin sensitivity 
measurements of liver and muscle would further characterise the insulin sensitive 
phenotype of the FMO5 KO animal.   Regardless, in the FMO5 KO, we propose a 
reduced inflammatory tone of visceral adipose tissue results in heightened insulin 
sensitivity of the tissue.   
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5.3.3 Plasma Endotoxin Measurement 
 
A wealth of studies has proposed an increase in intestinal permeability, or ‘leaky gut’, 
and the subsequent infiltration of LPS (endotoxin), as a gut-derived trigger for 
peripheral and systemic inflammation (Cani et al., 2007a; Boroni Moreira and de 
Cássia Gonçalves Alfenas, 2012; Delzenne et al., 2011; Delzenne and Cani, 2011).  
Plasma endotoxin measurements of the WT and FMO5 KO animal however revealed 
no observable difference in circulating levels (Figure 5.3).   
 
 
Therefore, the protection from the low-grade adipose tissue inflammation, and 
subsequent increased insulin sensitivity of the FMO5 KO, cannot be specifically 
attributed to a difference in endotoxaemia.  This is in agreement in the gross 
morphological analysis of WT and FMO5 KO intestinal tissue (see 4.3.4); no 
difference in barrier integrity was observed.   
 
  
Figure 5.3 – Plasma endotoxin levels 
in the WT and FMO5 KO animal.   
Plasma endotoxin was measured in 10-
week old WT (n=3) and FMO5 (n=3) 
male mice.  Data is expressed as mean 
± SEM. 
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5.3.4 Difference in Plasma RELMβ in the WT and FMO5 KO Animal 
 
Along with changes in the intestinal microbiota, differences were observed in the 
expression of the colonic hormone RELMβ.  In the WT and FMO5 KO colon no 
gross difference was observed in RELMβ expression levels and the dimeric form of 
the protein was detected in both genotypes.  The active monomer was however 
specifically found in the colon of the WT animal (see Figure 4.11).  In addition, faecal 
detection revealed the FMO5 KO excretes more RELMβ (see Figure 4.13). Taken 
together, this suggests a lack of RELMβ processing in the KO colon results in less of 
the luminal hormone infiltrating host tissue/ circulation.  The pro-inflammatory nature 
of RELMβ would therefore make it a potential source of variation in inflammation of 
the WT and FMO5 KO animal.  Using a sandwich-based ELISA, RELMβ was 
measured in plasma of WT and FMO5 KO animals fed a standard chow (Figure 5.4).   
 
High variation exists between individuals in both colonic and plasma measurements 
of RELMβ (Hildebrandt et al., 2009; Neilson et al., 2011).  In plasma measurements, 
RELMβ tended to be higher in the WT animal.  However, due to the high variability 
in measurements, the difference between WT and FMO5 KO levels was not 
statistically significant when analysed with Student’s t-test (p=0.09).  To investigate 
the influence of high-fat feeding, measurements were also conducted in high-fat diet 
(HFD) fed WT and FMO5 KO animals (Figure 5.5). 
Figure 5.4 – Plasma levels of 
RELMβ in WT and FMO5 KO male 
mice   Plasma RELMβ was measured 
between 9-11 am in 30-week old WT 
(n=10) and FMO5 KO (n=10) male 
mice.  Data is expressed as mean ± 
SEM.   
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In high-fat diet fed animals, plasma RELMβ was again higher in WT plasma when 
compared to FMO5 KO levels.  However, due to high variation in samples, results 
were again not statistically significant.  Plasma RELMβ is reported to be elevated in 
response to high-fat feeding (Shojima et al., 2005).  We did not observe this trend in 
our analysis.  In fact, although not significant, the HFD values were lower in both 
genotypes (Table 5.1).  This is likely to be due to the lipaemia in HFD plasma 
interfering with the ELISA method of detection.  Normally this can be overcome by 
taking plasma from starved animals, thereby reducing the lipid content of plasma, 
however RELMβ expression is attenuated during fasting.   
 
Figure 5.5 – Plasma levels of 
RELMβ in WT and FMO5 KO male 
mice fed a high fat diet (HFD).   
Plasma RELMβ was measured 
between 9-11 am in high fat diet fed 
WT (n=6) and FMO5 KO (n=6) male 
mice.  Data is expressed as mean ± 
SEM.   
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Table 5.1 – Plasma levels of RELMβ in WT and FMO5 KO 
male mice fed standard chow or a high fat diet.   RELMβ 
was measured between 9-11 am in standard chow fed (WT: 
n=10, FMO5 KO: n=10) and high fat diet fed (WT: n=6, and 
FMO5 KO: n=6) male mice.  Data is expressed as mean ± 
SEM.   
RELMβ (pg/ml)
WT FMO5 KO
Standard Chow
High-Fat Diet
26.36 ± 3.63 
17.65 ± 2.80
17.63 ± 3.28 
12.47 ± 3.37
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5.3.5 Changes in Circulating TNFα in the WT and FMO5 KO Animal 
 
In both in vivo and in vitro, RELMβ activates macrophages resulting in the release of 
TNFα.  McVay et al. specifically described the colon of the RELMβ KO mouse to 
have lower levels of TNFα (McVay et al., 2006).   This suggests even breaching the 
intestinal barrier, and not necessarily entering circulation, RELMβ can instigate 
intestinal inflammation.  TNFα is an inflammatory cytokine, well characterised in its 
ability to diminish the activity of the insulin pathway.  It is also known to have a 
paracrine/endocrine function; mediating effects peripheral to its site of production.  
To assess a potential role of the observed differences in RELMβ, and postulate a link 
to the difference in insulin sensitivity of the WT and FMO5 KO mouse, plasma TNFα 
was measured before and after antibiotic treatment (Figure 5.6). 
 
 
In the untreated WT and FMO5 KO animals, TNFα was found to be higher in the WT 
(WT, 18.92 ± 3.34 pg/ml, n=5; FMO5 KO, 5.91 ± 1.67 pg/ml, n=4) (p<0.05).  
Therefore, coincident with higher insulin sensitivity and lower adipose tissue 
inflammation, the FMO5 KO also has a lower systemic inflammatory tone.  
Furthermore, circulating TNFα was found to be lower in antibiotic treated WT 
animals (WT AB, 5.47 ± 0.67 pg/ml, n=3) when compared to the untreated controls 
Figure 5.6 – Plasma levels of TNFα in control and antibiotic 
treated WT and FMO5 KO mice.   TNFα was measured between 9-
11 am in control treated animals (WT; n=5, FMO5; n=4) and antibiotic 
treated animals (WT AB; n=3, FMO5 KO AB; n=3) Data is expressed 
as mean ± SEM.  *: p<0.05. 
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(WT, 18.92 ± 3.34 pg/ml, n=5;) (p<0.05), whereas the treatment had no effect on 
TNFα levels in the FMO5 KO.   
The effect of the antibiotic treatment on TNFα levels is in parallel with that seen in 
the gross metabolic measurements.  Antibiotic treatment lowers circulating TNFα, 
plasma glucose and insulin and improves glucose tolerance in specifically the WT 
animal, whilst eliciting no effect in the FMO5 KO.  As a result, The WT animal 
adopts the apparent ameliorated low-grade inflammation and hyperinsulinsensitivity 
of the FMO5 KO.   
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5.4 CONCLUSIONS 	  
The antibiotic treatment was designed to reduce the microbial load of the intestine.  In 
agreement, microbial-induced RELMβ expression was attenuated and the caecum 
became enlarged; an observed characteristic of germ-free mice.  We hypothesize the 
low dose course of antibiotics relieved the burden of the microbiota in the WT animal, 
ameliorated expression of microbial sensor RELMβ, thereby improving inflammatory 
tone and insulin signaling. 
 
The heightened insulin sensitivity of the FMO5 KO observed from a young age, and 
the absence of any effect in antibiotic treatment, suggests FMO5 to be a host protein 
involved in the intestinal microbiota mediated increase in inflammatory tone, and 
subsequent decline in insulin signaling.  A potential mechanism outlined in Chapter 3 
is the processing, hence activation, of colonic hormone RELMβ.   
  
From what is known about RELMβ, and the observed difference in the WT and 
FMO5 KO animal, alternative processing of the colonic hormone is a good candidate 
for the altered metabolic phenotype.  Although involved in intestinal barrier integrity, 
microbiota-induced RELMβ also has pro-inflammatory properties.  Host goblet cells 
produce the hormone, and it is secreted into the colonic lumen.  Here, it is believed to 
act as a mucosecretagogue; positively regulating the formation of the mucus layer.  In 
agreement, the intestine of the RELMβ KO is more permeable.  RELMβ infiltration of 
host tissue is however deleterious, as RELMβ-activation of macrophages results in 
inflammatory TNFα release (McVay et al., 2006; Hogan et al., 2006; Krimi et al., 
2008).  The proposed active, monomeric form of RELMβ was specifically found in 
the WT colon, and there was a trend of higher levels of RELMβ in WT plasma.  Akin 
to colonic measurements (see Figure 4.11), the absence of FMO5 does not impair 
RELMβ expression; both the WT and FMO5 KO produce the hormone.  However it 
may be FMO5, also expressed in host colonic cells, mediates a change in the dimeric 
nature of the protein, hence promoting the infiltration and/or proinflammatory actions 
of the hormone.  
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Cytokine measurement in plasma is problematic and detection methods often lead to 
underestimation.  Cytokines are active at very low concentrations, often at the lower 
limit of detection assays, and recognition is further complicated by the short half-life, 
rapid degradation of cytokines and cytokines existing in multiple forms (e.g. 
oligomers and glycosylated) (Bienvenu et al., 1998).  Furthermore, plasma detection 
provides no information of origin.  Immune cells, ubiquitously found across the body, 
produce cytokines.  Cytokines are pleiotropic; they often elicit various effects in 
different cell types, and operate in a complicated network involving several other 
mediators.  In this investigation it is possible infiltrating RELMβ activates intestinal 
macrophages and resultant circulating TNFα causes inflammation in peripheral 
adipose tissue.  Alternatively, RELMβ itself in circulation has the potential to activate 
adipose tissue macrophages, provoking an immune response in adipose tissue leading 
to higher circulating TNFα.  Specific tissue measurement of TNFα would resolve this.  
Using tissue homogenates in ELISA-based detection of cytokines has been described 
(Matalka et al., 2005; McDuffie et al., 2006; Amsen et al., 2009), however in our 
analysis it was not successful.  Real-time polymerase chain reaction or 
immunohistochemical investigations of specific tissues would be appropriate for 
future investigations.   
 
Regardless of the ambiguity in origin of inflammation, it is of note the C3 and TNFα 
measurements were conducted at 10- and 20- week old mice respectively. The 
difference observed in these two markers predates the difference in weight and fat pad 
size recorded in the WT and FMO5 KO.  The difference in gross body weight only 
presents after 21 weeks of age and the visceral fat pad of the FMO5 KO is only 
reported to be significantly smaller at 30 weeks of age.  The elevated levels of C3 and 
TNFα cannot therefore be directly attributed to an increase adiposity of the WT.  
Considering the timeline of the phenotype, it seems more likely an increased 
inflammatory tone, originating from the gut, has a deleterious effect on the insulin 
signaling of the WT animal, eventually causing an increase in adiposity and body 
weight in older age. 
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Chapter 6 - Discussion
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6.1 Summary 
The flavin-containing monooxygenases (FMOs) catalyse the oxygenation of a broad 
range of substrates and are fundamental to the Phase I processing of xenobiotic 
compounds (Cashman, 2003).  In the absence of substrate, the enzymes are able to 
activate molecular oxygen and the activated FMO complex is thought to be the most 
prominent form in the cell (Ziegler, 2002; Zhang et al., 2007).  Due to the resultant 
broad substrate specificity of the isoforms, and the inefficiency of antibody-mediated 
catalytic inhibition, the further characterisation of FMOs requires the utilization of 
mouse knockout models (Shephard and Phillips, 2010).  FMO knockout mouse 
models have clarified the role of particular isoforms in xenobiotic metabolism 
(Hernandez et al., 2009) and, in further investigations, have also revealed a potential 
endogenous role of isoforms FMO1 and 5 (Veeravalli et al., 2014; Gonzalez Malagon 
et al., unpublished). 
 
Several properties of FMO1 and FMO5 indicate an endogenous role of these isoforms 
and FMO5 in particular has been defined as an atypical FMO.  There are very few 
non-synonymous mutations of FMO1 and FMO5 (Furnes et al., 2003; Sevasti B 
Koukouritaki, 2005; Motika et al., 2007) and, unlike other isoforms, FMO5 is shown 
to be inducible and large inter-individual variations are reported (Miller et al., 1997; 
Overby et al., 1997; Rae et al., 2001; Krusekopf and Roots, 2005).  In the study of the 
FMO1,2,4 KO mouse, FMO1 was shown to be a regulator of energy homeostasis as 
well as a drug metabolising enzyme (Veeravalli et al., 2014).  Mutant mice have a 
higher total energy expenditure, which is not accompanied by an increase in calorific 
intake.  Characterisation of an FMO5 KO mouse further revealed an unexpected role 
for this isoform in endogenous metabolism (Gonzalez Malagon et al., unpublished).  
By the age of 30 weeks, KO mice have lower circulating glucose and cholesterol and 
weigh less when compared to the wild-type (WT).  The investigations of this thesis 
further corroborate an endogenous role of FMO5.  Inactivation of Fmo5 imparts a 
heightened insulin sensitivity in the animal, coincident with, and perhaps, as a result 
of a lower inflammatory tone.   
 
In the further characterisation of the FMO5 KO metabolic phenotype, we report the 
FMO5 KO mouse is protected from the deleterious consequences of high-fat feeding.  
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Furthermore, although eliciting the canonical response in the WT animal; in 
improving parameters of insulin sensitivity, antibiotic targeting of the intestinal 
microbiota produced no measurable affect in the KO mouse.   
 
In novel experiments, we have shown FMO5 to be expressed through the entirety of 
the WT digestive tract.  Faecal microbiota analysis of the WT and FMO5 KO animal 
revealed FMO5 influences the resident bacteria of the lumen.  An increased 
representation of the Bacteroidetes phyla, and concomitant decrease in the Firmicutes, 
was reported in the FMO5 KO.  This dysbiosis has been extensively linked with a 
lean phenotype, explained by a difference in energy harvest of the microbiota.  This 
originally proposed the dysbiosis as a cause for the different energy phenotype of the 
WT and FMO5 KO.  However, a disparity in the high-fat feeding experiments 
indicated this not to be the case.  Upon high-fat feeding, the intestinal microbiota of 
the FMO5 KO became equivalent to the WT, both animals now harboring a profile 
commonly associated with excessive energy storage.  However, the FMO5 KO mouse 
remained lean, thereby indicating the protection mediated by the absence of FMO5 
supersedes the presence of an unfavourable microbiota.   
 
Along with microbiota modulation, the absence of FMO5 changed the processing of 
colonic hormone RELMβ.  Both the WT and FMO5 KO animal produce the hormone, 
however the proposed active monomer of RELMβ was only identified in the WT 
mouse.  RELMβ has been described as a mucosecretagogue (Krimi et al., 2008) as 
well as a modulator of host inflammation (McVay et al., 2006; Hogan et al., 2006; 
Krimi et al., 2008).  In the absence of the active monomer, the FMO5 KO mouse 
exhibits lower levels of mucosecretion in the colon and a lower systemic 
inflammatory tone.  Inflammation is now regarded as a potent contributor to the 
pathogenesis of insulin resistance (Shoelson et al., 2006).  We therefore propose the 
lower inflammatory tone of the FMO5 KO imparts a higher sensitivity to insulin, 
thereby preventing age-related increases in cholesterol, glucose and weight gain 
observed in the WT animal.   
 
The further induction of RELMβ in high-fat feeding, and apparent lack of activation 
in the FMO5 KO, explains the further disparity in high-fat diet fed WT and FMO5 
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KO animals.  Furthermore, we know RELMβ to be the microbial sensor of the 
intestine; induction is dependent on the presence of the microbiota.  In antibiotic 
mediated clearance of the intestinal microbiota, hence ablation of colonic RELMβ 
expression, the inflammatory tone and insulin sensitivity of the WT animal was 
improved, subsequently resembling that of the FMO5 KO.  Akin to overexpression of 
Fmo5 in a model of intestinal stress (Zhang et al., 2009), we also show intestinal 
FMO5 expression is induced in high-fat feeding, however expression was not strictly 
dependent on the presence of the microbiota.  Regardless, the strong influence of 
FMO5 in the response to an increase or amelioration in intestinal stress described 
implicates it as a factor in the host’s recognition to its commensal bacteria and/or the 
luminal environment of the intestine.   
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6.2 Mechanism 
From the investigations presented, the processing of RELMβ is a good candidate for 
the actions of FMO5.  In the absence of FMO5, although protein expression and 
localization remains unaffected, a difference in the dimerization of RELMβ is 
observed.  This could be explained by the FMO mediated oxidation of cysteamine to 
cystamine, a powerful thiol oxidant critical for the formation of disulphide bonds and 
correct protein assembly.  Poulsen et al. proposed the FMOs to therefore be 
implicated in the folding of nascent proteins by influencing the local oxidising 
environment (Poulsen and Ziegler, 1977).  RELMβ is rich in cysteine residues, which 
mediate intramolecular disulphide bonds.  The inactivation of Fmo5 may therefore 
result in the incorrect folding of the hormone, resulting in a loss of activity.   
 
In addition to modifying the oxidising environment of a cell, FMO activity may also 
result in the production of reactive oxygen species (ROS).  Regardless of substrate 
availability, the FMO catalytic cycle can short-circuit, resulting in the oxidation of 
NADPH and the generation of H2O2 or a superoxide anion (Siddens et al., 2014).  
Mammalian epithelial cells have been shown to respond to intestinal microbiota by 
the rapid generation of ROS (Kumar et al., 2007).  Consequently, intestinal epithelia 
generated ROS is proposed to constitute a microbial-instigated protection and signal 
cascade in the host (Neish, 2009).  Fmo5 mRNA was found to be the most prominent 
of all the isoforms in the intestine (Janmohamed et al., 2001; Zhang and Cashman, 
2005) and our investigations have localized the protein to the intestinal epithelium of 
the WT mouse.  FMO5 generated ROS may therefore participate and its absence 
could result in a beneficial dampening of the response to the commensal microbes of 
the intestine in the FMO5 KO.   
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6.3 The FMO5 KO Mouse 
The investigations of this thesis have focused on the intestinal phenotype of the 
FMO5 KO, in particular the differences observed in the colon of WT and FMO5 KO 
animals.  The proposal of FMO5 in modulating the cellular environment, and the 
pervasive expression of the isoform, would however suggest an effect much greater 
than solely the processing of a colonic hormone.  This is supported by additional 
observations of the FMO5 KO mouse outside the scope of this thesis.  For instance, 
FMO5 is expressed throughout the digestive tract and in investigations of the stomach 
we also observe differences in the resident bacteria of this organ (see Appendix).  
Akin to the faecal analyses, FMO5 KO animals have higher levels of Bacteroidetes 
and lower levels of Firmicutes when compared to the WT.  In fact, the microbial shift 
between genotypes is even greater in the stomach.  Although the relevance of an 
altered microbiota remains unclear, this warrants further investigation into the role of 
FMO5 in sites of the digestive tract other than the colon.  In addition, FMO5 is also 
expressed in murine skin, most concentrated in the sebaceous glands (Janmohamed et 
al., 2001).  Observations of ageing WT and FMO5 KO animals also indicate a role of 
FMO5 at this site; KO animals maintain a fuller coat of hair and greying of the hair is 
not as severe as that seen in the WT.  Once again at an interface of host cells and 
commensal bacteria, the skin may therefore present a novel site for functional analysis 
of FMO5. 
 
Furthermore, Fmo5 mRNA levels indicate it is the most prominent isoform in mouse 
liver (Janmohamed et al., 2004; Zhang and Cashman, 2005) and work conducted by 
colleagues has focused on the hepatic consequence of the absence of FMO5.  
Proteomic analysis in liver samples of 30-week old WT and FMO5 KO mice revealed 
three enzymes of glucose metabolism to be downregulated in the KO; fructose 
bisphosphate aldolase B, glycerol-3-phosphate dehydrogenase and ketohexokinase.  
This may be a consequence of the absence of hepatic FMO5 catalysis, however we 
have since described a lower inflammatory tone and heightened insulin sensitivity of 
the FMO5 KO from young, resulting in lower plasma glucose at 30 weeks of age.   It 
is therefore possible the downregulation of these hepatic enzymes is secondary to the 
reduced intestinal inflammation and subsequent lower circulating glucose of the 
FMO5 KO.  Proteomic analysis of younger animals, when glucose and insulin levels 
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are comparable in the WT and FMO5 KO, would help decipher the cause of the 
change in protein expression.   
 
Malic enzyme 1 (ME1) a lipogenic enzyme of the liver was also found to be 
downregulated in the FMO5 KO mouse.  FMO5 mediated ME1 modification was 
found to be post-transcriptional; ME1 mRNA levels were unchanged in the WT and 
FMO5 KO mouse.  ME1 catalyses the conversion of malate to pyruvate and CO2,, 
reducing NADP to NADPH.  The generated NADPH is required for long chain fatty 
acid synthesis and also key steps in cholesterol synthesis, therefore the reduction in 
ME1 may contribute to a decrease in fatty acid biosynthesis and also to the decreased 
plasma cholesterol of the FMO5 KO mouse.  However, what remains unclear is 
whether the decrease in ME1 is due to the absence of hepatic FMO5 catalysis, or 
another consequence of a heightened insulin sensitivity of the FMO5 KO.  
Experiments have revealed adipose tissue of the FMO5 KO to be more insulin 
sensitive and subsequently lower levels of circulating insulin were detected in 
comparison to the WT.  Additionally, studies have discussed the positive regulation of 
insulin on ME1 at both the transcriptional and post-transcriptional level (Davis et al., 
1988; Katsurada et al., 1988; 1989; Goodridge et al., 1989).  If the hepatic insulin 
sensitivity of the WT and FMO5 KO is comparable, it may therefore be possible 
higher circulating insulin in the WT results in higher hepatic ME1 expression.  Again, 
ME1 measurement in younger WT and FMO5 KO animals, with equivalent insulin 
levels, and hepatic insulin sensitivity measurements would prove crucial in 
determining the cause of the disparity in ME1 expression.   
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6.4 Conclusions and Future Work 
 
We propose FMO5 to be involved in the host’s response to the commensal bacteria of 
the intestine.  The FMO5 KO is impervious to the intestinal stress caused by high-fat 
feeding and non-responsive to the elimination of the intestinal microbiota.  A 
beneficial dampening in the intestinal epithelial response to the commensal bacteria 
results in a lower inflammatory tone and resultant modest increase in insulin 
sensitivity of the FMO5 KO.   
 
The investigations of this thesis propose a potential mechanism in the descriptions of 
a colonic hormone; FMO5 expression seems necessary for the activation of the 
microbial sensor RELMβ.  Moreover, in considering the expression and elusive 
activity of the isoform, we postulate the endogenous capacity of FMO5 is not 
mediated by a straight-forward substrate catalysis.  Instead, we predict a more global 
function of FMO5 in regulating the cellular reducing environment and in the 
production of reactive oxygen species.   In doing so, we also predict other site-specific 
consequences of FMO5 expression, for instance the greying of coat hair in ageing.  
Cellular measurement of NADP/ NADPH and H2O2, in experimental FMO5 
overexpression and silencing, would prove fundamental in further mechanistic 
explanation.  Furthermore, the use of stable lines of a specific lineage, for example the 
goblet cell, would help delineate FMO5’s specific, or in fact general, action in the 
different tissues.   
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7. Appendix 
 
 
 	  	   	  
Bacteroidetes 
Firmicutes 
Other 
Unclassified 
Appendix I – Phyla-level microbiota analysis of WT and FMO5 KO stomach 
contents.  The stomach contents of three animals was pooled for each condition.  
Sequence reads were taken from samples of WT (n=44) and FMO5 KO (n=48) 30-
week old male mice.   
WT 
FMO5 KO 
Appendix II – Phyla-level microbiota analysis of WT and 
FMO5 KO stomach contents.  The stomach contents of 
three animals was pooled for each condition.  Sequence 
reads were taken from samples of WT (n=44) and FMO5 
KO (n=48) 30-week old male mice.   
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Appendix III – Family-level microbiota analysis of WT and FMO5 KO stomach 
contents.  The stomach content of three animals was pooled for each condition.  
Sequence reads were taken from samples of WT (n=44) and FMO5 KO (n=48) 30-week 
old animals.   
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8. List of Abbreviations 	  
AB   Antibiotic 
ASP  Acylation stimulating protein 
AUC  Area under the curve 
BCA  Bicinchoninic acid 
BMI  Body mass index 
bp  Base pair 
BSA  Bovine Serum Albumin 
C3  Complement component 3 
CF  Cystic fibrosis 
CTFR  Cystic fibrosis transmembrane conductance regulator 
CYP  Cytochrome P450 
DNA  Deoxyribonucleic acid 
dNTP  Deoxynucleotide triphosphate 
DPT  10-(N,N-dimethylaminoalkyl)- 2-(trifluoromethyl)phenothiazine  
DSS  Dextran sulphate sodium 
DTT  Dithiothreitol 
ECL  Enhanced chemiluminescence 
EDTA  Ethylenediaminetetraacetic acid 
ELISA  Enzyme-linked immunosorbent assay 
ER  Endoplasmic reticulum 
ERK  Extracellular signal-regulated kinase 
FAD  Flavin adenine dinucleotide 
FFA  Free fatty acids 
FIZZ  Found in inflammatory zones   
FMO  Flavin-containing monooxygenase gene (human) 
Fmo  Flavin-containing monooxygenase gene (mouse)  
FMO  Flavin-containing monooxygenase 
GI  Gastrointestinal  
HDL  High density lipoprotein 
HFD  High-fat diet 
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HRP  Horseradish peroxidase 
iAUC  Inverse area under the curve 
IBD  Inflammatory bowel disease 
IEC  Intestinal epithelial cell 
IgA  Immunoglobulin A 
IgG  Immunoglobulin G 
IHC  Immunohistochemistry 
IKK  IκKB kinase 
IL  Interleukin 
INFγ  Interferon γ 
IPTG  Isopropyl β-D-1-thiogalactopyranoside 
IRS1/2  Insulin receptor substrate1/2 
JNK  c-Jun N-terminal kinase 
kDa  Kilo Dalton 
KO  Knockout 
Lac  Lactose 
LAL  Limulus amebocyte lysate 
LB  Luria broth 
LDL  Low density lipoprotein 
LPS   Lipopolysaccharide 
MAPK  Mitogen-activated protein kinase 
ME1  Malic enzyme 1 
mRNA  Messenger ribonucleic acid 
MUC2  Mucin 2 
NADP+ Nicotine adenine dinucleotide phosphate (oxidised) 
NADPH Nicotine adenine dinucleotide phosphate (reduced) 
NFDM  Non-fat dried milk 
pAkt  phospho-Akt 
PBS  Phosphate buffered saline 
PCR  Polymerase chain reaction 
PI3K  Phosphatidylinositol-3-kinase 
PMSF  Phenylmethylsulfonyl fluoride 
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Pofut1  Protein O-Fucosyltransferase 1 
PPARγ Peroxisome proliferator-activated receptor γ 
RELM  Resistin like molecule 
rRNA  Ribosomal ribonucleic acid 
RNA  Ribonucleic acid 
ROS  Reactive oxygen species 
SDS   Sodium dodecyl sulphate 
SDS-PAGE Sodium dodecyl sulphate polyacrylamide gel electrophoresis 
SOC   Super optimal broth with catabolite repression 
T2D  Type 2 diabetes 
TBS  Tris-buffered saline 
TBS-T  Tris-buffered saline – 0.1 % tween 
Th1/2  T helper cells1/2 
TLR  Toll-like receptor 
TMA  Trimethylamine 
TMAU Trimethylaminuria 
TNBS  Trinitrobenzene sulphonate 
TNFα  Tumour necrosis factor α 
VAT  Visceral adipose tissue 
WAT  White adipose tissue 
WT  Wild-type 
X-gal  5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside 	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